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Summary: Mechanisms of Inflammation-induced Hepatocarcinogenesis 
The link between inflammation and carcinogenesis in general and more specifically in liver has been 
acknowledged for a long time. Hepatocellular carcinoma (HCC) is the most common primary liver cancer. 
It is associated with chronic liver damage as seen in Hepatitis B and Hepatitis C virus infection, chronic 
drug and alcohol abuse as well as autoimmune diseases which are typically accompanied by chronic 
hepatitis. 
Interestingly, only 30-40% of all patients with chronic hepatitis develop HCC. The molecular, genetic and 
cellular events that drive chronic hepatitis induced liver carcinogenesis remain largely elusive. 
Due to the lack of appropriate animal models with chronic hepatitis induced HCC research has focused 
either on (a) animal studies using carcinogenic substances to induce liver cancer or (b) on patient samples. 
(a) In the past, scientists have used for example carcinogenic substances such as diethylnitrosamine (DEN) 
to induce liver cancer in mice. The pathogenesis of HCC in these mouse models differs from that in humans 
and thus may not be directly comparable to chronic hepatitis induced human HCC. However, DEN-induced 
HCC might have a genetic signature similar to that of human HCC with poor prognosis. Ablation of the 
multi-drug resistance gene 2 (mdr2) induces cholestatic hepatitis and liver cancer. Liver specific expression 
of the hepatitis B surface antigen (HBsAg) in mice demonstrates that chronic immune-mediated liver cell 
injury is critical for HCC formation.  
(b) Alternatively, research in humans has centreed on patient liver samples, with sometimes limited ability 
to dissect cellular and molecular events of chronic hepatitis induced HCC. Recent work with liver samples 
from patients with chronic hepatitis associated HCC has demonstrated that pro-inflammatory cytokines, 
Lymphotoxin (LT)  and , are specifically upregulated on hepatocytes and oval cells. In addition, a recent 
study has provided evidence that LT receptor (LTR) and LT are actively involved in hepatitis C virus 
replication. In order to establish a mouse model for chronic hepatitis induced HCC LTand LT were 
ectopically expressed in hepatocytes (AlbLT mice, high expressing line 1223 and therefore named 
tg1223 throughout the following thesis). I can show that these mice develop laboratory evidence and 
histological signs of insidiously developing chronic hepatitis at 6 to 9 months of age persisting through life 
time. Indeed, at 12 months of age, about 20% (6/34) of tg1223 mice developed macroscopically visible 
nodules that were classified histologically as HCC. Tumor frequency increased with age reaching ~35% 
(18/51) by 18 months, whereas C57BL/6 mice did not develop HCC (0/35; P<0.0001).
Hepatitis B and C viruses (HBV, HCV) cause chronic hepatitis and HCC by poorly understood 
mechanisms. This work shows upregulation of the cytokines lymphotoxin (LT)  and their receptor 
(LTR) in HBV- or HCV-induced hepatitis and HCC. Liver-specific LT expression in mice induces liver 
inflammation and HCC causally linking hepatic LT overexpression to hepatitis and HCC. Development of 
HCC, composed in part of A6+ oval cells, depends on lymphocytes and IKappa B kinase  expressed by 
hepatocytes but is independent of TNFR1. In vivo LTR stimulation implicates hepatocytes as the major 
LT-responsive liver cells and LTR inhibition in LT-transgenic mice with hepatitis suppresses HCC 
formation. Thus, sustained LT signaling represents a hitherto unknown pathway involved in hepatitis-
induced HCC.  
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Pharmacological inhibition of LTR signaling reduces pathogen- and concavalin A (ConA)-induced liver 
injury while LTR signaling on hepatocytes appears beneficial during liver regeneration. This work 
demonstrates that sustained hepatic LT expression in mice can be injurious causing chronic hepatitis and 
HCC. Enhanced hepatic LTR signaling might be of potential clinical relevance since LTR and its ligands 
are drastically increased in human HBV- and HCV-induced hepatitis and HCC when compared to normal 
livers or non-viral, benign liver diseases. Thus, hepatic LT signaling might be advantageous if transiently 
active during liver regeneration, but detrimental if chronically triggered. I propose that suppression of 
hepatic LTR signaling might be beneficial in liver diseases with chronic LT, LT or LIGHT 
overexpression.
Zusammenfassung 
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Zusammenfassung: Mechanismen Entzündungs-induzierter 
Leberkarzinogenese 
Die Assoziation von Entzündung und Karzinogenese wurde bereits vor langer Zeit, insbesondere auch für 
die Leber, beschrieben. Das hepatozelluläre Karzinom (HCC) ist der häufigste Primärtumor der  Leber. Es 
ist assoziiert mit chronischer Leberschädigung, wie sie im Rahmen von Hepatitis B/C Virus-Infektionen, 
chronischer Medikamenteneinnahme und Alkoholabusus, ebenso wie auch bei Autoimmunerkrankungen 
auftritt. Diese Veränderungen sind typischerweise mit einer chronischen Hepatitis vergesellschaftet. 
Interessanterweise entwickeln lediglich 30-40% aller Patienten mit chronischer Hepatitis ein HCC, und die 
molekularen, genetischen und zellulären Ereignisse, welche ursächlich für durch chronische Hepatitis 
induzierte Leberkarzinomentstehung sind, sind bisher noch weitgehend unbekannt. Aufgrund des Fehlens 
von Mausmodellen für die durch chronische Hepatitis induzierten HCC hat sich die Forschung bisher in 
zweierlei Weise orientiert. Zum einen (a) wurden Tierstudien unter Verwendung von karzinogenen 
Substanzen zur HCC-Induktion, zum anderen (b) wurden Studien an Patientengewebe durchgeführt.  
(a) In der Vergangenheit haben Forscher beispielsweise chemische Karzinogene wie Diethylnitrosamin 
(DEN) oder Mitogene wie z.B. Concavalin A (Con A) verwendet, um bei Mäusen Leberkrebs zu 
induzieren. Die Pathogenese von HCC unterscheidet sich in diesen Modellen deutlich von der humanen 
Situation und ist daher nicht direkt vergleichbar zum durch chronische Hepatitis induzierten humanen HCC. 
Allerdings hat das DEN-induzierte HCC möglicherweise eine genetische Signatur, welche ähnlich humanen 
HCC mit schlechter Prognose ist. Die Entfernung des multi-drug resistance-Gens 2 (mdr2) induziert eine 
cholestatische Hepatitis und Leberkrebs. Leber-spezifische Expression des Hepatitis B-Oberflächenantigens 
(HBsAg) bei Mäusen zeigte, dass ein chronischer Immun-vermittelter Leberzellschaden entscheidend für 
die HCC-Entstehung ist.  
(b) Alternativ hat sich die Forschung auf Lebergewebe von Patienten gestützt, wobei die Möglichkeit zur 
genauen Auftrennung der zellulären und molekularen Ereignisse bei durch chronische Hepatitis bedingter 
Leber-Karzinogenese nur eingeschränkt bestand. Eine erst kürzlich erschienene Arbeit zu Lebergeweben 
von Patienten mit durch chronische Hepatitis induziertem HCC zeigte, dass die proinflammatorischen 
Cytokine, Lymphotoxin (LT)  und  spezifisch auf Hepatozyten und den sogenannten “Ovalzellen“ 
hochreguliert sind. Zusätzlich zeigte eine aktuelle Studie, dass der LT-Rezeptor und LT aktiv in der 
Replikation des Hepatitis C-Virus involviert sind. 
Um ein Mausmodell für ein durch chronische Hepatitis induziertes HCC zu etablieren, wurde LT und LT 
ektop spezifisch in Hepatozyten (tg1223 Mäuse) exprimiert. Ich kann zeigen, dass diese Mäuse 
laborchemische und histologische Zeichen einer chronischen Hepatitis im Alter von 6 bis 9 Monaten 
entwickeln. Dieser Entzündungsstatus persistiert über die gesamte Lebensspanne der Tiere. Tatsächlich 
entwickelten etwa 20% (6/34) der tg1223 Mäuse im Alter von 12 Monaten makroskopisch erkennbare 
Knoten, die histologisch als HCC zu klassifizieren sind. Die Tumorhäufigkeit stieg mit dem Alter an um 
etwa ~35% (18/51) im Alter von 18 Monaten zu erreichen, wohingegen C57BL/6 Mäuse keine HCC 
Zusammenfassung 
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entwickelten (0/35; P<0.0001). Hepatitis B- und C-Viren (HBV, HCV) verursachen chronische 
Leberentzündung und HCC über bislang schlecht verstandene Mechanismen. Diese Arbeit zeigt eine 
Hochregulation des Cytokins Lymphotoxin (LT)  und seines Rezeptors (LTR) in HBV- oder HCV-
bedingter Leberentzündung und in HCC. Mittels Leber-spezifischer LT-Expression in Mäusen, welche 
Hepatitis und HCC entwickeln, kann ein kausaler Zusammenhang zwischen Leber-spezifischer LT-
Überexpression, Hepatits und HCC hergestellt werden. Die Entwicklung von HCC, die in einem Teil aus 
A6+ Oval-Zellen bestehen, hängt von Lymphozyten und der IKappa B Kinase , welche von Hepatozyten 
exprimiert wird, ab. Sie ist aber unabhängig von TNFR1. In vivo LTR-Stimulierung aktiviert Hepatozyten, 
welche sensitiv für LT sind. Eine Blockade des LTR bei LT-transgenen Mäusen mit Leberentzündung 
unterdrückt die HCC-Bildung. Somit stellt der LT-abhängige Signaltransduktionsweg einen bisher 
unbekannten, wesentlichen Pfad bei durch Hepatitis induzierter Leberkrebsentstehung dar. Die 
pharmakologische Hemmung der LTR-Signaltransduktion reduziert Pathogen- und ConcavalinA-
induzierten Leber-Schaden, während die Stimulierung des LTR, der auf Hepatozyten signalisiert, 
vorteilhaft während der Leber-Regeneration zu sein scheint. Diese Arbeit zeigt, dass die verstärkte 
hepatische LT-Expression in Mäusen schädlich ist, indem sie chronische Hepatitis und HCC verursachen 
kann. Verstärkte hepatische LTR-Signaltransduktion könnte potenziell von klinischer Relevanz sein, da 
LTR und dessen Liganden bei HBV- und HCV-bedingter Leberentzündung und HCC beim Menschen im 
Vergleich zu normalen Lebern oder nichtviral induzierten Leber-Krankheiten drastisch erhöht sind. So 
könnte hepatisches LT, wenn es limitiert aktiv während der Leber-Regeneration sezerniert wird, vorteilhaft 
sein. Es kann aber schädlich sein wenn es dauerhaft getriggert wird. Ich schlage vor, dass die 
Unterdrückung des hepatischen LTR Signaltransduktionsweges bei Leber-Krankheiten mit einer 
chronischen LT-, LT-Überexpression vorteilhaft sein könnte.  
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Selected Definitions  
Cytokines: Cytokines are signaling proteins, which either exist in a soluble or membrane bound form and 
that regulate immune mediated signalings through interactions with specific receptors. The action of 
cytokines may be autocrine or paracrine. 
 
Chemokines: Cytokines that recruit inflammatory cells to the site of inflammation by a process called 
chemoattraction. Therefore they are chemotactic cytokines. Some are considered pro-inflammatory and can 
be induced during immune responses in order to promote cells of the immune system to a site of infection, 
while others are considered homeostatic and are involved in controlling the migration of cells during normal 
tissue maintenance or development. 
 
Germinal centre: A structure found in the follicles of secondary lymphoid tissues composed of 
specialized B-lymphocytes. 
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Follicular dendritic cells (FDCs): Mesenchymal, radio-resistant cells that reside within white pulp 
follicles of germinal centres of lymphoid tissue. These cells possess long dendrites and carry intact antigens 
in immune complexes on their surfaces. These cells differ from dendritic cells as the latter are of 
hematopoietic origin. 
 
Inflammation: A complex response of the immune system to harmful stimuli like pathogens, cell death or 
other irritants, such as physical or chemical stimuli. Inflammation is an organism or organ specific strategy 
to remove damaging agents or stimuli in order to guarantee tissue remodeling and maintenance of organ 
integrity. The basic symptoms of inflammation are redness (rubor), swelling (tumor), heat (calor), pain 
(dolor) and deranged function (functio laesa). The first four have been known since ancient times. Loss of 
function was added to the definition of inflammation by Rudolf Virchow. Inflammation can be classified as 
either acute or chronic. 
Acute inflammation is an early innate immune response that is generally short and self-limiting. 
Characteristically neutrophils and macrophages, under specific circumstances, also eosinophils are the main 
hallmark cells present at a cellular level in acute inflammation. Under certain conditions acute inflammation 
can develop into a chronic inflammatory state that lasts longer and which may be prolonged in a way that 
the inflammatory immune response can even lead to considerable tissue destruction and loss of proper 
functionality. The cellular components being characteristic for chronic inflammation are predominantly 
lymphocytes and plasma cells. It is well established that these cells often organize themselves in secondary 
lymphoid organs. Inflammation of the liver is termed hepatitis.  
 
Lymphoreticular system (LRS): The lymphoreticular system is divided into primary and secondary 
lymphoid tissues. Primary lymphoid organs are anatomical sites where the cells of the LRS are generated, 
including bone marrow and thymus. Secondary lymphoid organs are specialized tissues to trap antigens, to 
allow the initiation of adaptive immune responses providing signals that sustain recirculating lymphocytes. 
Secondary lymphoid organs include the spleen, the lymph nodes, the appendix and the mucosa associated 
lymphoid tissues. Tertiary lymphoid tissues ectopically arise at sites of chronic inflammation. 
 
Lymphotoxin (LT): LT and LT are proinflammatory cytokines that are part of the tumor necrosis factor 
(TNF) superfamily. They are mainly expressed by B- and T- lymphocytes and natural killer (NK) cells. LTs 
exist as membrane bound heterotrimers (LT12 or LT21) or as secreted homotrimer (LT3). LTs bind to 
TNFR1, TNFR2 or LTR triggering a signaling pathway which is essential for the maturation and 
maintenance of secondary lymphoid organs and of follicular dendritic cells (FDCs).   
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1. Introduction  
1.1 The most important signaling pathways in liver diseases 
1.1.1 Overview about various signal transduction pathways  
Liver homeostasis and appropriate liver cell function is ensured by the action of various well established 
signaling pathways. These include the function of the vascular endothelial growth factor, IL-
6/gpl30/STAT3, insulin dependent pathways, the hepatic tumor necrosis factor signaling, the Fas/FasL 
signaling pathway, the TGF- and the Smad pathway in hepatic fibrogenesis, interferon signaling, the 
interaction of CD14 and Toll-like receptors, the Wnt/-Catenin pathway, the Notch signaling, calcium 
signaling, MAP kinase pathways, PI3K, PTEN, Akt, TOR-signaling and the NF-ĸB-signaling pathways. 
The liver has an important role as the major detoxifying organ of the body and as the first line of defense 
against ingested toxins and infectious agents. Consequently, the liver has conserved various adaptive 
responses including the ability to regenerate and protect itself against tissue damage (Fausto, 1999, 2000; 
Michalopoulos and DeFrances, 1997). Interleukin-6 (IL-6) has been demonstrated as critical during the 
acute response phase, proliferation and protection against injury in hepatic regenerative processes. While 
STAT3 appears to be the dominant signal in the IL-6/glycoprotein 130 (gp130)-mediated acute phase 
response and provides a basis for many of the hepatoprotective properties of IL-6/gp 130 signaling (Taub, 
2003), STAT3 does not account for the full proliferative effect of IL-6/gp 130, and it appears that the 
mitogen-activated protein kinase (MAPK) signaling downstream of IL-6/gp 130 also contributes to the 
proliferative effects. IL-6 binds to its receptor, IL-6R, that binds to the gp 130 receptor, activating a janus 
kinase (JAK), which is an intracellular tyrosine kinase (Heinrich et al., 2003). 
Stimulation of JAK results in tyrosine phosphorylation of gp130 at several sites and its 
autophosphorylation. Then tyrosine phosphorylation of gp130-associated STAT3 and SHP2 (SH2 domain 
containing tyrosine phosphatase) follows. This leads to signal transduction via the STAT3 and MAPK 
signal transduction pathways. This again results in the activation of the MAPK pathway and activation of 
STAT3 by tyrosine phosphorylation. Dimerized STAT3 is able to translocate into the nucleus and to 
activate gene transcription. The described process has been reported to promote liver regeneration and 
hepatoprotection against Fas and toxic damage. STAT3 is activated by tyrosine phosphorylation at a single 
site (Y705) and by serine phosphorylation at a MAPK consensus site within its transactivation domain. 
Tyrosine phosphorylation mediated by JAK is required for STAT3 dimerization, nuclear translocation, and 
DNA binding. 
Triggering gp130 leads not exclusively to STAT signaling but also to activation of the MAPK cascade. 
MAPK signaling is important for proliferation (Talarmin et al., 1999). IL-6 signaling might also directly 
activate PI3 kinase, protein kinase B and AKT which are other kinases that impact on cell survival 
(Heinrich et al., 2003). Efficient inhibitors of STATs include PIAS (protein inhibitor of activated STATs) 
and SOCS (suppressors of cytokine signaling) (Campbell et al., 2001; Chung et al., 1997). Knockout mice 
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for IL-6, gp130, STAT3 could demonstrate the importance of these molecules (Alonzi et al., 2001; Fattori 
et al., 1994; Kopf et al., 1994) in pathological liver states. 
 
1.1.2 The VEGF (Vascular Endothelial Growth Factor) signaling pathway 
Vascular endothelial growth factor (VEGF) has been reported to be the main inducer of angiogenesis. 
VEGF, targeting vascular endothelial cells, is known to play an important role in liver regeneration, hepatic 
fibrogenesis, portal hypertension and hepatocarcinogenesis (Benjamin et al., 1999; Ferrara and Davis-
Smyth, 1997). In chronic hepatitis C, an increase in hepatic VEGF expression and angiogenesis in portal 
tracts has been reported by one group (Medina et al., 2003) while another group did not find any differences 
in VEGF mRNA expression ratios among steatohepatitis, chronic hepatitis C and HCC (Shimoda et al., 
1999). Besides hypoxia, mutations in tumor suppressor genes, oncogenes and viral proteins also lead to the 
upregulation of VEGF during hepatocarcinogenesis. HCC is a strongly vascularized tumor and therefore 
depends on VEGF (Yamaguchi et al., 1998). During the process of hepatocarcinogenesis, expression of 
VEGF increases gradually from low-grade dysplastic nodules to high-grade dysplastic nodules and to early 
HCC (Park et al., 2000). The degree of VEGF expression during HCC development correlates with the 
vessel density (Park et al., 2000). High serum levels of VEGF significantly correlated with the presence of 
intrahepatic metastasis, presence of microscopic venous invasion, advanced stage and postoperative 
recurrence. Moreover, levels of biologically active VEGF in patients with malignant ascites are higher in 
comparison to patients with ascites due to non-malignant or cirrhotic causes (Zebrowski et al., 1999). 
 
Figure 1. Signaling pathways triggered by VEGF. The activity of VEGF is mediated through three receptor tyrosine 
kinases: VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), and VEGFR-3. VEGFR-1 is expressed on endothelial cells and 
monocytes mediating cell motility. The proliferative and mitogenic activities of VEGF, as well as vascular 
permeability, are mediated primarily through VEGFR-2. VEGFR-3, also known as Flt-4, being homologous with the 
neurophilin-1 receptor, is thought to mediate lymphoangiogenesis; adapted from (Giles, 2001).  
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1.1.3 The Tumor Necrosis Factor signaling pathway 
Tumor necrosis factor- (TNF) is a proinflammatory cytokine involved in liver regeneration, injury and 
inflammation. It is produced primarily by activated macrophages, but can also be produced by epithelial 
cells, adipocytes and endothelial cells (Kern et al., 2001; Loffreda et al., 1997). TNF is produced as a 26-
kDa type II transmembrane protein with an extracellular C-terminal domain for receptor interaction, a 
single transmembrane domain, and an intracellular N-terminal domain essential for cell signaling. The 
membrane form of TNF is a homotrimer (Banner et al., 1993). A soluble form (sTNF) is generated through 
proteolytic cleavage of the transmembrane form by the metalloprotease TNF converting enzyme (TACE), 
being a member of the mammalian adamalysin (ADAM) family (Black et al., 1997). The bioactivity of 
membrane-bound TNF is higher than that of sTNF.  
TNF exerts its biological effects by binding to the TNF receptor type 1 (TNF-R1) or TNF receptor type 2 
(TNF-R2). These receptors belong to the TNF receptor superfamily. Whereas the membranous and soluble 
forms of TNF induce equivalent activation of TNF-R1, full activation of TNF-R2 needs membrane-bound 
TNF (Grell et al., 1999). Recent studies have demonstrated that rather than receptor trimerization occurring 
after ligand binding, the TNF-R exists as a preformed multimer to which the ligand binds in its 
homotrimeric form (Aggarwal, 2003). Both receptor types are expressed in the liver, but it is unclear 
whether type II receptors are expressed only on non parenchymal cells (NPC) such as Kupffer cells, or on 
hepatocytes. TNF-R1 is generally required for the induction of apoptosis, while the role of TNF-R2 seems 
to be less well defined. TNF-R2 possesses a lower binding affinity and higher dissociation rate for TNF 
than TNF-R1. This suggests that TNF-R2 may transiently bind and then release TNF, in order to increase 
local concentrations of TNF that acts on TNF-R1 (Grell et al., 1998a; Grell et al., 1998b). This phenomenon 
is known as ligandpassing and may allow TNF-R1 activation at much lower TNF concentrations (Barbara et 
al., 1994). Alternatively, overexpression of TNF-R2 can also inhibit TNF signaling by competing with 
TNF-R1 for the ligand. This is why the overall biological effect of TNF might depend, at least partially, on 
the relative ratio of the two receptors (Fotin-Mleczek et al., 2002). Initially, the adaptor molecule TRADD 
binds to the TNF-R1. The survival pathway is activated following recruitment of TRAF-2 and RIP to 
TRADD. This complex triggers IKK, which phosphorylates IKB. Phosphorylated IKB undergoes 
proteasomal degradation, releasing NF-ĸB heterodimers which translocate to the nucleus and activate genes 
necessary for TNF-induced hepatocyte proliferation. In parallel, NF-ĸB-regulated gene products block the 
TNF driven apoptotic death pathway. Signaling through TRAF-2 leads to activation of the JNK/cJun/AP-1 
pathway. AP-1-dependent gene expression promotes hepatocyte proliferation, but sustained AP-1 activation 
can also induce the apoptotic death pathway.  
In the death pathway, the TRADD-TRAF-2-RIP complex dissociates from the TNF-R1 and recruits FADD 
and procaspase-8. Caspase-8 is released after its autolytic activation. Caspase-8 cleaves Bid, resulting in a 
truncated and active Bid which activates the pro-apoptotic Bcl-2 family members Bax and Bak. Their 
oligomerization and integration into the mitochondrial membrane leads to cytochrome c release. The 
complex of cytochrome c and APAF-1 recruits procaspase-3 resulting in apoptosis. Caspase-8 activation 
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also causes release of the lysosomal enzyme cathepsin B, which induces the mitochondrial death pathway. 
Binding between TNF and TNF-R occurs at the plasma membrane through interactions between the 
receptor and the trimeric ligand. This results in a conformational change in the receptor and translocation of 
the receptor-ligand complex to lipid-enriched membrane microdomains, known as lipid rafts. There is 
evidence that the sources of TNF production after partial hepatectomy are biliary and endothelial cells 
(Loffreda et al., 1997). Of note, neutralizing anti-TNF antibodies inhibit hepatocyte proliferation following 
partial hepatectomy, clearly implicating TNF as a hepatocyte mitogen in this model (Akerman et al., 1992). 
Studies of partial hepatectomy in tnfr1-/- mice have basically confirmed these data. Inhibition of the 
biological activities of TNF leads to reduced activation of the downstream transcriptional regulators NF-ĸB, 
STAT3 and AP-1 (Yamada et al., 1997). On the other hand, posthepatectomy liver regeneration was normal 
in tnfr2-/- mice. Absence of the type 2 receptor had essentially no effect on NF-ĸB and STAT3 binding or 
IL-6 production. However, it caused a delay in AP-1 binding. Therefore it is believed that TNF-induced 
proliferation occurs exclusively through TNFR1 mediated signaling. Infiltrating cytotoxic T-lymphocytes 
decrease HBV gene expression and replication in the liver of HBV transgenic mice through the secretion of 
TNF as well as IF and IF(McClary et al., 2000). In summary, TNF has been proposed to be important in 
human liver diseases (Khoruts et al., 1991; Streetz et al., 2000).  
 
1.1.4 The NF-B signaling pathway 
Nuclear factor (NF)-B was first described in 1986 as a nuclear factor necessary for immunoglobulin K 
light chain transcription (Sen and Baltimore, 1986a, b). It exists in virtually all known cell types, and 
regulates the transcription of many genes including those involved in immune and inflammatory response, 
cell death and proliferation (Karin and Lin, 2002). The mammalian the NF-ĸB family includes five cellular 
DNA-binding subunit proteins: p50 (NF-ĸB 1), p52 (NF-ĸB 2), c-Rel (Rel), p65 (Re1A) and RelB. The NF-
ĸB DNA-binding subunits share an N-terminal Rel homology domain (RHD). It forms a unique butterfly-
shaped structure composed of 13 strands arranged in a pattern similar to immunoglobulin domains. This 
region is responsible for DNA binding, dimerization, nuclear translocation and interaction with the 
inhibitory IKB proteins. RelA (p65), RelB and c-Rel contain C-terminal transactivation domains that trigger 
target gene transcription. Of these proteins, p65, which contains two potent transactivation domains (TADs) 
within its C-terminus, mediates the strongest gene activation (Schmitz and Baeuerle, 1991). The other two 
members, p52 and p50 become active by either constitutive (p105) or regulated (p100) processing steps 
(Amir et al., 2004). They are generally not activators of transcription, unless they form heterodimers with 
p65, RelB or c-Rel. NF-ĸB commonly refers to a p50/p65 heterodimer. The activity of NF-ĸB is controlled 
by IBs, a family of cytoplasmic inhibitory proteins that share a number of protein/protein interaction 
domains called ankyrin repeats. The precursors p105 and p100 are also included in this family, since they 
contain IKB-like repeats and therefore inhibit NF-ĸB activation (Baeuerle and Baltimore, 1996). NF-ĸB is 
effectively sequestered in the cytoplasm by IB in an inactive state via complex formation and the ability of 
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IKB to mask the nuclear localization site (NLS) of NF-ĸB. As IB is an NF-ĸB-target gene, it also 
terminates NF-ĸB activation at transcriptional level: increased synthesis of IKB shuts down NF-ĸB-
induced gene expression by IB-mediated nuclear export of the DNA-binding subunits, thereby acting in a 
negative feedback loop (Arenzana-Seisdedos et al., 1997). To date, the so-called canonical and non-
canonical pathways and the DNA damage-induced NF-ĸB pathway are established. Moreover, further 
mechanisms such as p65 posttranslational modifications regulate the activity of this transcription factor. 
The canonical pathway is probably the most important mediator of NF-ĸB activation in response to 
cytokines. An essential step during this pathway is the disruption of cytoplasmic NF-ĸB. After 
phosphorylation, polyubiquitination of IB- by a specific, constitutively active ubiquitin ligase takes place 
(Karin, 1999). The ubiquitin-marked IB proteins are quickly degraded by the 26S proteasome, resulting in 
unmasking of the nuclear localization site (NLS) of NF-ĸB. This allows nuclear entry, DNA binding and 
transcriptional activity of NF-ĸB. The activation of this IKB-independent pathway involves the IKK subunit 
IKK and results in the release of p52/RelB and p50/RelB dimers (Senftleben et al., 2001; Xiao et al., 
2001). It is induced for example by LT and leads to NIK- and IKK-dependent processing of the p100 
precursor protein, which results in the release of p52 (Pomerantz and Baltimore, 2002). LT employs 
canonical and non-canonical pathways. While in the canonical pathways, signaling is abrogated quickly by 
induction of IB, the non-canonical pathway comprises slower p100 processing, thus inducing a delayed 
NF-ĸB activation (Coope et al., 2002; Dejardin et al., 2002). DNA-damage-induced NF-ĸB activation, in 
contrast to the previously described pathways, occurs in an IKK-independent manner. It has been observed 
after doxorubicin stimulation or UV radiation and involves mitogen-activated protein kinase (MAPK)-
dependent alternative IKB phosphorylation (Kato et al., 2003). Post-translational modifications of NF-ĸB 
subunits may also influence NF-ĸB activation. In particular, the phosphorylation of p65 and also its 
acetylation appear to modify its transcriptional activity significantly. In vitro, IKK and IKK can form 
homo- and heterodimers (Zandi et al., 1998). 
Besides its anti-apoptotic function in TNF-mediated liver apoptosis, NF-ĸB might also play a role in other 
apoptotic pathways. ConA stimulation in mice leads to activation of NF-ĸB, and this pathway is blocked by 
anti-TNF treatment (Trautwein et al., 1998). HBV is the leading cause of hepatic failure worldwide, 
followed by HCV infection. Both HBV and HCV modulate the NF-ĸB pathway (Tai et al., 2000). 
Numerous chemical compounds and viral vectors that inhibit NF-ĸB have been developed or are under 
development (Karin et al., 2002). The ubiquitous presence of NF-ĸB in virtually all cells and its 
involvement in different cellular pathways makes administration of drugs which inhibit NF-ĸB non-
specifically possibly dangerous. Especially, the subunits of the IKK complex are widely discussed as 
therapeutic targets for development of anti-inflammatory and anticancerous agents (Kato et al., 2003). 
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Classical Pathway                              Alternative Pathway 
 
Figure 3. Signaling pathways leading to the activation of different nuclear factor B transcription factors. The 
classical pathway is induced by pro-inflammatory triggers such as TNF, LPS and DNA-damaging agents. This leads to 
an IKK and IKK dependent phosphorylation of IKBs, resulting in their proteasomal degradation, and the subsequent 
liberation of NF-ĸB dimers. These subsequently translocate into the cell nucleus. The alternative NF-ĸB pathway is 
activated by certain TNF family members and leads, independent of IKK and IKK to the phosphorylation of P100 
by IKK and the degradation of its carboxy-terminal part by the action of the proteasome. Finally, p52-Rel-B dimers 
translocate to the nucleus; from (Karin and Greten, 2005). 
 
Figure 4. Selected ligands and receptors of the TNF / lymphotoxin family. The TNF signaling pathway is 
activated by TNF or LT3-induced signaling through both TNF receptors, TNFR1 (p55) and TNFR2 (p75). Regarding 
the LT/LIGHT-dependent pathway signal transduction is mediated by the LT receptor (LTR) that binds two 
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ligands, the LT12 heterotrimer or homotrimeric LIGHT. LIGHT might also signal via the HVEM; modified from 
(Gommerman and Browning, 2003). 
1.1.5 The Interferon signaling pathway / JAK-STAT signaling pathway  
The interferons (IFNs) are cytokines produced by many cell types responding to viral infections and other 
triggers. Two types of IFNs exist. Type I IFNs are secreted in response to viral infections by various cell 
types. Type II IFN, also known as IFN, is produced by activated T-cells and macrophages upon mitogenic 
or antigenic stimulation of the immune defense machinery. It is involved in antigen-specific immune 
responses. Upon recognizing viral antigens, the cell activates different signaling cascades in order to 
produce cytokines that both inhibit pathogen replication and stimulate immune responses (Akira et al., 
2001; Huang et al., 2001). After specific phosphorylations, interferon regulatory factor 3 (IRF3) dimers 
migrate into the nucleus to stimulate the expression of certain IFNs during the very early phase of the 
cellular response to infections, whereas IRF7 is recruited later for amplifying the interferon response. 
Binding of endogenous secreted interferons, or of exogenous interferon in treated patients, to their cell 
surface receptors activates a tyrosine kinase signaling cascade which leads to the activation of latent 
cytoplasmic STATs. Current therapy of chronic hepatitis C virus (HCV) infection is based on type I 
interferon (IFN). Despite the introduction of new potent antiviral drugs able to inhibit hepatitis B virus 
(HBV) replication, type I IFNs are still commonly used in the treatment of HBV-infected patients and 
represent the only treatment that can efficiently achieve a permanent suppression of HBV replication and 
HBsAg loss. Both transformed and virally infected cells have evolved mechanisms to resist the biological 
activities of IFNs. Interferon-stimulated genes encode for proteins displaying strong antiviral, 
antiproliferative and anti-tumoral activity. IFNalso regulates antiviral immune responses involving 
dendritic and natural killer cells (Biron, 2001). However, the efficacy of IFN treatment in human tumors is 
hampered by rapid development of resistance. Viruses have developed different strategies to intercept IFN 
signaling, in order to inhibit IFN-induced antiviral responses (Katze et al., 2002). Many viruses perturb 
signaling components of the JAK-STAT pathway, thus preventing the proper cellular response to IFN. 
Among the viral factors, infection with HCV types 1 and 4, high viral load, long-lasting HCV infection, 
higher levels of HCV, NS5A variability within and outside the so-called interferon sensitivity determinant 
region (ISDR) are believed to be the best predictive factors of poor response to IFN. Decreased levels of 
IFN receptor expression are found in HCV patients and IFN receptor mRNA levels are higher in the 
responders than in non-responders suffering from chronic active hepatitis irrespective of HCV genotypes 
(Fujiwara et al., 2004). While HCV products inhibit IFN signaling and IFN-induced antiviral activity, IFN 
itself inhibits HCV "replicon amplification" (Chung et al., 2001). 
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Figure 5. Activation of the JAK-STAT pathway and additional signaling pathways by three types of IFNs. Type 
I IFNs (only IFN-α and IFN-β are shown for simplicity), type II IFN (IFN-γ) and type III IFNs (IFN-λ1/ IL-29, IFN-
λ2/IL-28A and IFN-λ3/IL-28B) bind to their receptor complex as shown. All of them activate the canonical JAK-
STAT pathway. Type III IFNs were reported to activate STAT1 and STAT2 through the activation of JAK kinases, 
leading to downstream gene induction in an ISGF3- or GAF/AAF-dependent manner. It is not yet clear which JAKs 
are associated with the type III receptor subunit (IFN-λR1). STAT5 is associated with Tyk2, while v-crk sarcoma 
virus CT10 oncogene homologue (avian)-like (CrkL) constitutively associates with the guanine-nucleotide-exchange 
factor (GEF) C3G. Following type I IFN stimulation, CrkL is recruited to Tyk2, which phosphorylates both STAT5 
and CrkL, resulting in heterodimer formation. This dimer translocates into the nucleus to activate GAS-mediated gene 
induction. Type I IFNs also activate the PI3-kinase-mediated signaling pathway downstream of JAK1 and Tyk2, 
through the phosphorylation of insulin receptor substrate (IRS)-1 and IRS-2, most probably independently of STATs. 
The activated PI3-kinase consequently increases the activities of v-akt murine thymoma viral oncogene homologue 3 
(Akt) and protein kinase Cδ (PKCδ). Moreover, type I IFNs can activate MAP kinases, the so called extracellular-
signal-regulated kinase 2 (ERK2) and p38, both of which are capable of phosphorylating Ser 727 of STAT1 in vitro; 
from (Takaoka and Yanai, 2006).  
 
1.1.6 The Wnt/-catenin signaling pathway 
The role of the Wnt/-catenin pathway is well established in vertebrates in embryogenesis and 
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carcinogenesis (Pennisi, 1998). The importance of the Wnt/-catenin pathway in liver development and 
hepatocellular carcinogenesis has been discussed. The Wnt/-catenin pathway appears to be critical for 
biliary epithelial cell growth (Sekhon et al., 2004). A significant increase in the total -catenin protein 
within the first few minutes after hepatectomy was observed. This was mediated by an epigenetic or post-
translational mechanism and it occurred independently of transcriptional modifications (Monga et al., 
2001). Nuclear and cytoplasmic localization of -catenin have been shown in 90 - 100% of 
hepatoblastomas (Jeng et al., 2000). In addition, abnormal cytoplasmic and/or nuclear localization of -
catenin was observed in 30 - 46% of hepatic adenomas (Chen et al., 2002). In contrast, no significant 
changes in the pathway were observed in FNH. Altered Wnt/-catenin activation has been demonstrated in 
many cancers and it is one of the important aberrant pathways in HCC in man and animals (Laurent-Puig et 
al., 2001; Polakis, 2000). Moreover, more than 40% of HCV-associated HCC have been reported to display 
mutations in the -catenin gene and nuclear accumulation of the respective protein (Huang et al., 1999) 
while HBV-related HCC display an overall lower frequency of -catenin mutations (Boutros et al., 1998). 
Although mutations in its gene were infrequent, aflatoxin-driven HCC have been described to frequently 
accumulate -catenin in around 45% of cases (Devereux et al., 2001).  
 
Figure 6. The Wnt signaling pathway. The Wnt family consists of more than 15 closely related secreted 
glycoproteins. Receptors for the Wnt proteins are members of the frizzled family of transmembrane proteins, and the 
Wnt signal is transduced to a cytoplasmic protein, Dishevelled (Dvl). Upon activation by the Wnt signal, Dvl inhibits 
the activity of glycogen synthase kinase-3β (GSK-3β). In the absence of the Wnt signal, GSK-3β phosphorylates β-
catenin and induces the degradation of β-catenin. Thereby, the Wnt signal induces the accumulation of β-catenin, 
which in turn associates with TCF/LEF family transcription factors, altering the expression of Wnt signaling target 
genes; from (Akiyama, 2000).  
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1.2 The TNF superfamily with focus on Lymphotoxin  
1.2.1 The TNF superfamily 
Up to date, more than 40 members of the TNF superfamily are known (Aggarwal, 2003). Cytokines of this 
family can occur as secreted or membrane-bound proteins. They are critically involved in the regulation of 
cell growth, differentiation, and activation of immune cells by mediating signals to effector immune cells. 
LTs have been identified as one of the most important factors in lymphoid organogenesis, organization and 
maintenance of specified lymphoid tissue (Futterer et al., 1998; Mebius et al., 1997; Yoshida et al., 1999). 
LT is indispensable for maintenance of secondary lymphoid organ architecture (Fu et al., 1998b; Rennert et 
al., 1996; Tumanov et al., 2003; Wang et al., 2001). LT and TNF were first identified in 1975 and their 
respective cDNAs were then cloned (Locksley et al., 2001). LT and many ligands such as TNF, CD40L, 
LIGHT, FasL, BAFF, and their corresponding receptors belong to the TNF receptor superfamily (Aggarwal, 
2003; Fu et al., 1998b; Locksley et al., 2001). LT and LT which are proinflammatory cytokines are 
cytotoxic to normal and transformed cells in vitro (Ruddle and Waksman, 1967). LT, LT and TNF are 
structurally similar, including their assembly into functionally active homotrimers and / or heterotrimers. 
Remarkably, the genes encoding for LT, LT, and TNF are also in close proximity to each other, within 
the major histocompatibility locus (Muller et al., 1987). Most TNF superfamily members are expressed by 
immune cells. LTs are mainly expressed by natural-killer cells (NK-cells), by lymphoid tissue inducer cells 
(LTIs), on the surface of B-lymphocytes and by activated T-lymphocytes. The TNF superfamily ligands are 
type II transmembrane proteins (intracellular N-terminus) that are biologically active as self assembling, 
non-covalent bound trimers. The LT subunit in the heterotrimeric complex modifies the receptor binding 
specificity to engage with high affinity the LT receptor. This is expressed by stromal cells (Browning et 
al., 1993; Cupedo et al., 2004). LT mRNA expression is inducible in B-cells, while LT mRNA is 
constitutively produced. The generation of surface LT depends on the formation of complexes with LT 
(Worm and Geha, 1994). Surface LT expression enhances production and secretion of homeostatic 
chemokines by stromal cells within the spleen and other secondary lymphoid organs (Ngo et al., 1999; 
Shakhov et al., 2000). Homeostatic chemokines, which are expressed by LT-responsive cells like for 
example FDCs, upregulate surface expression of the LT complex on B-lymphocytes (Ansel et al., 2000), 
and signal as a positive feedback loop which is required for the organization of lymphoid follicles and for 
the formation of tertiary lymphoid follicles in non-lymphoid organs. It therefore becomes increasingly 
apparent that LT-signaling controls secondary lymphoid organogenesis (Browning et al., 1993; Drayton et 
al., 2003). Ectopic expression of LT in the kidney or pancreas leads to the generation of lymphoid 
aggregates, resembling tertiary folliclels (Kratz et al., 1996; Picarella et al., 1992). These are quite similar to 
activated lymphoid follicles found in spleen or in lymph nodes. 
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1.2.2 The TNF superfamily members 
The pro-inflammatory and homeostatic cytokines LT and LT are members of the TNF superfamily. 
Under physiological conditions LTs are expressed by activated T-, B-, NK- and lymphoid tissue inducer 
cells (Fu et al., 1998b; Ware, 2005) and are crucial for organogenesis and maintenance of lymphoid tissues 
(Tumanov et al., 2003). Whereas LT contains a transmembrane domain, LT is soluble. Consequently, LT 
can exist as membrane bound heterotrimers (LT12 or LT21) interacting with LTR or as soluble 
secreted homotrimers (LT3) triggering TNF receptor 1, 2 (TNFR1, TNFR2) and the herpes virus entry 
mediator receptor (HVEM) (Browning et al., 1997; Ware, 2005). LTR and TNFR1 signaling can be 
activated by the HCV-core protein (Chen et al., 1997; Zhu et al., 1998) involving the canonical or non-
canonical NF-ĸB signaling pathways (Ware, 2005; You et al., 1999). Furthermore, HBV- or HCV-
infections lead to increased hepatic LT expression in vivo and in vitro (Lee et al., 2005; Lowes et al., 2003) 
and HCV replication has been demonstrated to depend on components of the LT signaling pathway in 
vitro (Ng et al., 2007).
LTs can directly act on hepatocytes which physiologically express high levels of LTR but little LT 
(Browning and French, 2002). T-cell-derived LT and LIGHT (LT-like, exhibits inducible expression, 
competes with HSV glycoprotein D for HVEM, expressed by T-lymphocytes) signaling to hepatocytes 
controls lipoprotein homeostasis (Lo et al., 2007). In addition, LT signaling is important for liver 
regeneration through T-cell-derived LT expression (Tumanov et al., 2008) and regulates HSC function and 
wound healing (Ruddell et al., 2009). Thus, hepatic LTR signaling controls liver homeostasis in both 
health and disease. 
 
1.2.3 NF-ĸB and tumor development 
Triggering TNFR1 or LTR induces the classical and alternative NF-ĸB signaling pathways, which are 
linked to inflammation-induced carcinogenesis (Greten and Karin, 2004). However, the precise role of these 
pathways in HCC pathogenesis is controversial (Vainer et al., 2008). Mice lacking IKappa B kinase  
(IKK specifically in hepatocytes (IKKhep) exhibit a marked increase in DEN-induced HCC formation 
suggesting a protective function of IKK in HCC development (Maeda et al., 2005). In contrast, NF-ĸB 
signaling promotes HCC development in mdr2-/- mice and anti-TNF treatment is protective (Pikarsky et 
al., 2004). Interestingly, mice with a hepatocyte-specific deletion of IKK develop steatohepatitis and HCC 
(Luedde et al., 2007). Consequently, the role of NF-ĸB signaling in hepatocarcinogenesis might depend on 
the mouse model and the type or degree of liver inflammation and injury (Vainer et al., 2008). During my 
thesis, I investigated a possible causal relationship between sustained hepatic LTR-signaling, chronic 
hepatitis and HCC development. 
Introduction 
 
27
1.3 Overview on liver diseases 
1.3.1 Liver anatomy and physiological function 
The liver is divided by the ligamentum falciforme and the ligamentum teres hepatis in the bigger right lobe 
and the smaller left lobe. From the liver gate arches the quadrate lobe to the front, at the back the dorsal 
caudate lobe. The organ contains a crude capsule which is transected by sensitive nerves that are 
responsible for pain when stretching the liver capsule due to liver enlargement. The internal anatomical 
structure is given by the branching of the liver vessels defining liver segments. These allow segmental 
surgical resections. The morphological subunits, the liver lobes, are consisting of liver cell plates and 
intervening sinusoids. These sinusoids converge to the central vein. The main entrance fields lie between 
the liver cell plates and contain vessels, nerves and bile ducts. They are surrounded by liver cells of the 
parenchymal border plate. The sinusoids are lined by Kupffer cells and endothelial cells. The incoming 
blood is provided by the branches of the portal vein and the hepatic artery which lie in the main entrance 
field. The blood flows through the sinusoids into the central vein in the centre of the liver lobes. The central 
veins merge to sublobular veins and to the hepatic veins by which the blood from the liver runs off. The bile 
flows in the opposite direction. Bile is secreted into bile canaliculi which have a wall formed by the 
canalicular liver cell membranes. The other drain of the bile occurs via the canals of Herring (cholangioles), 
the ductuli and the interlobular cystic ducts in the main entrance fields, and about the right and left hepatic 
duct in the ductus choledochus. However, Rappaport description based on the functional circumstances 
does better justice to the acinar structure of the liver. The centre of the acinus gets blood from parts of the 
main entrance field and the smallest branches of the portal artery and the hepatic artery. The central veins 
lie within the acinar periphery. The Rappaport zone 1 lies around the main entrance field of the liver 
parenchyma for receiving oxygen and blood richer in nutrient and richer in hormone than the Rappaport 
zone 3 lying around the central vein. The intervening Rappaport zone 2 takes an interposition. The liver 
cells form approximately 80% of the hepatic cell population. They own functionally different membranes 
(sinusoidal, lateral, canalicular). The canalicular membranes form the bile canaliculi carrying numerous 
microvilli. Between the liver cell plates and the endothelial cells lies the space of Disse. The sinusoids lined 
by endothelial cells are fenestrated. As a continuous basal membrane is absent, a communication is possible 
between sinusoid and the space of Disse. The Kupffer cells represent the monocyte-macrophage system 
within the liver and play an important role in defense processes. In the space of Disse specified cells, the 
lipid and vitamin A containing, so called Ito- or stellate cells lie. The liver fulfils metabolic (glucose 
metabolism, fat metabolism), synthetic (serum proteins, coagulation factors), catabolic and 
biotransformatory duties (dismantling of serum proteins, hormones, transformation of foreign matters) as 
well as storage (glykogen, triglyceride, metals, vitamins) and removal functions (biliary components). 
Hence, a disturbance of the liver function is connected with a distinctive clinical symptomatology.  
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1.3.1.1 Liver cell types 
1.3.1.1.1 Hepatocytes 
Hepatocytes are the main cellular components of the liver. They display an eosinophilic cytoplasm, 
reflecting numerous mitochondria, and basophilic stippling due to large amounts of rough endoplasmic 
reticulum and free ribosomes. Brown lipofuscin granules are also detectable together with irregular 
unstained areas of cytoplasm corresponding to cytoplasmic glycogen and lipid stores which are removed 
during routine histological preparation. The average life span of a human hepatocyte is about 5 months. 
Hepatocytes display a high regenerative capacity. Their nuclei are round with dispersed chromatin and 
prominent nucleoli. Anisokaryosis is common and reflects tetraploidy and polyploidy, a normal feature of 
over 50% of hepatocytes. Binucleated cells are quite common. Hepatocytes are organised into plates 
separated by vascular channels (sinusoids), an arrangement supported by a reticulin (collagen type III) 
network. The hepatocyte cords are one cell thick in humans as well as in mice. Sinusoids display a 
discontinuous, fenestrated endothelial cell lining. The endothelial cells have no basement membrane and are 
separated from the hepatocytes by the space of Disse which drains lymph into the portal tract lymphatics. 
The hepatocyte manufactures serum albumin, fibrinogen, and the prothrombin group of clotting factors. It is 
the main site for the synthesis of lipoproteins, ceruloplasmin, transferrin, complement and glycoproteins. 
Hepatocytes manufacture their own structural proteins and intracellular enzymes as well. Synthesis of 
proteins is undertaken by the rough endoplasmic reticulum (RER), and both the rough and the smooth 
endoplasmic reticulum (SER) are involved in secretion of the proteins formed. The endoplasmic reticulum 
(ER) is involved in conjugation of proteins to lipid and carbohydrate moieties synthesized by, or modified 
within, the hepatocytes. The liver produces fatty acids from carbohydrates and synthesizes triglycerides 
from fatty acids and glycerol. Hepatocytes also synthesize apoproteins with which lipoproteins (VLDL, 
HDL) are exported. Hepatocytes are able to metabolize, detoxify, and inactivate exogenous compounds 
such as drugs, and endogenous compounds such as steroids. In addition, it should be mentioned that 
hepatocytes are polar, meaning that they contain two membrane domains. One is the apical membrane 
domain. This is formed by a small bile duct (canaliculus bilifer) and its neighbouring cell. This membrane 
carries numerous microvilli and secretes bile. The small bile ducts are sealed by a zonula occludens, zonula 
adhaerens and macula adhaerens. The other domain is the so called basolateral membrane. The wide 
basolateral membrane domain borders on the space of Disse or on the sinusoids being responsible for the 
material exchange with the blood.  
 
1.3.1.1.2 Biliary epithelial cells 
Beside from hepatocytes also from other cell types in the liver tumors can arise. These cell types are the so 
called cholangiocytes. These cells are the origin of cholangiocellular carcinomas (CCC). Cholangiocytes 
are polarized cells constituting about 5 % of the whole liver mass. These cells are critical for bile production 
as bile has to be modified several times until it reaches the duodenum. In man some primary biliary diseases 
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are well known, such as PBC, PSC, biliary atresia or cystic fibrosis. It has become clear that for the 
regulation of ductular bile secretion and bile duct proliferation cholangiocytes depend on second 
messengers like cAMP, calcium and kinases such as PKC, MAPK and PI3-K. As cholestasis is one of the 
major manifestation types of liver diseases it appears to be important to understand what the 
pathophysiological prerequisites for cholangiocellular dysfunction are as these lead to secretion impairment 
(Roberts et al., 1997). Various models of ductular cholestasis using for example bile duct ligation could 
show that expression of the secretin receptor and cAMP producrtion are still preserved. In contrast, these 
functions are even enhanced (Alpini et al., 1994). On the other hand, calcium signaling pathways are 
severely impaired in various cholestatic models and diseases (Alvaro et al., 1997). As I am mainly 
interested in inflammation driven carcinogenesis it is of high interest that a major predisposing factor for 
the development of CCC is an inflammatory state within the bile ducts. Here inflammation induces a p38 
MAPK stress signaling cascade. Thereby cholangiocellular proliferation might be facilitated by 
translational regulation of protein synthesis. Therefore, gene silencing of eIF-4E (eukaryotic translation 
initation factor 4E), has been suggested as a possible therapeutic strategy (Yamagiwa et al., 2003). Since 
cholangiocytes are accessible by percutaneous or endoscopic interventions, and as at least in animal models 
introducing genes into cholangiocytes via retrograde biliary infusions has been demonstrated, gene 
therapies might become an attractive therapeutic strategy for treating CCC (Hommel et al., 2003). 
 
1.3.1.1.3 Kupffer cells 
These liver resident macrophages are named after the pathologist C. von Kupffer, who first recognized this 
non-parenchymal cell (NPC). Kupffer cells (KC) represent about 35% of the hepatic NPC in normal adult 
mice. These cells reside within the lumen of the liver sinusoids, adherent to the endothelial cells which form 
the blood vessel walls. KC, found in highest number in the periportal area, constitute the first macrophage 
line of the body to come in contact with bacteria, bacterial endotoxins, and microbial debris derived from 
the gastrointestinal tract, being transported to the liver via the portal vein (Fox et al., 1987). Thereby, KC 
are constantly exposed to factors which act as macrophage activators. Upon activation, KC themselves, 
release various products, including cytokines, prostanoids, nitric oxide, and reactive oxygen species 
(Decker, 1990). In other words, KC are intimately involved in the liver's response to infection, toxins, 
ischemia, resection and various other stresses. The most important activators of KC are the complement 
factors C3a and C5a (Schieferdecker et al., 2001; Su, 2002). LPS activates KC directly via TLR signaling 
(Su, 2002). In addition, high LPS concentrations can stimulate KC indirectly via complement activation in 
either the portal or the systemic circulation (Jaeschke et al., 1994). After complement activation, cleavage 
of C3 and C5 leads to the generation of the potent anaphylatoxins C3a and C5a followed by the activation 
of their receptors C3aR and C5aR (Ember and Hugli, 1997). Moreover, hepatic CD14 expression is 
increased in various liver diseases (Su, 2002). Signaling through TLR4 requires MD-2, a secreted protein 
closely linked to the extracellular domain of TLR4. Downstream of TLR4, signaling occurs via MyD88, 
which associates with the interleukin1 receptor-associated kinase (IRAK) and TNF-activated factor 6 
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(TRAF-6). TRAF-6 mediated signaling pathways activate NF-ĸB, which results in the production of 
proinflammatory cytokines (Akira et al., 2001). As KC eliminate activated neutrophils they suppress their 
production of toxic metabolic compounds and degradative enzymes. Thus, activation of KC is necessary for 
the optimal regenerative ability of the liver. Hepatocyte proliferation in vivo, at least in part, occurs through 
NF-ĸB and STAT3. The respective events have been shown to be triggered by leukocyte-KC interaction 
under the mediation of the intracellular adhesion molecule ICAM-1 (Selzner et al., 2003) as livers from 
ICAM-1-deficient mice exhibited impaired regenerative capacitiy after 70% hepatectomy, which was 
paralleled by a dramatic decrease in leukocyte recruitment and tissue TNF and IL levels. Taken together, 
KC are intimately involved in the hepatic response to various damaging insults.  
 
1.3.1.1.4 Hepatic stellate cells 
Hepatic stellate cells (HSC) are located along the sinusoids and they form the space of Disse as they are 
lying in close proximity to the hepatocytes as well as to the sinusoidal endothelium. The whole 
microcirculatory network is covered by the HSC although they just constitute about 5 - 8 % of the entire 
liver cell number. This cell type is important as it is potentially involved in the fibrogenic transformation of 
liver tissue following chronic injury. Because of their anatomical location, ultrastructural features, and 
similarities with pericytes regulating blood flow in other organs, HSC have been functionally described as 
liver-specific pericytes. The most evident ultrastructural feature of HSC in normal adult liver is the presence 
of cytoplasmic lipid droplets ranging in diameter from 1 to 2 m. These lipid droplets are involved in the 
hepatic storage of retinyl esters, indicating the storage of retinoids by HSC (Blomhoff and Wake, 1991). 
Interestingly, after prolonged culture on plastic, HSC undergo activation from a quiescent "storing" 
phenotype to a highly proliferative "myofibroblast-like" phenotype. The activated phenotype is 
characterized by a dramatically increased synthesis of collagen types I and III, which appears predominant 
over the synthesis of collagen type IV and other ECM components. Various soluble factors, including 
growth factors, cytokines, chemokines and oxidative stress products, have been reported to influence the 
activation of HSC. After activation of stallate cells into myofibroblasts due to tissue injury, they start to 
proliferate and contribute to scarring, fibrosis or cirrhosis.  
 
1.3.1.1.5 Hepatic sinusoidal endothelial cells 
Hepatic sinusoidal endothelial cells (HSEC) are a morphologically distinct cell population that lines the 
liver sinusoids. Features that distinguish HSEC from endothelial cells in other organs and in larger hepatic 
vessels are the presence of multiple fenestrae throughout the cells and the lack of an underlying basement 
membrane. The sinusoids are located between hepatocyte plates and they start at the portal tract and 
terminate at the central vein. The sinusoids are separated from the adjacent hepatocytes by the 
perisinusoidal space, termed the space of Disse. HSEC are the first cells in contact with blood flow into the 
sinusoids and serve to compartmentalize the vascular sinusoidal channels from the hepatic parenchyma. As 
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they are smaller than red and white blood cells, there is distortion of both cell types and the sinusoids during 
passage of blood cells (Fraser et al., 1995). This process has been referred to as "endothelial massage", 
which allows efficient exchange of compounds from the blood through sinusoidal fenestrae into the space 
of Disse. 
 
1.3.2 Liver cell injury 
Obligate primary liver toxins usually induce liver cell necrosis at the periphery of the liver lobes (Rappaport 
zone 1), while secondary liver toxins cause areas of necrosis mainly in the centre of the liver lobes 
(Rappaport zone 3). This is due to higher transformation activity of liver cells in the centre of the liver lobe 
where more toxic products originate from. Examples of primary liver toxins are the yellow phosphorus, the 
secondary liver toxin carbon tetrachloride or amanita poisons. The toxins cause coagulation necrosis. No or 
mild inflammation is present. Fulminant hepatitis courses are found with 0.1-1% of the HBV infections. 
They frequently occur with concurrent HDV infection (2 - 20%). With HCV infections fulminant hepatitis 
is very rare.  
 
1.3.2.1 Cholestasis 
The term cholestasis can be defined in different ways. In general, it describes the disturbance of the bile 
outflow. The causes can lie within the liver cells themselves, therefore termed intrahepatic non-mechanical 
cholestasis or an impediment of the bile flow can be due to alterations in the intrahepatic bile ducts, named 
intrahepatic mechanical cholestasis. Alternatively, the cause for cholaestasis can also lie outside the liver, 
this is the so called extrahepatic cholestasis. From a morphological point of view cholestasis means the 
retention of bilious pigment in the liver cells (intracytoplasmic bilious pigment) and in the bile ducts as bile 
thrombi. Also, the simple stagnation of the bile flow can be called cholestasis. Clinically, the retention of 
substances ordinarily eliminated via the bile in blood and tissues are also called cholestasis. Several 
molecular defects of bile secretion cause cholestasis. Mutations of certain transport systems can lead to 
innate, autosomal recessive inherited syndromes of cholestasis like progressive informal intrahepatic 
cholestasis (PFIC). It is worth mentioning that the different PFIC-subtypes are assigned to different 
transport defects. Mutations of the bilirubin-export pump (multidrug resistance-related protein, MRP2) are 
responsible for the Dubin Johnson syndrome which is marked by a disturbed secretion of conjugated 
bilirubin and an unusually high concentration of other organic conjugates. Although up to now still no 
mutations of the drug-export pump (multidrug resistance protein 1, MDR1) have been described, these 
could be responsible for drug induced types of cholestasis, particularly as a disturbed elimination of drugs 
could lead to the intracellular accumulation in hepatocytes and secondary inhibition of other canalicular 
transport systems. The latter proteins are particularly of interest as mdr2-/- mice display a phenotype 
characterized by cholestatic hepatitis (Pikarsky et al., 2004). Extrahepatic cholestasis occurs as a result of a 
mechanical bilious drain obstacle beyond the liver (gallstones, tumors of the cystic duct, the papilla Vateri, 
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the pancreas, enlarged lymph nodes in the liver gate, inflammatory swelling of the head of the pancreas, 
bile duct stricture with scars and extrahepatic bile duct atresia). Above the obstruction the cystic ducts are 
extended. Bacterial infections are favored by the biliary holdup with development of a cholangitis. The 
morphology is similar in intra- and extrahepatic cholestasis, irrespective of the cause. The morphologically 
detectable effects of cholestasis arise from the retention of toxic bilious components, in particular from 
bilirubin and bile acids. Deposits of bilirubin can be detected in hepatocytes and KC as well as bile thrombi 
in bile canaliculi. These changes predominate in the early phases of the cholestasis in the central segment of 
the liver acini (Rappaport zone 3) and extend then towards the periphery (Rappaport zone 1). With more 
distinctive liver cell damage a net-like change of the cytoplasm in the firm of a so called net degeneration or 
federy degeneration develops with time. Vaster necroses are termed bilious infarcts. Consequently, at the 
periphery of the liver lobes bile ductuli can start to proliferate. Periductal fibrotic changes, lengthening and 
serpentiform alterations of bile ducts, the so called cystic duct proliferation as well as the development of 
fibrous septae are often the result of a secondary inflammation. The secondary biliary cirrhosis is also a 
typical complication of the bile duct atresia. Clinically, hyperbilirubinemia often manifests as ikterus 
(jaundice). A rise of the bilirubin concentration in the blood at more than 1 mg/dl is called subikterus, more 
than 2 mg/dl as an ikterus. An ikterus appears clinically in a yellow color of the sklerae first, then of the 
skin, the body liquids as well as the inner organs. With respect to the pathogenesis different types of ikterus 
can be distinguished including the prehepatic, intrahepatic and posthepatic causes of hyperbilirubinemia. 
 
1.3.3 General mechanisms of hepatitis 
Inflammatory liver disorders can affect the liver parenchyma as hepatitis, the intrahepatic bile duct system 
as cholangitis or vessels. In addition to toxic agents, metabolic disturbances and immunological reactions, 
various possible causes (viruses, bacteria, mushrooms, parasites) are known to account for these disorders. 
The acute viral hepatitis is of high social importance as the number of new infections is very high (Wasley 
et al., 2007). The lethality of the acute illness is low. The acute viral hepatitis is marked by liver cell 
degeneration, liver cell necrosis, Kupffer cell proliferation, inflammatory infiltrates and does not continue 
longer than 6 months. Beside the classical hepatitis viruses (hepatotropic viruses), namely hepatitis A virus 
(HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D virus (HDV) and hepatitis E virus 
(HEV), a list of other causes (e.g., Epstein Barr virus, yellow fever virus, Cytomegaly virus) is able to cause 
hepatits. Surprisingly, the different hepatitis viruses cause a similar clinical and morphological picture, 
although they belong to different virus families. Whether the hepatitis G virus (HGV) also concerns a 
hepatotropic virus with primary replication in the liver is still under debate. 
 
1.3.4 Virus induced hepatitis 
Viruses can cause either acute or chronic hepatitis. A chronic viral hepatitis lasts longer than 6 months and 
shows more or less distinctive clinical symptoms. As the most frequent causes, the hepatitis virus B, which 
Introduction 
 
33
frequently occurs in combination with hepatitis D, and C can be named. Approximately 5-10% of the 
patients with acute hepatitis B develop a chronic HBV infection. Risk groups for chronic HBV infection are 
people with immune defects (e.g. dialysis patients, newborns, immunocompromised patients after 
transplantation), homosexuals, drug dependent and cognitively disabled persons (e.g. Down's syndrome). 
The HDV infection is bound to a concurrent HBV infection and HBV acts as "an assistant virus". The HCV 
infection leads in approximately 80% of the cases to chronic hepatitis. Positive virus carrier status is 
observed in about 1-2% of clinically healthy individuals in the population. The course of the chronic 
hepatitis C is usually made worse by alcoholism. With HBV-induced chronic hepatitis the liver cell damage 
decreases predominantly due to the effect of cytotoxic CD8+ T-lymphocytes which are directed against cell 
membrane associated viral antigens (in association with HLA-class-I-molecules). A chronic infection 
results from an insufficiency of the immunological elimination mechanisms. Morphologically, in the light 
form of chronic hepatitis, lymphocytic infiltrates are limited to the main entrance field. The parenchymal 
border plate remains intact. Liver cell necroses and inflammatory infiltrates in the liver lobes are discrete. In 
HBV associated cases hepatocytes with milk-glassy homogenised cytoplasm ("milk glass cells") can be 
seen. These cytoplasmic changes correspond to increased SER. In these cells, the presence of HBsAg and 
often also HBcAg can be shown by immunhistochemistry. A reliable distinction between B and C hepatitis 
based on the light-microscopic picture is not possible while specific features are suggestive of the 
underlying cause. However, milk glass cells are absent in hepatitis C, while steatosis, cystic duct changes 
with irregular, several cell layers thick epithelium and lymphatic follicles are frequently found in the main 
entrance fields. In the severe form of chronic hepatitis lymphohistiocytic inflammation is seen in addition to 
the main entrance field inflammation in which also more or less plasma cells are detected in the liver lobes. 
Thereby the so called border zone hepatitis or interface hepatitis which esentially represents apoptosis of the 
liver cells at the parenchymal border plate is generated. Single cell degeneration with apoptosis, hepatocyte 
ballooning and lytic necrosis is found in irregular distribution, accompanied by activated KC, in form of so 
called KC nodule and lymphocytic infiltrates. In clinically severe courses, also confluent and bridge-
forming necrosis can be seen. In addition, often fibrosis with formation of liver septae and, finally, in 
approximately 20-50% destruction of liver lobes occurs. This manifests as liver cirrhosis. 
Clinicopathological correlations with clinically asymptomatic HBV bearers found a regular liver 
architecture in 75% of the patients without inflammatory changes. The rest regularly shows minimum 
hepatitis or a chronic hepatitis with different activity stages. Most patients with chronic hepatitis B are free 
of pain. Laboratory-diagnostics of blood from most patients display a mild elevation of aminotransferase 
levels. A part of the cases heals; a low percentage can pass into a severe chronic hepatitis. Patients suffering 
from a highly active chronic hepatitis B mention variable complains picture with decreased power, loss of 
appetite, steady elevation of aminotransferase levels and occasional ikterus (Mellen et al., 2009). Liver 
biopsies, as they were used in the presented work, are required for defining the entity one is dealing with, to 
control the illness course and the therapy efficiency. About 20-50% of all chronically infected patients 
develop liver cirrhosis within 5-10 years. Only in few patients the HBV is eliminated in the course of time. 
Chronic hepatitis D resembles chronic hepatitis B, however, shows often a heavier course. Chronic hepatitis 
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C is a progressive liver illness and, however, a statement about the course of the illness is difficult in many 
cases. After many years' course liver cirrhosis often develops. There is a correlation between progression 
and the degree of histologically provable inflammation and fibrosis in the liver. Stop of alcohol 
consumption is extremely important as alcohol accelerates the cirrhotic process. The autoimmune hepatitis 
is often accompanied by a distinctive clinical symptomatology with tiredness, feeling of sickness, appetite 
loss, fever, joint pains, and the illness often starts with an acute hepatitis. Primarily women (about 80%) are 
affected before the 30th year or in the menopause. The illness is often accompamied by endocrinological 
disturbances and extrahepatic autoimmune phenomena like thyreoiditis, vasculitis, colitis, anaemia or 
urtikaria. The aminotransferase levels are steady, while the inflammatory boosts raises. The appearance of 
antinuclear antibodies (ANA), antibodies against smooth muscle actin and of antibodies against mikrosomal 
antigens and against cytosolic proteins is regularly observed. The illness has untreated a bad prognosis. 
Hence, untimely diagnosis and immunsuppressive treatment are of great importance (Fernandez Rodriguez 
and Alonso Lopez, 2009).  
 
1.3.4.1 Hepatitis B Virus 
The main cause of HCC worldwide is HBV. HBV is an enveloped hepatotropic DNA virus causing several 
liver diseases such as acute to chronic hepatitis, cirrhosis and HCC. During prolonged infection, viral DNA 
sequences integrate into the host genome, causing mutations, chromosomal instability and general genomic 
rearrangements. The genome of HBV is a circular, partially double-stranded DNA molecule and it is 
characterized by its four overlapping open reading frames (ORF) that encode for surface (S), core (C), 
polymerase (P) and X proteins (HBx). The expression of viral genes, in particular genes encoding for HBx, 
may deregulate the control of cellular growth and viability and sensitize hepatocytes to exogenous and 
endogenous carcinogens (Wu et al., 2001). The oncogenic capacity of HBx is a result of the fact that some 
of the genes activated by HBx, such as ICAM-1 (Hu et al., 1992), c-myc (Terradillos et al., 1997) and c-fos 
(Avantaggiati et al., 1993), are important for cell adhesion and proliferation. 
The frequency of virus carriers is especially high in South-East Asia and Africa while in Central Europe and 
Northern Europe only approximately 0,1-0,5%, in Africa and Asia up to 15% of the population are infected 
with HBV. The transfer of the virus occurs through blood and blood products as well as through saliva, 
seminal liquid, vaginal secretion, mother's milk and other body liquids. The "vertical" transfer from the 
mother to the child, usually during birth, also plays an important role. The transfer by blood and blood 
products during transfusions today has drastically decreased due to the regular testing for HBsAg of 
donated blood products. 
HBV is not or only mildly cytopathic. However, the destruction of virus-infected liver cells seems to occur 
about a cellular immunological reaction against cell surface antigens dependent on the virus. After infection 
with HBV in 20-30% of the cases an acute and in approximately 60% a subclinical course is observed. In 
most cases spontaneous healing occurs. Through cell destruction acute hepatitis leads to virus elimination, 
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and is therefore selflimiting.  
 
1.3.4.2 Hepatitis C Virus 
The HCV is a linear single-phase RNA virus. It counts to the family of the Flaviviridae. HCV is transferred 
by blood and blood products and is responsible for approximately 80% of the earlier so called Non-A-Non-
B-hepatitis forms. Antibodies against HCV appear in blood circulation 1-3 months after onset of the acute 
illness. The virus is found in a low concentration in blood and can be diagnosed by means of PCR. The 
RNA genome encodes three structural proteins like core and cover proteins and four enzymes which are 
necessary for the virus replication. The virus shows a distinctive genetic instability with a high mutation 
rate. Currently it is calculated that in the USA alone, nearly 4 million HCV infected individuals, many of 
which appear to be clinically healthy virus carriers. This represents a major health issue as infection maybe 
spread by intravenous drug abuse and dialysis treatment. 
After an incubation time of approximately two months only to 15-20% of the cases develop an acute ikteric 
illness which is similar to hepatitis B. However, the spontaneous healing is very limited, with only about 
15-20% of the infected population. The majority will develop a chronic course and a chronic virus carrier's 
status. The trend towards development of a chronic course after acute hepatitis is high and remains at 
approximately 80%. Of this approximately 20% spontaneously develop liver cirrhosis. At a later stage HCC 
can develop in the cirrhotic liver. Currently, the therapy of choice is interferon α for both, acute as well as 
chronic hepatitis C. 
 
1.3.5 Non virus induced hepatitis 
Non-virus related liver diseases with hepatitis include alcoholic steatohepatitis (ASH), cholestasis (CH), 
which is also frequently associated with inflammation, primary biliary cirrhosis/autoimmune cholangitis 
(PBC), end stage liver cirrhosis due to alcoholic liver disease (CIR), 1-antitrypsin deficiency (1-AT) and 
focal liver fibrosis (FLF). 
 
1.3.5.1 Primary biliary cirrhosis / Autoimmune hepatitis 
Autoimmune hepatitis accounts for 5-20% of all chronic hepatitis cases. It appears preferentially in women 
at a younger age and after menopause (women: men = 8: 1). It is associated with hypergammaglobulinemia, 
HLA-B8- and -DR3-status and circulating autoantibodies (anti-actin antibody, antinuclear and other 
antibodies). In PBC a T-cell attack against hepatocellular membrane antigens is the underlying 
pathomechanism. Besides, a suppressor-T-cell-defect also seems to play a role. Also a cellular cytotoxicity 
dependent on antibodies is involved and the autoimmune attack could be initiated by viral infection. In drug 
induced chronic hepatitis immune phenomena could also be involved. HCC often complicates PBC, in 
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which copper accumulates in the liver (Melia et al., 1984; Nakanuma et al., 1990). 
 
1.3.5.2 Alcoholic hepatitis 
Mallory bodies, intracytoplasmic irregular inclusions, occur in HCC cells of alcoholic and non-alcoholic 
patients alike (Nakanuma and Ohta, 1985, 1986) as they do also in liver-cell adenomas (Malatjalian and 
Graham, 1982). This observation suggests a link in the pathogenesis of alcoholic liver disease and of liver 
cancer. Alcoholic hepatitis or nutritional and toxically induced steatohepatitis is histologically characterized 
predominantly by necrosis in the centre of the liver lobes. It is accompanied by neutrophilic infiltrates and 
the appearance of Mallory-Denk bodies or alcoholic hyalin and enlarged, balloned hepatocytes. The 
Mallory bodies show a filamentous ultrastructure and contain unusual keratin, but also non-keratin derived 
components like Ubiquitin. In a rather high percentage of patients distinctive signs of cholestasis are also 
found. The often co-existing fatty liver does not correlate with the severity of the alcoholic hepatitis. 
Fibrotic changes also occur frequently. However, the morphological changes are not specific for alcohol 
and can occur in the setting of morbid obesity, type-II-diabetes-mellitus, Wilson`s disease, various 
metabolic illnesses or induced by drugs that lead to liver damage.  
The prognosis of alcoholic hepatitis depends on the gravity of liver cell damage. The lethality rate reaches 
30%. With abstinence from alcohol consumption alcoholic hepatitis is reversible. However, often residual 
damaged foci remain. With continuous alcohol abuse a rather high percentage of approximately 30% of the 
patients with alcoholic hepatitis develop liver cirrhosis in a relatively short time, mostly within 1-2 years 
 
1.3.5.3 Non alcoholic steatohepatitis 
Non-alcoholic steatohepatitis (NASH) has gained increasing interest as it is the most severe form of non-
alcoholic fatty liver disease (NAFLD), characterized by the presence of macrovesicular steatosis along with 
inflammatory activity, and sometimes associated with fibrosis. The molecular mechanisms involved in 
tissue damage during NASH are poorly understood. However, it has recently been demonstrated that Fas 
expression, activation of caspase-3 and -7 and hepatocyte apoptosis are enhanced in the liver of NASH 
patients, and positively correlated with the biochemical and histopathologic markers of liver injury 
(Feldstein et al., 2003a; Feldstein et al., 2003b). Mitochondrial function is often impaired in the liver of 
subjects with NASH (Perez-Carreras et al., 2003). Activation of Fas results in mitochondrial dysfunction 
which is associated with generation of reactive oxygen species, which are able to induce apoptosis, further 
exacerbating tissue injury and inflammation. Thus, Fas inhibition may be an effective therapy to reduce 
liver damage and prevent development of cirrhosis in NASH. 
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1.3.6 Other non virus related liver disorders 
Non-virus related liver diseases without hepatitis include steatosis (ST), hemochromatosis / siderosis 
(HE/SID), and Wilson’s disease (WD) while it has to be mentioned that in all of these diseases 
inflammation, to various degree, may also occur. Especially iron and copper storage is often paralleled by 
drastic inflammation. Focal nodular hyperplasia (FNH) represents a benign primary liver tumor. Diseases 
such as 1AT (●), FLF (▲), HE/SID (•), and WD (Δ) are listed under “other liver diseases” (OLD) in the 
experimental chapter.  
 
1.3.6.1 Steatosis hepatis 
The content of lipids in the normal liver amounts to approximately 5% of the liver weight. In fatty liver 
disease a prevailing accumulation of triglycerides can be observed. The lipid content increases to 40-50% of 
the liver weight under these conditions. The fatty liver is a frequent finding in liver biopsies. The underlying 
disturbance of the fat metabolism determines the clinical picture. The morphology proves the definitive 
diagnosis. The fatty liver is reversible with discontinuation of the causing agent. However, this can be the 
starting point for a progressive liver disorder e.g. alcoholic hepatitis or NASH. Fatty acids are taken up by 
the hepatocyte from blood and are converted partly again into triglycerides, are used partly for the synthesis 
of cholesterol and phospholipids. They are also oxidized in part. Besides, fatty acids can also originate in 
the liver. The triglyceride synthesis of free fatty acids can be supported by the gylcolysis and the formation 
of gylcerine. The fatty liver is based on a disturbance of the fatty acid and triglyceride metabolism. Fat 
storage “per se” does not lead to liver cirrhosis. 
 
1.3.6.2 Hemochromatosis / Liver siderosis 
Hereditary hemochromatosis is an autosomal recessive disorder. The responsible HFE-gene has been 
located on the short arm of chromosome 6. A single G to A mutation, resulting in a cysteine to tyrosine 
substitution (C282Y) is the cause for most cases. The genetic defect leads to iron accumulation in the liver, 
resulting in a progression to liver cirrhosis. Males are predominantly affected (Crawford et al., 1998; 
Niederau et al., 1999). The risk to develop HCC on the basis of hemochromatosis is high. An association 
with additional risk factors such as alcohol consumption and chronic infection with HBV and HCV has 
been reported (Fargion et al., 1994). Of note, proliferative, frequently dysplastic iron-free areas of liver cells 
are present in most cases before HCC develop (Deugnier et al., 1993). The treatment of hemochromatosis 
remains symptomatic with phlebotomy as an effective therapy. 
 
1.3.6.3 Wilson`s disease 
Large amounts of copper accumulate in Wilson's disease, which is an autosomal recessively inherited 
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disease that tends to affect males and frequently results in liver cirrhosis (Cheng et al., 1992). 
 
1.3.6.4 1-Antitrypsin deficiency 
1AT is an inhibitor of serine proteinases. It is synthesized in hepatocytes and secreted into the blood 
stream. The pattern of inheritance of 1-Antitrypsin (1AT) deficiency is complex and is under the control 
of Pi (protease inhibitor) genes. 1AT deficiency leads to the accumulation of PAS-positive, diastase-
resistant globules that consist of 1AT. The disease is associated with neonatal jaundice and cirrhosis in 
early childhood, with pulmonary emphysema and liver cirrhosis in adult life (Rubel et al., 1982). 
 
1.3.6.5 Liver fibrosis and cirrhosis 
Liver fibrosis means connective tissue increase in liver which can be proven in an objective manner by 
chemical regulation of the whole collagen content. The normal lobular liver architecture is still, at least 
partially, protected. During fibrogenesis collagen type I is increasingly deposited by activated stellate cells. 
Morphologically one can divide liver fibrosis into portal fibrosis, perisinusoidal fibrosis, central pericellular 
or perivenular fibrosis or in fibrosis affecting the periphery of the liver lobes (periportal fibrosis). Many 
chronic liver disorders lead to liver fibrosis as the primary disorders are accompanied by inflammation. 
Certain substances (e.g., alcohol, acetic aldehyde, iron) can directly stimulate the collagen synthesis. The 
responsible mechanisms seem to be quite complicated. Various cytokines (TNF-α, TGF-) are involved as 
stimuli of the collagen synthesis. The development of the fibrosis stands in relationship with duration and 
gravity degree of the damage. The duration of the development of liver fibrosis is variable. Liver cirrhosis, 
also termed liver fibrosis stage IV, is a final stage of various severe inflammatory and necrotizing liver 
damages with soft tisssue production. Thereby the normal liver architecture is lost. Most HCC arise in 
cirrhotic livers though the proportion varies. The pattern of cirrhosis tends to be macronodular and inactive 
in chronic alcoholic patients and in HBV infected patients whereas it is frequently micronodular and active 
in HCV-related cases (Takenaka et al., 1995).  
 
1.3.7 Human liver tumors 
In clinical practice, a wide variety of benign and malignant lesions present as hepatic masses and are 
subjected to needle biopsy. For practical purposes, these lesions can be broadly classified into: (1) clearly 
hepatocytic and malignant; (2) clearly hepatocytic and of uncertain clinical nature and malignant potential; 
(3) clearly malignant and of uncertain lineage; and (4) neither clearly hepatocellular nor malignant. The 
diagnostic approach to each of these requires integration of clinical, laboratory and imaging data. Work-up 
usually requires histochemical and immunohistochemical stains. Liver biopsies are generated by 
percutaneous, transjugular, laparoscopic or open surgical routes, with or without imaging guidance. Recent 
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advances in imaging techniques allow better distinction among these lesions. However, diagnostic 
challenges are often encountered in clinical practice. In general, liver biopsies are assigned to one of three 
categories, based on the clinical indication: (1) medical disorders, (2) tumor evaluation, and (3) post-
transplant biopsy. In many laboratories routinely, nine initial sections from the paraffin block are obtained, 
and levels 1, 3 and 7 are stained with H&E. Sections from biopsies for evaluation of medical disorders are 
stained with trichrome, reticulin, Berlin blue and diastase with periodic acid-Schiff reaction (DPAS) stains. 
For other categories, the unstained sections are held for stains that are determined after evaluating the HE-
stained sections.  
Mass lesions found in liver biobsies (Table 1) can be classified into four categories. The first category 
consists of lesions that are clearly hepatocytic in nature and appear malignant. This is represented largely by 
well to moderately differentiated HCC. The second category includes lesions that are well differentiated and 
clearly hepatocytic in nature, and the diagnostic issue is the clinical nature and potential malignant 
behavior. This category includes regenerative nodules, dysplastic nodules (DN), FNH, hepatic adenoma 
(HA) and well differentiated HCC. The third category includes lesions that clearly appear malignant, and 
the diagnostic issue is the lineage of the neoplasm, e.g. HCC versus non-hepatocytic tumor, such as CCC, 
other primary liver tumors and metastases. The last category is composed of a very small number of cases 
that do not belong to any of these well-defined categories, and appear neither clearly hepatocellular nor 
clearly malignant. 
The number of people affected by liver masses in Africa and South-East Asia is large, over one million per 
year. Numerous studies indicate that the marked geographical variability in incidence is due to just one 
tumor type, namely HCC, which predominates in tropical Africa and South-East Asia but also in other 
regions of the world. Intrahepatic duct carcinoma is the next commonest. It occurs with approximately the 
same frequency everywhere, except in South East Asia where its high incidence is clearly associated with 
liver fluke infestation. 
All other liver tumor types are rare. Overall, liver cancer ranks eighth in frequency in the world (sixth 
among men and eleventh among women). In general, the outlook for malignant hepatobiliary tumors is 
extremely poor. Epidemiological and etiologic aspects of liver tumors have been largely reported (Bosch et 
al., 1999; Okuda, 1997).  
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Table 1: The following tumor entities in liver are known: 
Benign epithelial 
tumors 
Malignant epithelial 
tumors 
Benign non-
epithelial tumors 
Malignant non-
epithelial tumors 
Tumor-like 
lesions 
Hepatocellular 
adenoma 
Hepatocellular 
carcinoma 
Hemangioma Rare primary tumors Various 
reactive 
conditions 
Bile-duct adenoma Hepatoblastoma Angiomyolipoma Metastatic tumors  
Bile-duct 
cystadenoma 
Bile-duct carcinoma 
(cholangiocellular 
carcinoma) 
Other benign 
tumors 
Hemangiosarcoma  
Biliary 
papillomatosis 
Bile-duct 
cystadenocarcinoma 
 Epithelioid 
hemangioendothelioma 
 
 Mixed liver-cell and 
bile-duct carcinoma 
 Embryonal sarcoma  
 Sarcomatoid, hepatoid 
and other malignant 
epithelial tumors 
 Rhabdomyosarcoma  
 Combined and mixed 
carcinomas 
 Other sarcomas, 
lyrnphomas or germ-cell 
tumors 
 
 
1.3.7.1 Focal nodular hyperplasia  
This lesion occurs in both sexes and at all ages but most commonly in young adult women. Most of them 
are discovered incidentally and only about 15% cause symptoms, usually recognized as a mass or upper 
abdominal pain. Rupture and hemoperitoneum are rare. Focal nodular hyperplasia (FNH) is usually 
solitary, around 5 cm in size and typically forms a well-circumscribed fibrous globular mass. It tends to 
bulge on its cut surface and displays multiple yellow-brown nodules of liver parenchyma separated by 
fibrous septs. Histologically, it resembles cirrhosis except that the lesion occurs focally and the rest of the 
liver is normal. A central stellate scar is often seen and may contain thick-walled vessels. A mild to 
moderate Iymphocytic infiltrate is present in the septs. Whether or not this condition is related to oral 
contraceptive use and pregnancy has been debated for years but the evidence speaks against it. Gonadal 
steroids and pregnancy may, however, increase the vascularity of the lesion and predispose it to rupture. It 
has been suggested that FNH is essentially a vascular malformation with arteriovenous anastomoses and 
localized overgrowth of all liver constituents. Its polyclonal nature has been confirmed by chromosome 
studies. Most patients are treated conservatively and surgery is only necessary for those with symptoms. 
 
Introduction 
 
41
1.3.7.2 Hepatocellular carcinoma 
HCC represents the most frequent, aggressive hepatocyte driven tumor with poor prognosis. Its occurrence 
is known to be related to chronic hepatitis B and C virus infections and exposure to aflatoxin. Genetic 
factors have been shown not to be of significant importance. 
The macroscopic and microscopic appearances of HCC have been described in detail over the years and 
criteria for diagnosis and nomenclature have been defined many times (Okuda, 1997). Classifications (Yuki 
et al., 1990) have divided liver-cell carcinomas into infiltrative or expansive, single or multinodular, and 
mixed types with observations on encapsulation, intrahepatic venous spread and special subtypes. HCC 
form soft, haemorrhagic, occasionally bile-stained nodules and masses with a tendency to necrosis. As HCC 
have an arterial blood supply but both the hepatic and portal veins proliferate alongside and cavernous 
structures develop in collaterals (Terada et al., 1989) intra- and extrahepatic spread can take place to all 
parts of the liver (Toyosaka et al., 1996), hepatic veins, inferior vena cava, right atrium (Kojiro et al., 1984) 
and the portal system. The likelihood of HCC for local intravascular spread has been noted for many years 
but distant metastases may not occur until quite late. 
HCC microscopically show broadening of liver cell cords, loss of reticulin fiber networks and increased 
proliferation rates of hepatocytes. HCC are characterized by cellular pleomorphism with often huge and 
multiple bizarre hepatocyte nuclei. These are seldom numerous but at times occupy large areas and form 
solid masses; in some instances. Then the trabecular or plate-like growth pattern is almost or completely 
lost. Clear cells can predominate but are usually still arranged in cords separated by sinusoids. The clarity of 
the cytoplasm is most often due to massive glycogen storage. Sometimes it can be also due to water or fat. 
An oncocytic appearance is characteristic for the fibrolamellar variant of liver-cell carcinoma. Such cells, 
containing numerous mitochondria can also be seen in small numbers in otherwise ordinary HCC. 
 
Pedunculated liver-cell carcinoma 
The pedunculated liver-cell carcinoma does not greatly differ from an ordinary HCC with regard to age and 
sex distribution, association with cirrhosis and chronic HBV infection, production of AFP and microscopic 
appearances. The main characteristics are a small size, ranging from 2 to 3 cm, slow growth, fibrous 
encapsulation, an almost invariable association with cirrhosis, low prevalence of HBV infection and serum 
levels of AFP usually below the level of 500ng/ml. The histological features do not differ from those of 
'ordinary' HCC except for the fact that these tumors usually appear well differentiated. 
 
Fibrolammelar liver-cell carcinoma 
The fibrolamellar carcinoma differs in most aspects from common HCC yet it is of liver-cell origin and 
malignant. Fibrolamellar carcinomas often occur under 35 years of age and less than 5% over the age of 50. 
Very rarely, cases have been described in patients aged 70 - 85 years (Hodgson, 1987). There is no gender 
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disparity or association with cirrhosis. Patients present with abdominal pain, malaise and weight loss. 
Serum AFP is seldom raised and less than 10% of patients show evidence of HBV or HCV infection. 
Jaudice does not occur in most cases. In rare cases, an elevated level of CEA has been reported. 
Fibrolamellar carcinomas are usually solitary and often large, 5-25 cm in size and can weigh up to 1000g. 
The surgical resectability rate is high. Multiple tumors may still be cured by hepatectomy and 
transplantation (Pinna et al., 1997; Ringe et al., 1992; Schlitt et al., 1999). The 5-year survival rate recorded 
in large series has been around 50% and progress is slow even when the tumor has not been completely 
eradicated. Tumor cells are large, eosinophilic and polygonal, with vesicular nuclei and prominent, usually 
single, nucleoli. 
 
1.3.8 Epidemiology on human hepatitis and hepatocellular tumorigenesis  
The highest rates of all HCC cases are seen in South-East Asia and tropical Africa where frequencies have 
been estimated to be up to 150/100.000/year. In these areas, the tumor is the commonest or next commonest 
in the list of all cancers. The lowest rates are found in Western countries, South America and Australia. 
Intermediate rates prevail in Japan, the Middle East and the Mediterranean countries (Simonetti et al., 
1991). The possible role of racial and genetic factors has been extensively studied but discounted in favor of 
environmental agents.  
Variation in incidence might be explained by differences in alcohol consumption and smoking. In the latter, 
it may be related to variable levels of exposure to aflatoxins (Omata, 1987). The relationships between HCC 
and viral infections, chemical substances, hormones, alcoholism, nutrition and presence or absence of 
cirrhosis were investigated in detail (Kaldor and Bosch, 1990; Okuda, 1992). The incidence of HCC 
increases with age in all populations but there is a tendency for it to fall off in the elderly. Overall, the age 
peak is inversely related to the frequency of the tumor, patients being the youngest in high and the oldest in 
low incidence areas. A male to female predominance is observed everywhere and ranges from 4:1 in low to 
8:1 in high incidence areas. Malnutrition is common in most areas with a high HCC incidence but so are 
hepatitis B and C virus infections and exposure to hepatotoxic agents. Existing knowledge on diet and 
cancer indicates that it is over-nourishment, rather than lack of calories or deficiency of protein, that 
promotes tumor development (Willett and MacMahon, 1984). Epidemiological reports indicate a 
relationship between high dietary fat, cholesterol, obesity and carcinomas of the breast and endometrium in 
women, carcinoma of the prostate in men, and carcinomas of the colon and pancreas in both sexes. In one 
study from Japan, inadequate and unbalanced nutritional intake were more common in patients with 
cirrhosis and HCC than in the general population but it was unclear whether this was based on a causal 
relationship. HCC incidence was also correlated to various substances that have been found in drinking 
water, foodstuffs and native remedies (Willett and MacMahon, 1984). Most of them are simply suspected to 
carry carcinogenic potential. Aflatoxins induce acute liver necrosis, dysplasia and HCC in man and animals 
(Ross et al., 1992). Other mycotoxins are less efficient inducers of HCC. Chronic alcohol abuse frequently 
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leads to cirrhosis and HCC, particularly in low incidence areas where hepatitis B and C virus infections are 
uncommon (MacSween, 1982; MacSween and Anthony, 1982). Alcohol might act as a co-carcinogen with 
hepatitis B and C virus infections, aflatoxins and smoking, in addition to its general role as a cirrhosis-
inducing agent. 
It is certain that continued alcohol consumption is not necessary for the development of HCC once cirrhosis 
is established and the risk actually increases with time after cessation of drinking (Lee, 1966). Currently, the 
incidence of HCC is rising in Western countries and in Japan (Akriviadis et al., 1998; Omata, 1987; 
Simonetti et al., 1991). The reasons are not entirely clear but the spread of chronic hepatitis C infection is 
most probably the cause. To sum it up, risk factors in all parts of the world are male sex, age and cirrhosis 
(Simonetti et al., 1991).  
 
1.3.9 Murine HCC models 
Chemically induced HCC mice models mimic the injury-fibrosis-malignancy cycle by administration of a 
genotoxic compound alone or, if necessary, followed by a promoting agent. In xenograft models, the tumor 
nodules are generated by injecting human cancer cells from a lab culture into immune deficient mice 
(Heindryckx et al., 2009). Alternatively, transgenic mice can be used as model system. Promotion of HCC 
formation by chronic inflammatory stimuli has been recapitulated in various models. Ablation of the multi-
drug resistance gene 2 (mdr2) induces cholestatic hepatitis and liver cancer (Pikarsky et al., 2004) and 
administration of the chemical carcinogen diethylnitrosamine (DEN) causes acute liver injury and HCC 
(Maeda et al., 2005). Liver specific expression of the hepatitis B surface antigen (HBsAg) in transgenic 
mice demonstrates that chronic immune-mediated liver cell injury is critical for HCC formation (Nakamoto 
et al., 1998). In various animal models a gender disparity has been observed as apparently experimental 
liver tumors are more easily induced in males than in females. Moreover, orchiectomy reduces the 
carcinogenic effect of chemicals in male rodents to the level found in females. It is very unlikely that sex 
steroids are carcinogenic by themselves but they might possibly promote tumor growth (Carr and Van 
Thiel, 1990; Eagon et al., 1985; Ohnishi et al., 1986; Porter et al., 1987). Chemically induced models 
include several compounds that induce tumor formation when administered in sufficiently high doses. DEN 
is often used as a carcinogenic substance as it can alkylate DNA and thereby induces hepatocarcinogenesis. 
Reactive oxygen species (ROS) generated by the P450-dependent enzymatic system might induce oxidative 
stress by the formation of hydrogen peroxide and superoxide anions. Production of ROS is known to cause 
DNA, protein and lipid damage. Therefore, oxidative stress most probably plays an important role in liver 
carcinogenesis (Heindryckx et al., 2009). Tumors in mice that have been induced by DEN harbor activating 
mutations in the H-ras proto-oncogene. These are rarely seen in humans and they correlate with metastasis 
and poor prognosis. After a long-term repetitive administration of DEN, 100% of male mice and 30% of 
female mice develop HCC. DEN can be used as an initiator and phenobarbital (PB) as a promoting agent. 
PB can increase the expression of cytochrome P450 a 100-fold, supporting an enhanced effect of DEN 
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(Waxman and Azaroff, 1992). Promotion with PB leads to tumors that exhibit mutations in the -catenin 
proto-oncogene (Loeppen et al., 2002). -catenin mutations are associated with non-invasive tumors and a 
significantly higher 5-year survival rate in humans. Aflatoxin B1 (AFB) is also used as inducer of HCC in 
mice (Ghebranious and Sell, 1998; Heindryckx et al., 2009). Carbon tetrachloride (CCl4) is a very potent 
hepatotoxin. Mice subjected to a long-term choline deficient ethionine supplemented (CDE) diet develop 
HCC at the age of 50–52 weeks (Knight et al., 2000). The proposed mechanism of carcinogenicity by CDE 
diet is through the formation of oval cells, which are believed to represent the precursors of hepatocytes. 
Thioacetamide (TAA) is an additional hepatotoxin. Its repeated administration over a period of 10–15 
weeks results in liver fibrosis in mice (Heindryckx et al., 2009).  
Different aspects of HBV-induced hepatocarcinogenesis have been investigated by generating transgenic 
mice expressing complete fragments of the HBV genome, under control of either the HBV promoter, or 
constitutive (mouse albumin) or inducible (mouse metallothionein) liver-specific promoters. The first HBV-
related transgenic mouse model were generated in 1985 (Chisari et al., 1985). Others followed (Koo et al., 
2005). Transgenic lineages with lower HBx copy number showed lower tumor incidence comparable with 
that of wild-type mice (Koike et al., 1994), while other experiments did not encounter any tumors in HBx 
transgenic mice (Lee et al., 1990). HBx transgenic mice have been reported to be more sensitive for HCC 
development after a single DEN-injection when compared with their non-transgenic counterparts (Sell et 
al., 1991). 
A number of HCV proteins, such as core, NS3 and NS5A (Heindryckx et al., 2009) play an important role 
in hepatocarcinogenesis. When the complete viral protein is expressed, steatosis and HCC occur in 15% of 
the mice after approximately 90–100 weeks (Heindryckx et al., 2009). The expression of HCV core leads to 
progressive hepatic steatosis in several lines of constitutive transgenic mice, followed by HCC after 80–105 
weeks in 32% of the male mice (Heindryckx et al., 2009). Inducible expression of core protein by 
tetracycline and Dox administration leads to a peak in steatosis after 2 months but no HCC occurs (Chang et 
al., 2008). Transgenic mice expressing core, E1 and E2 structural proteins developed HCC after 60 weeks 
in 23% of the male mice (Naas et al., 2005). The Myc protein is a transcription factor that activates the 
expression of several genes through binding on consensus sequences and recruitment of histone 
acetyltransferases (Nilsson and Cleveland, 2003). Transgenic mice over-expressing c-myc develop liver 
tumors after a long period of latency (35–90 weeks) (Thorgeirsson and Santoni-Rugiu, 1996). Interestingly, 
Myc transgenic mice are genetically close to human HCC that have a good prognosis. β-catenin mutations 
are considered to be an early event in hepatocarcinogenesis (Laurent-Puig and Zucman-Rossi, 2006). When 
mutations in both the β-catenin and H-ras genes are introduced by adenovirus-mediated Cre expression, 
early HCC are found in mice already 8 weeks after induction. High grade HCC could be established after 
approximately 26 weeks. Transgenic mice over-expressing human TGF-α under the inducible 
metallothionein 1 promoter get tumors in their livers. These lesions are genetically similar to human HCC 
associated with poor prognoses. Double transgenic mice carrying both c-myc (albumin promoter) and TGF-
α (metallothionein promoter) display a massive acceleration of HCC development compared to the single 
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transgenic mice overexpressing either c-myc or TGF-α (Thorgeirsson and Santoni-Rugiu, 1996). Moreover, 
over-expression of the secreted form of the epidermal growth factor (EGF) results in multiple highly 
malignant hepatic tumors after 24–36 weeks (Tonjes et al., 1995). In double transgenic mice expressing 
EGF and myc, HCC development has been reported as accelerated (Tonjes et al., 1995). One model that 
does not require liver- specific expression for the onset of HCC is a transgenic mouse model over-
expressing fibroblast growth factor 19 (FGF19) in skeletal muscle which leads to the occurrence of HCC in 
50% of the mice after approximately 52 weeks (Nicholes et al., 2002). The Simian vacuolating virus 40 
(SV40) is a DNA-virus that can cause tumor formation. When the SV40 T-antigen is expressed under a 
promoter like albumin, α1 antitrypsin, serum amyloid P component or antithrombin III, liver tumors can 
arise after a short period of latency (4–12 weeks). Metastasis to the lungs may occur in these models 
(Heindryckx et al., 2009). Alpha-1 antitrypsin (AAT) -deficient mice develop HCC after 52–90 weeks 
(Geller et al., 1994). Phosphatase and tensine homolog (PTEN) is a tumor suppressor gene. Liver-specific 
PTEN-deficient mice develop hepatic steatosis, inflammation, fibrosis and tumors, alterations resembling 
the ones seen in human livers affected by non-alcoholic steatohepatitis (NASH) (Watanabe et al., 2007). 
Members of the platelet-derived growth factor (PDGF) family are important for tumorigenesis. In addition, 
they have been associated with several diseases, including hepatic fibrosis. Liver cirrhosis induced by over-
expression of PDGF-A, PDGF-B, PDGF-C or PDGF-D is associated with hepatic stellate cell activation 
possibly as a result of the induction of profibrotic genes such as TGF-β1 (Campbell et al., 2005; Thieringer 
et al., 2008). Long-term over-expression of the PDGF genes induces HCC after approximately 52 weeks 
(Campbell et al., 2005) TGF-β1 is known to be an important player in the pathogenesis of liver fibrosis 
(Williams and Knapton, 1996). Transgenic mice over-expressing TGF-β1 present the most extensive liver 
fibrosis after approximately 10 weeks. In addition, tumor formation has also been described in this model as 
well (Schnur et al., 2004). 
 
1.4 Inflammation and cancer 
1.4.1 Chronic inflammation and carcinogenesis 
The link between inflammation and cancer has been acknowledged for a long time (Lu et al., 2006). 
Interestingly, chronic inflammatory diseases may be associated with increased cancer risk, mostly in an 
organ specific manner, while in other areas of the body chronic inflammatory states rather lead to 
degenerative disorders, as observed in articular joints. The association between the immune system and 
cancer has been known for a long time. Already Rudolf Virchow speculated ~150 years ago about 
inflammatory origins of cancer. Moreover, epidemiological data clearly demonstrate that susceptibility to 
cancer increases when tissues are chronically inflamed. 
Chronic inflammation of the liver, as seen in chronic viral hepatitis, is associated with HCC. Chronic 
gastritis, as seen in helicobacter infection, is associated with stomach cancer (Oh et al., 2005). Chronic 
esophagitis, as seen in chronic gastroesophageal reflux disease, can lead to Barrett’s esophagus and 
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esophageal carcinoma (Gomes et al., 2005). Finally chronic ulcerative colitis is tightly linked to the 
development of colorectal carcinomas (Itzkowitz and Yio, 2004). Some of these associations have been 
investigated and are currently being confirmed and studied in mouse models of chronic inflammation. 
Bacterial infections can result in chronic colitis associated colorectal cancer in immune compromised mice 
(Erdman et al., 2003; Greten et al., 2004). Helicobacter felis infection results, also in mice, in chronic 
gastritis and eventually gastric cancer (Goldenring and Nomura, 2006). Different patterns of gastritis, 
associated with different helicobacter genotypes and host factors, have been linked to distinctly increased or 
reduced (Meireles et al., 2004; Wen et al., 2004) risks of cancer. While antral gastritis is associated with 
duodenal ulceration, multifocal or diffuse gastritis that is associated with atrophy shows a strong association 
with gastric cancer. Similarly, chronic colitis in diverticular disease is not associated with an increased 
cancer risk while chronic ulcerative colitis is. In line, it has been shown that long-term use of non-steroidal 
anti-inflammatory drugs (NSAIDs) is capable of reducing the risk of several cancer types (Gupta and 
Dubois, 2001). In general, it is suggested that a single mutagenic event does not result in formation of a 
malignant tumor. Additional genetic and epigenetic events are necessary for the progression to a tumor 
state. The essential requirements being characteristic of a tumor cell are self-sufficiency in growth signals, 
insensitivity to growth-inhibitory signals, evasion of programmed cell death (apoptosis), limitless 
replicative potential, sustained angiogenesis, and tissue invasion and metastasis (Hanahan and Weinberg, 
2000). Carcinogenesis is commonly regarded as a three step process. These phases are the initiation phase 
with first genomic alterations. During the promotion phase proliferation of genetically altered cells is 
ongoing and finally, during the progression phase the tumors increase in size. In summary, the formation of 
malignant tumors is the result of uncontrolled growth of a given cell type which then gains the ability to 
invade the surrounding tissue and then malignant cells spread theoretically at least, throughout  the whole 
body. Functionally, various factors, either directly or indirectly, suffice to induce cell proliferation, 
recruitment of inflammatory cells and to trigger production of reactive oxygen species leading to oxidative 
DNA damage. In parallel reduced DNA repair leads to a lack of protection against pro-tumorigenic events.  
On the effector level different mechanisms have been proposed, including HIF-1, COX-2, iNOS and 
peroxynitriles, NF-ĸB signalling, and numerous cytokines (Lu et al., 2006). Most research efforts have 
addressed the sequence of events associated with the progression of chronic inflammation to overt 
carcinoma. While these studies have brought insight into the genetic alterations that accumulate within 
target cells during their progression from normal tissue to cancer, they have brought little knowledge on the 
characteristics of the inflammation itself that drives the critical events during tumorigenesis. Little is known 
on the characteristics of the inflammations that are associated with cancer and many open questions remain 
to be answered. 
 
1.4.2 Chronic inflammation and hepatocellular carcinoma 
While in most cases, inflammatory responses of the immune system are beneficial as a defense mechanism 
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against pathogenic agents, when tissue homeostasis is constantly disturbed by inflammation, this can lead to 
dramatically increased cell death, excessive tissue remodeling with compensatory proliferation and 
oxidative stress-related protein and DNA alterations. In addition, in the past, research efforts were directed 
to understand the sequence of tumorigenic processes by treating animals with chemical carcinogens like 
DEN which most probably does not reflect virus triggered hepatic carcinogenesis. A causal relationship 
between chronic hepatitis, hepatocellular damage and regeneration with fibrosis and carcinogenesis is well 
established from epidemiological studies (Berasain et al., 2009; El-Serag, 2002; El-Serag et al., 2007). 
Various etiologies, including chronic alcohol consumption, drug abuse, autoimmune disorders, exposure to 
toxins (e.g. aflatoxin B) or infections with hepatotropic viruses (e.g. HBV, HCV) can lead to chronic 
hepatitis, liver fibrosis and finally cirrhosis. HBV- and HCV-infections are by far the most common cause 
of chronic hepatitis in humans (Malhi et al., 2006). Chronic HBV- and HCV-infections are frequently 
associated with HCC, the most prevalent primary human liver cancer (El-Serag and Rudolph, 2007), and 
except for HBV-infections, liver cirrhosis precedes HCC in most cases. The exact mechanisms driving 
chronic hepatitis-induced liver cancer remain elusive. Among others, aberrant expression of cytotoxic 
cytokines is thought to be critically involved (Greten and Karin, 2004; Karin, 2006; Lee et al., 2005; Lowes 
et al., 2003; Maeda and Omata, 2008; Vainer et al., 2008).  
Many cell types that are susceptible to the actions of cytokines are residing in the liver. Hepatocytes express 
a variety of cytokine receptors such as for IL-1, TNF-, LT, LT and IL-6. NPC, such as the resident 
liver macrophages (KC) not only synthesize various cytokines, but the actions of these cells is also affected 
by cytokines. 
 
1.5 The role of NF-B in liver pathology 
1.5.1 Impact of NF-ĸB on hepatitis and chronic hepatitis induced liver carcinogenesis 
The pro-inflammatory and homeostatic cytokines LT and LT are members of the TNF superfamily. 
Under physiological conditions LTs are expressed by activated T-, B-, NK- and lymphoid tissue inducer 
cells (Fu et al., 1998a; Ware, 2005) and are crucial for organogenesis and maintenance of lymphoid tissues 
(Rennert et al., 1996; Tumanov et al., 2003). Whereas LT contains a transmembrane domain, LT is 
soluble. Consequently, LT can exist as membrane bound heterotrimers (LT12 or LT21) interacting with 
LTR or as soluble secreted homotrimers (LT3) triggering TNF receptor 1, 2 (TNFR1, TNFR2) and the 
herpes virus entry mediator receptor (HVEM) (Browning et al., 1995; Ware, 2005). LTR and TNFR1 
signaling can be activated by the HCV-core protein (Chen et al., 1997; Zhu et al., 1998) involving the 
canonical or non-canonical NF-B signaling pathways (Ware, 2005; You et al., 1999). Furthermore, HBV- 
or HCV-infections lead to increased hepatic LT expression in vivo and in vitro (Lee et al., 2005; Lowes et 
al., 2003) and HCV replication has been demonstrated to depend on components of the LTR signaling 
pathway in vitro (Ng et al., 2007). 
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LTs can directly act on hepatocytes which physiologically express high levels of LTR but little LT 
(Browning and French, 2002). T-cell-derived LT and LIGHT (LT-like, exhibits inducible expression, 
competes with HSV glycoprotein D for HVEM, expressed by T- lymphocytes) signaling to hepatocytes 
controls lipoprotein homeostasis (Lo et al., 2007). In addition, LT signaling is important for liver 
regeneration through T-cell-derived LT expression (Tumanov et al., 2008) and regulates hepatic stellate cell 
function and wound healing (Ruddell et al., 2009). Thus, hepatic LTR signaling controls liver homeostasis 
in both health and disease. Promotion of HCC formation by chronic inflammatory stimuli has been 
recapitulated in various models. Ablation of the multi-drug resistance gene 2 (mdr2) induces cholestatic 
hepatitis and liver cancer (Pikarsky et al., 2004) and administration of the chemical carcinogen 
diethylnitrosamine (DEN) causes acute liver injury and HCC (Maeda et al., 2005). Liver specific expression 
of the hepatitis B surface antigen (HBsAg) in transgenic mice demonstrates that chronic immune-mediated 
liver cell injury is critical for HCC formation (Nakamoto et al., 1998). 
Triggering TNFR1 or LTR induces the classical and alternative NF-B signaling pathways, which are 
linked to inflammation-induced carcinogenesis (Greten and Karin, 2004). However, the precise role of these 
pathways in HCC pathogenesis is controversial (Vainer et al., 2008). Mice lacking IKappa B kinase  
(IKK specifically in hepatocytes (Ikkhep) exhibit a marked increase in DEN-induced HCC formation 
suggesting a protective function of IKK in HCC development (Maeda et al., 2005). In contrast, NF-B 
signaling promotes HCC development in mdr2-/- mice and anti-TNF treatment is protective (Pikarsky et 
al., 2004). Interestingly, mice with a hepatocyte-specific deletion of IKK (also called NEMO) develop 
steatohepatitis and HCC (Luedde et al., 2007). Consequently, the role of NF-B signaling in 
hepatocarcinogenesis might depend on the mouse model and the type or degree of liver inflammation and 
injury (Vainer et al., 2008). Here, I investigated a possible causal relationship between sustained hepatic 
LTR-signaling, chronic hepatitis and HCC development.  
 
In my thesis I describe a new mouse model for HCC development. I also aimed at elucidating the impact of 
NF-B and of inflammatory cells for HCC formation. Moreover, I was interested in TNFR1 and I wanted to 
find out which parallels do exist between the presented murine model and human liver data. I hypothesized 
that liver disorders with inflammation would significantly differ from diseases without inflammation, 
irrespectively of a viral background. I thought that most probably liver tumors would not differ regarding 
their origin. I also did not expect to be able to prove metastasis in the presented mouse model based on 
preliminary data where I had not found any lung metastases. In order to disprove all these hypotheses and to 
address the questions I have performed various experiments with the following experimental outcome.  
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1. Results Mechanisms of Inflammation-induced Hepatocarcinogenesis 
1.6 LT-driven mechanisms inducing chronic hepatitis and HCC 
1.6.1 Upregulation of LT, LT and LTR in HBV or HCV infected human livers 
The specific role of LT signaling in the pathogenesis of virus-induced hepatitis and HCC formation is not 
completely defined. I analyzed transcriptional levels of LT, LT, LIGHT, TNF, LTR and TNFR1 in 
human HBV- or HCV-induced chronic hepatitis and HCC or in non-viral HCC compared to healthy liver 
specimens (Figs. 7 and 8).  
 
Figure 7: mRNA expression of TNF-superfamily members in viral (HBV, HCV induced) and non-viral liver 
diseases. Analysis of hepatic LT LT and LTR transcription by real-time PCR. Healthy individuals (Ctrl; n=1 5), 
patients chronically infected with HBV (n=19), HCV (n=49), affected by HCC (n=30) or suffering from various non-
virus related liver disorders were investigated. Non-virus related liver diseases with hepatitis include alcoholic 
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steatohepatitis (ASH; n=13), cholestasis (CH; n=3), primary biliary cirrhosis/ autoimmune cholangitis (PBC; n=5), end 
stage liver cirrhosis due to alcoholic liver disease (CIR; n=8), 1-antitrypsin deficiency (1AT; n=1) and focal liver 
fibrosis (FLF; n=2). Non-virus related liver diseases without hepatitis include steatosis (ST; n=5), 
hemochromatosis/siderosis (HE; n=3), and Wilson’s disease (WD; n=1). Focal nodular hyperplasia (FNH; n=8) was 
investigated as a benign primary liver tumor. Diseases such as 1AT (●), FLF (▲), HE/SID (•'), and WD (Δ) are 
listed under “other liver diseases” (OLD). Horizontal bars represent the average mRNA expression level. The y-axis 
describes the CT values on a log2 scale. *, **, *** indicate statistical significance: * = p≤0.05; ** = p<0.001; *** = 
p<0.0001. 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: mRNA expression of TNF-superfamily members in viral (HBV, HCV induced) and non-viral liver 
diseases. Analysis of hepatic LIGHT, TNFR1, and TNF transcription by real-time PCR. Healthy individuals (Ctrl; 
n=1 5), patients chronically infected with HBV (n=19), HCV (n=49), affected by HCC (n=30) or suffering from 
various non-virus related liver disorders were investigated. Non-virus related liver diseases with hepatitis include 
alcoholic steatohepatitis (ASH; n=13), cholestasis (CH; n=3), primary biliary cirrhosis/ autoimmune cholangitis (PBC; 
n=5), end stage liver cirrhosis due to alcoholic liver disease (CIR; n=8), 1-antitrypsin deficiency (1AT; n=1) and 
focal liver fibrosis (FLF; n=2). Non-virus related liver diseases without hepatitis include steatosis (ST; n=5), 
hemochromatosis/siderosis (HE; n=3), and Wilson’s disease (WD; n=1). Focal nodular hyperplasia (FNH; n=8) was 
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investigated as a benign primary liver tumor. Diseases such as 1AT (●), FLF (▲), HE/SID (•'), and WD (Δ) are 
listed under “other liver diseases” (OLD). Horizontal bars represent the average mRNA expression level. The y-axis 
describes the CT values on a log2 scale. *, **, *** indicate statistical significance: * = p≤0.05; ** = p<0.001; *** = 
p<0.0001. 
 
Figure 9: mRNA expression in non-virus related HCC; gender distribution, correlation analysis of LT and 
LT mRNA expression with Knodell score, fibrosis, as well as mRNA expression analysis of chemokines in non 
virus related HCC. (A) Real-time PCR analysis for LT, LT, LIGHT, LTR, TNF and TNFR1 transcripts in non-
virus related HCC (NVH). Each symbol represents one individual patient. Horizontal bars represent the average LT 
and LT mRNA expression level. The y-axis describes the CT values on a log2 scale. Ctrl left and NVH right. (B) 
Box plot analysis depicts age and gender distribution of respective patients. Ctrl: healthy control patients. HBV: 
Hepatitis B virus. HCV: Hepatitis C virus. HCC: Hepatocellular carcinoma. Each symbol represents one individual 
patient. Horizontal bars represent the average LT or LT mRNA expression level. The y-axis describes the CT 
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values on a log2 scale. (C) Correlation analysis of LT and LT mRNA expression with Knodell score (ranging from 
0-16) in HCV-infected livers. (D) Correlation analysis of LT and LT mRNA expression with fibrosis score (ranging 
from 0-4) in HCV-infected liversHorizontal bars represent the average mRNA expression level. The y-axis describes 
the CT values on a log2 scale. Standard deviation (+/- SD) is indicated by error bars. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: mRNA expression in non-virus related HCC; age and gender distribution, correlation analysis of 
LT and LT mRNA expression with Knodell score, fibrosis, age, and HCV genotype, as well as mRNA 
expression analysis of chemokines in HBV- or HCV-infected livers and HCC. (A) Correlation analysis of LT and 
LT mRNA expression with age (ranging from the 3rd to the 8th decade) in HCV-infected livers. (B) Correlation 
analysis of LTand LT mRNA expression with HCV genotypes. (C) Analysis of CCL2, CCL3, CCL5, CXCL1, and 
CXCL10 mRNA expression by real-time PCR in human livers of healthy controls (n=15), patients chronically infected 
with HBV (n=19) or HCV (n=49) and patients suffering from HCC (n=30). Horizontal bars represent the average 
mRNA expression level. The y-axis describes the CT values on a log2 scale. Standard deviation (+/- SD) is 
indicated by error bars. 
 
LT, LT and LTR mRNA expression was increased on average ~27 to 210 fold in HBV- or HCV-induced 
A
B
C
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hepatitis and HCC (P<0.001), whereas LIGHT transcripts were less elevated (on average ~23 to 25 fold; 
P<0.001). Likewise, TNFR1 mRNA expression was significantly increased in HBV- or HCV-induced 
hepatitis and HCC (on average ~27 to 29 fold; P<0.0001).In contrast, TNF was only slightly upregulated in 
HBV-induced hepatitis (P=0.04), while no significant increase was observed in HCV-induced hepatitis 
(P=0.3) and HCC (P=0.4). In most cases, HCV genotype, degree of inflammation (Knodell score), fibrosis 
(Metavir score) and liver enzyme levels (ALT; AST) were assessed (Tables 2-5).  
Levels of LT, LT and LTR mRNA expression did not correlate with the degree of liver inflammation 
(P=0.5), fibrosis (P=0.5), patient age (P=0.5), gender (P=0.5), HCV genotype or type of virus infection 
(HBV; HCV; HBV/HCV co-infection in the case of some HCC; P=0.5) (Figures 9 and 10; data not shown). 
To determine whether upregulation of LT ligands and receptors was specific for HBV- or HCV-induced 
liver diseases, I examined transcript levels in non-viral liver diseases. These included liver disorders with 
hepatitis [alcoholic steatohepatitis (ASH); cholestasis (CH); primary biliary cirrhosis/autoimmune 
cholangitis (PBC); end-stage liver cirrhosis due to alcoholic liver disease (CIR)] and liver diseases without 
inflammation [steatosis (ST), focal nodular hyperplasia (FNH)]. Additionally, other liver diseases (OLD) 
such as hemochromatosis/siderosis, Wilson’s disease, focal liver fibrosis, 1-antitrypsin deficiency and 
non-viral HCC (NVH) were investigated. 
Levels of LT, LT and LTR mRNA were significantly lower in all non-viral liver diseases analyzed 
except NVH when compared to virus-induced chronic hepatitis and HCC (LTP<0.0001; LT: P=0.05; 
LTR: P<0.0001; Figs. 7 - 101). This was irrespective of whether non-viral liver diseases were associated 
with inflammation or not. LIGHT and TNFR1 mRNA expression in non-viral liver diseases including NVH 
was similar to HBV- or HCV-induced chronic hepatitis and HCC. In contrast, TNFα mRNA expression was 
significantly higher in non-viral liver diseases with inflammation and NVH compared to healthy livers 
(P<0.0001), HBV- or HCV-induced hepatitis and HCC (P<0.0001). 
Levels of LT, LT and LTR mRNA expression did not correlate with the degree of liver inflammation 
(P=0.5), fibrosis (P=0.5), patient age (P=0.5), gender (P=0.5), HCV genotype or type of virus infection 
(HBV; HCV; HBV/HCV co-infection in the case of some HCC; P=0.5) (Figures 9 and 10; data not shown). 
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Table 2: Overview of HCV infected chronically inflamed human livers that were incorporated in the analysis. 
Etiology, patient age, patient gender, degree of inflammation (0-2), deg ree of fibrosis (0-4), transaminase levels 
[Aspartat-Aminotransferase (AST), Alanin-Aminotransferase (ALT)], and HCV subtype are indicated. Degree of 
inflammation and fibrosis was evaluated by using the Metavir Score; nd: not determined. 
Etiology Age (years) Gender AST (U/l) ALT (U/l) Inflammation Fibrosis HCV genotype 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
44 
45 
47 
36 
57 
34 
45 
35 
57 
38 
64 
47 
52 
66 
37 
45 
25 
69 
37 
45 
39 
55 
47 
45 
75 
54 
66 
58 
25 
66 
49 
39 
38 
31 
45 
42 
64 
71 
54 
54 
42 
69 
46 
58 
40 
57 
40 
38 
64 
F 
M 
M 
M 
F 
M 
M 
F 
M 
F 
M 
M 
M 
M 
M 
M 
M 
F 
M 
F 
F 
M 
M 
F 
F 
M 
M 
F 
M 
F 
M 
M 
M 
F 
F 
F 
M 
M 
F 
F 
M 
F 
M 
M 
F 
F 
M 
M 
M 
20 
42 
33 
9 
58 
77 
40 
44 
18 
36 
nd 
13 
53 
16 
20 
59 
54 
36 
28 
113 
36 
43 
56 
20 
83 
24 
16 
131 
60 
71 
30 
46 
86 
32 
30 
13 
52 
51 
28 
28 
27 
86 
72 
29 
25 
35 
36 
64 
67 
34 
91 
79 
6 
71 
152 
72 
93 
32 
44 
nd 
6 
43 
33 
45 
55 
147 
71 
32 
182 
34 
50 
38 
26 
91 
26 
33 
59 
144 
89 
38 
39 
177 
51 
32 
26 
52 
106 
24 
24 
44 
144 
109 
36 
22 
57 
103 
129 
91 
1 
1 
0 
0 
1 
1 
1 
0 
1 
0 
nd 
2 
nd 
2 
1 
1 
2 
1 
1 
2 
1 
1 
1 
1 
2 
1 
2 
2 
1 
2 
1 
1 
2 
1 
0 
0 
2 
1 
1 
1 
2 
1-2 
1 
1 
0 
1 
1 
1 
1 
3 
3 
2 
0 
2 
1 
2 
1 
1 
1 
nd 
3 
nd 
3 
1 
2-3 
2 
2 
2 
3 
2 
2 
0 
2 
3 
2 
3 
4 
1 
3 
1 
1 
3 
2 
1 
0 
2 
1 
1 
1 
3 
2 
1 
3 
0 
2 
2 
2 
3 
3 
1 
1 
2 
3 
1 
3 
1 
1 
3 
nd 
1 
3 
1 
1 
1 
1 
1 
3 
3 
3 
1 
1 
1 
1 
2 
1 
1 
1 
1 
3 
nd 
3 
1 
3 
1 
1 
1 
2 
2 
1 
1 
1 
1 
3 
1 
3 
1 
1 
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Table 3: Overview of HCV and HBV infected chronically inflamed human livers that were incorporated in the 
analysis. Etiology, periportal inflammation (0-10), intralobular inflammation (0-4), portal inflammation (0-4), degree 
of fibrosis (0-4) and Knodell score (0-16) are indicated. Degree of hepatitis activity and fibrosis was evaluated by 
using the Knodell necroinflammatory score; nd: not determined. 
Etiology Periportal 
(0-10) 
Intralobular 
(0-4) 
Porta 
(0-4) 
Score 
(sum)
K fibrosis 
score 
Entire score 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
nd 
1 
4 
3 
4 
4 
4 
1 
1 
3 
1 
4 
4 
3 
1 
1 
1 
3 
4 
1 
3 
3 
4 
4 
3 
3 
4 
4 
1 
4 
3 
3 
4 
3 
nd 
1 
3 
1 
3 
1 
4 
1 
1 
1 
1 
4 
1 
1 
3 
3 
3 
3 
4 
1 
3 
1 
4 
4 
1 
1 
4 
3 
1 
4 
3 
1 
4 
1 
nd 
3 
4 
4 
4 
4 
4 
3 
4 
3 
3 
4 
3 
4 
1 
3 
3 
3 
4 
3 
4 
4 
4 
4 
3 
3 
4 
4 
1 
4 
3 
3 
4 
4 
nd 
5 
11 
8 
11 
9 
12 
5 
6 
7 
5 
12 
8 
8 
5 
7 
7 
9 
12 
5 
10 
8 
12 
12 
7 
7 
12 
11 
3 
12 
9 
7 
12 
8 
nd 
1 
4 
3 
3 
1 
4 
1 
3 
1 
1 
4 
3 
1 
1 
1 
1 
1 
1 
1 
3 
1 
3 
3 
1 
3 
3 
3 
0 
1 
1 
1 
4 
1 
nd 
6 
15 
11 
14 
10 
16 
6 
9 
8 
6 
16 
12 
9 
6 
8 
8 
10 
13 
6 
13 
9 
15 
15 
8 
10 
15 
14 
3 
13 
10 
8 
16 
9 
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Etiology Periportal 
(0-10) 
Intralobular 
(0-4) 
Porta 
(0-4) 
Score 
(sum)
K fibrosis 
score 
Entire score 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
HCV 
 
HBV 
HBV 
HBV 
HBV 
3 
1 
1 
1 
4 
3 
1 
1 
3 
3 
3 
1 
4 
4 
1 
3 
4 
4 
3 
4 
3 
3 
3 
1 
3 
4 
1 
3 
0 
 
1 
4 
1 
1 
3 
1 
1 
1 
3 
1 
1 
1 
3 
1 
3 
1 
4 
4 
1 
1 
3 
3 
1 
3 
4 
1 
1 
1 
0 
1 
1 
1 
0 
 
1 
1 
2 
1 
4 
3 
4 
1 
4 
1 
3 
1 
4 
3 
4 
1 
4 
4 
3 
3 
4 
4 
3 
4 
3 
3 
3 
3 
3 
4 
3 
3 
3 
 
3 
9 
4 
3 
10 
5 
6 
3 
11 
5 
5 
3 
10 
7 
10 
3 
12 
12 
5 
7 
11 
11 
7 
11 
10 
7 
7 
5 
6 
9 
5 
7 
3 
 
3 
9 
4 
3 
3 
2 
3 
0 
1 
1 
1 
3 
3 
0 
4 
0 
3 
3 
1 
1 
3 
1 
1 
4 
1 
1 
1 
1 
1 
3 
0 
3 
0 
 
0 
3 
1 
0 
13 
7 
9 
3 
12 
6 
6 
6 
13 
7 
14 
3 
15 
15 
6 
8 
14 
12 
8 
15 
11 
8 
8 
6 
7 
12 
5 
10 
3 
 
3 
12 
5 
3 
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Table 4A: Overview of HBV infected chronically inflamed human livers that were incorporated in the analysis. 
Etiology, patient age, patient gender, degree of inflammation (0-2), degree of fibrosis (0-4) and transaminase levels 
[Aspartat-Aminotransferase (AST), Alanin-Aminotransferase (ALT)] are indicated. Degree of inflammation and 
fibrosis was evaluated by using the Metavir Score; nd: not determined. 
 
Etiology Age 
(years) 
Gender AST (U/l) ALT (U/l) Inflammation Fibrosis HCV 
genotype 
HBV/HCV 
HBV 
HBV 
HBV 
HBV 
HBV 
HBV 
HBV 
HBV 
HBV 
HBV 
55 
34 
33 
44 
42 
51 
69 
23 
54 
61 
48 
M 
M 
F 
M 
M 
M 
M 
F 
M 
M 
M 
60 
34 
38 
56 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
98 
79 
104 
95 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
0 
1 
0 
2 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
0 
0 
0 
3 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
 
 
Table 4B: Overview of HBV infected chronically inflamed human livers that were incorporated in the analysis. 
Diagnosis, HBsAg and HBcAg status, patient age and gender; nd: not determined. HBsAg: Hepatitis B virus surface 
antigen. HBcAg: Hepatitis B virus core protein antigen.  
 
Diagnosis HbsAg HBcAg Age Gender 
HBV 
HBV 
HBV 
HBV 
HBV 
HBV 
HBV 
HBV 
+++ 
+++ 
+++ 
+++ 
+++ 
+++ 
++ 
++ 
- 
- 
+ 
+ 
- 
- 
+ 
- 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
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Table 5: Overview of human HCC that were incorporated in the analysis. Additional diagnosis, viral genotype, patient 
age and patient gender are indicated. HBsAg: Hepatitis B virus surface antigen. HBcAg: Hepatitis B virus core protein 
antigen. 
Diagnosis HbsAg HBcAg Age Gender 
HCC,HBV 
HCC,HBV 
HCC,HBV 
HCC,HBV 
HCC,HBV 
HCC,HBV 
HCC,HBV 
HCC,HBV 
HCC,HBV,HCV 
HCC,HBV 
HCC,HBV 
HCC,HBV 
HCC,HBV 
HCC,HBV 
HCC,HBV 
HCC,HBV,HCV 
HCC,HBV 
HCC,HBV 
HCC,HBV 
HCC,HBV 
HCC,HBV 
HCC,HBV 
HCC,HBV 
HCC,HBV 
HCC,HBV,HCV 
HCC,HBV,HCV 
HCC,HBV 
HCC,HBV 
HCC,HBV 
HCC,HBV 
+++ 
+++ 
+++ 
++ 
+ 
+++ 
+++ 
- 
++ 
- 
- 
- 
 
51 
nd 
32 
50 
45 
55 
62 
42 
47 
63 
70 
82 
45 
71 
67 
51 
77 
70 
56 
62 
48 
51 
50 
69 
47 
61 
60 
49 
61 
55 
M 
nd 
M 
M 
M 
M 
M 
M 
M 
M 
M 
M 
M 
M 
M 
M 
M 
M 
M 
M 
M 
M 
M 
M 
F 
F 
F 
F 
F 
F 
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1.6.2 Increased chemokine expression in HBV- or HCV-induced hepatitis and HCC 
To confirm that pro-inflammatory signaling cascades are activated during HBV- or HCVinduced hepatitis 
and HCC formation, chemokine mRNA expression levels were measured (Fig. 10). CCL2, CCL3, CCL5 
and CXCL10 mRNA expression was significantly higher in human HBV- (P<0.0001) or HCV- 
(P<0.0001) induced hepatitis and HCC (P<0.0001) compared to healthy controls. CXCL1 mRNA 
expression was significantly increased in HBV-induced hepatitis (P<0.0001) and HCC (P=0.02) but not in 
HCV-induced hepatitis (P=0.07). 
 
1.6.3 Upregulation of LT, LT, LIGHT upon HCV infection in vitro  
I next investigated whether LT, LT, LIGHT and LTR transcripts can be directly upregulated by 
hepatocytes as a consequence of viral infection. Thus, a human hepatocyte cell line (Huh-7.5; (Blight et 
al., 2002)) was challenged with infectious HCVcc (Pietschmann et al., 2006) and cytokine as well as 
chemokine expression was measured (Fig. 11A). 
At 48 to 72 hrs post infection, LT (P=0.05), LT (P=0.05), LIGHT (P=0.05), LTR (P=0.05) and 
chemokine transcripts (CCL2, CCL3, CXCL1 and CXCL10) were increased (2-32 fold) in HCVcc-infected 
compared to non-infected Huh-7.5 cells. 
 
1.6.4 Identification of liver cells expressing LTR and its ligands in HBV or HCV infections 
To identify the cellular source of LT, LT, LTR and LIGHT expression in human HCV-infected livers, 
cells were collected from HCV-induced hepatitis and HCC (Figs. 11A and 12). Liver cells were sorted 
according to their CD45 surface expression, resulting in CD45-enriched (T-, B-cells; monocytes, 
macrophages/Kupffer cells; dendritic and NK-cells) or CD45-depleted fractions (hepatocytes, oval cells, 
bile duct epithelial and endothelial cells). Purity of CD45-enriched or -depleted fractions was assessed by 
real-time PCR for lymphocyte (CD3; CD20; CD45) or hepatocyte (cytokeratin 18) markers. CD45-
depleted fractions displayed only a minor contamination with CD45 mRNA (~1-10%). Vice versa, CD45-
enriched fractions showed only a minor amount of cytokeratin 18 mRNA transcripts (~2-20%; Fig. 11C; 
data not shown). 
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Fig. 11: HCVcc infection of human hepatocytes in vitro and analysis of HCV-infected liver cells in 
vivo. (A) Real-time PCR analysis for the mRNA expression of LT, LT, LIGHT, LTR, CXCL1, CXCL10, 
CCL2 and CCL3 in a human hepatocyte cell line (Huh7.5) upon challenge with infectious HCVcc at 48 and 
72 hrs post infection. Horizontal bars represent the average mRNA expression levels. The y-axis describes 
the CT values on a log2 scale. For control, non-infected, time-matched control Huh7.5 cells were 
investigated. hrs: hours postinfection. Standard deviation (+/- SD) is indicated by error bars. (B) 
Immunohistological analysis of human healthy controls, HBV- and HCV-infected livers or HCC: H&E 
staining and staining for CD20 (B-cells) and CD3 (T-cells) was performed. H&E staining indicates 
morphological features of inflamed and fibrotic liver tissues (HBV- and HCV infected livers). HCC display 
transformed hepatocytes. The HCC border zone is indicated by a dashed line (upper row, right column). 
Inflammatory infiltrates were detected in HBV- or HCV-infected livers as well as at the border zones of 
HCC (scale bar: 100m). (C) Real-time PCR analysis for CD45 and Cytokeratin 18 mRNA expression to 
quantify the purification efficiency of CD45-enrichment or CD45-depletion. Cells were prepared from 
HCV-infected, inflamed livers (HCV) or from HCC with HCV etiology (HCV/HCC). Horizontal bars 
represent the average mRNA expression level. The y-axis describes the CT values on a log2 scale. 
Standard deviation (+/- SD) is indicated by error bars. 
 
Within HCV-induced HCC, CD45-enriched and -depleted liver cells expressed similar LTα or LT 
mRNA levels (LTα: P=0.8; LT: P=0.1) that were significantly higher than in unsorted liver cells 
of healthy individuals (P<0.0001) (Fig. 11A). 
 
1.6.5 Hepatocyte-specific LT and  overexpression induces chronic progressive 
hepatitis 
Whether sustained hepatic LTR signaling is causally linked to chronic hepatitis and liver cancer 
was investigated in transgenic mice. Two independent lines expressing LT and under the 
control of the albumin enhancer/promoter embedded in a Prnp half genomic construct (phgPrP; 
Raeber et al., 1999) were generated by Mathias Heikenwälder and Nicolas Zeller and analyzed by 
the three of us. These two lines express LTand  in a liver specific manner, either at low (i.e. 
tg1222) or at high level (i.e. tg1223; (Heikenwalder et al., 2005)). Although livers of tg1222 and 
tg1223 mice were histologically indistinguishable from those of negative littermates at three 
months of age (Fig. 13), the hepatic transcriptome was already considerably altered in tg1223 and 
to a lesser degree in tg1222 mice (Fig. 15; data not shown). Genes with the most dramatic 
expression changes were identified by DNA microarray analysis and confirmed by real-time PCR 
(Fig. 15). 
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Figure 12: Identification of cell types expressing TNF-superfamily members in virus-infected or HCC-affected 
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livers. (A) Histology of representative paraffin sections of healthy controls, HCV-infected livers, and HCC with HCV 
etiology. HCV-infected livers (HCV) and tumors (HCV/HCC) display leukocytic infiltrates. H&E: Hematoxylin and 
eosin staining. The tumor border is indicated by a dashed line (scale bar: 100m). (B) Real-time PCR analysis of 
sorted, CD45-enriched or CD45-depleted liver cells. For control, whole liver cell populations derived from healthy or 
diseased livers (HCV infected/HCC) were used. mRNA expression levels are normalized to unsorted, total cell 
populations of the respective liver disease and calculated as 100%. The average expression level is indicated as 
percentage of control (unsorted cells of the respective disease) and demarcated by horizontal bars. *, **, *** indicate 
statistical significance (Student’s T-test): * = p≤0.05; ** = p<0.001; *** = p<0.0001. (C) Immunohistochemical 
(upper and lower panel) and immunofluorescence analysis for LT expression in healthy, HBV- or HCV-infected and 
HCC-affected livers (scale bar: 50m). Arrowhead depicts LT+ leukocytes, arrow LT+ hepatocytes. LTR mRNA 
transcript levels were significantly higher in CD45-depleted compared to CD45-enriched (P=0.006) or unsorted liver 
cells of healthy individuals (P<0.0001). In contrast, LIGHT mRNA expression was significantly increased in CD45-
enriched when compared to CD45-depleted (P=0.008) or unsorted liver cells of healthy individuals (P=0.0007). 
Within HCV-induced hepatitis, CD45-enriched cells exhibited a trend towards increased LTα mRNA levels (P=0.089) 
and a significant rise in both LT and LIGHT transcripts compared to CD45-depleted or unsorted cells of healthy 
individuals (LT: P=0.006; LIGHT: P=0.01). Similar to HCV-induced HCC, LTR mRNA expression was 
significantly higher in CD45- depleted compared to CD45-enriched (P=0.002) or unsorted control liver cells 
(P<0.0001). Thus, CD45-enriched liver cells but also CD45-depleted cell fractions express LT, LT and LIGHT in 
HCV-induced hepatitis and HCC. Immunohistochemical analysis for LT protein expression corroborated these data: 
CD3+, CD20+ lymphocytes and hepatocytes express LT protein in HBV- or HCV-induced hepatitis and HCC, which 
was in contrast to healthy liver specimens (Fig. 12C). 
 
As expected, LT and LT transcripts were increased in tg1222 and tg1222 livers (Fig. 15A; data not 
shown). Additionally, mRNA expression of chemokines (Ccl2, Ccl7, Cxcl1, Cxcl10), genes involved in 
early growth response (e.g. Egr1, Egr2), cholesterol metabolism (e.g. Ch25h) and immediate early response 
(e.g. c-Fos, Jun-b, Socs-3) were significantly (P<0.0001) elevated. In contrast, genes involved in cell cycle 
control, histone modifications and cell metabolism were significantly downregulated (P<0.0001) (Fig. 15A; 
data not shown). In situ hybridization at 3 months of age revealed LT, LT, Cxcl10, Ccl2 and Egr1 mRNA 
transcripts in tg1223 hepatocytes (Fig. 14 and 15B). The latter experiment was mainly performed together 
with Juliane Bremer.  
At the age of 4 months a slight increase in intrahepatic CD11b+, CD68+ and MHCII+ cells was detected in 
tg1223 mice compared to age-matched tg1222 or C57BL/6 mice (Fig. 16; data not shown). At this time 
point, no significant increase in IL1, IFN, IL6 and TNF protein levels was found (data not shown). At 4-
6 months transgenic livers started to develop strong portal and lobular (tg1223) or weak portal (tg1222) 
inflammation consisting of CD4+, CD8+ T-cells, B220+ B-cells and CD11c+ dendritic cells (Fig. 16; 
(Heikenwalder et al., 2005)). 
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Figure 13: Immunohistological analysis of paraffin- or cryo-sections derived from 3 or 4-6 month-old C57BL/6 
and transgenic livers. (A) C57BL/6, tg1222 and tg1223 livers lacked detectable inflammatory infiltrates as 
highlighted by H&E (scale bar: 200m), by staining for B-cells (B220), T-cells (CD3), macrophages, Kupffer cells 
(F4/80) (scale bar: 100m). 
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Figure 14: In situ hybridization of paraffin- or cryo-sections derived from 3 or 4-6 month-old C57BL/6 and 
transgenic livers. (A) In situ hybridization of liver cryo-sections from C57BL/6 and tg1223 mice with antisense 
probes for the indicated mRNAs. Arrowheads indicate focal hepatocyte-specific expression of Lt, Lt, Cxcl10, Ccl2 
mRNA as well as broad Egr1 mRNA expression. The size of scale bars is indicated. (B) Hybridization with sense 
probes served as negative control and did not lead to detectable signals for Lt, Lt, Cxcl10, Ccl2 and Egr1 mRNA 
expression. The size of scale bars is indicated. (C) Immunohistochemical analysis for myeloid cells at the age of 4 
months in tg1223 and C57BL/6 livers. A slight increase in the number of CD11b+, CD68+ and MHCII+ cells was 
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 detected in tg1223 livers at 4 months of age when compared to age matched tg1222 or C57BL/6 livers (left panel). I 
could already detect small aggregates at this particular time point, mainly consisting of myeloid cells (arrow heads). At 
the age of 4-6 months, B220+, CD3+ or F480+ cells accumulated at portal sites of tg1223 livers (right panel). In tg1222 
livers, only small portal inflammatory infiltrates could be observed at that time point (scale bar: 200m).  
 
 
Figure 15: Characterization of tg1223 livers. (A) Real-time PCR analysis for mRNA expression in liver of candidate 
genes at the age of 3 months. Data are presented in a log2 scale (blue: upregulated; red: downregulated). Rows indicate 
individual mice; columns represent particular genes. Each data point reflects the median expression of a particular 
gene resulting from 3-4 technical replicates, normalized to the mean expression value of the respective gene in 
C57BL/6 livers. (B) In situ hybridization of C57BL/6: Ccl2 and Egr1 antisense probes (age of 3 months). Multiple 
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scattered foci of hepatocyte-specific LT, LT, Cxcl10, Ccl2 and Egr1 mRNA were detected (scale bar: 50m).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Characterization of tg1223 livers. (A) Immunohistochemical analysis of representative 9 month-old 
C57BL/6 and tg1223 livers. B220 stained B-cells, CD3 T-cells, F4/80 macrophages, Kupffer cells and A6 oval cells 
(scale bar: 150m). Ki67+ proliferating hepatocytes (arrow heads) and inflammatory cells are indicated (scale bar: 
50m). (B) ELISA for IL1, TNF, IFN and IL6 in C57BL/6 (hollow symbols), tg1223 (filled symbols) or tg1222 
(dotted symbols) liver homogenates (9 months). (C) Flow cytometry of intrahepatic lymphocytes at 9 months of age. 
CD4 (T-helper cells), CD8 (cytotoxic T-cells), TCR (T-cells), CD19 (B-cells), IFN (Interferon ). IFNexpression 
was monitored on CD4/CD8 gated T-cells. Representative flow cytometry analyses are shown. Numbers in each 
quadrant indicate the relative percentage of cells. Staining intensity is depicted on a log scale. FSC: Forward scatter.  
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At ≥9 months of age, tg1223 livers exhibited strong portal and lobular lymphocytic infiltrates (Fig. 16A). A 
pronounced influx of F4/80+ macrophages and proliferation of A6+ oval cells was observed. Chronic 
inflammation coincided with increased proliferating Ki67+ hepatocytes (tg1223: 17±5 Ki67 cells/mm2 liver 
section; C57BL/6: 0.5±0.3 Ki67+ cells/mm2 liver section; P=0.003), which was not significant in age-
matched tg1222 livers (P=0.08; Fig. 16A; data not shown). 
At this stage, hepatitis was accompanied by increased protein levels of IL1 (P=0.05), IFN(P=0.05) and 
IL6 (P=0.05) and, to a lesser degree, of TNF in tg1223 livers. In tg1222 livers I observed only a slight 
elevation of these cytokines compared to C57BL/6 (Fig. 16B). Quantitative analysis of total intrahepatic 
lymphocytes revealed an increase in tg1223 livers (C57BL/6: 17-24x106 cells/liver; tg1223: 35-73x106 
cells/liver P<0.05). Intrahepatic lymphocytes were further characterized by flow cytometry (Fig. 16C) in 
cooperation with Giandomenica Iezzi. Frequencies of CD8+ (C57BL/6: 18±11%; tg1223: 38±10%), CD4+ 
(C57BL/6: 16±3%; tg1223: 26±6%) and TCR+ T-cells (C57BL/6: 33.5±9%; tg1223: 63.5±4%) were 
elevated (n=4), while NK1.1+ cells (C57BL/6: 12±2%; tg1 223: 7±2%) were reduced in tg1223 livers. 
Furthermore, an increase in the frequency of CD19+ B-cells was found in tg1223 livers (C57BL/6: 25±7%; 
tg1223: 52±4%). Elevated frequencies of IFN-producing CD4+ and CD8+ T-cells were found in tg1223 
mice, while IL17-producing cells remained unchanged (Fig. 16C; data not shown).  
 
1.6.6 LTand LT overexpression induces hepatotoxicity 
To determine whether chronic hepatitis leads to hepatocyte cell death in tg1222 or tg1223 mice, I analyzed 
serum transaminase levels (ALT and AST). From the age of 19 weeks on, serum ALT and AST levels were 
significantly elevated (P=0.05) in tg1223 but not in tg1222 mice (Fig. 17A). 
In line, apoptotic hepatocytes were frequently detected in tg1223 mice (tg1223: 40.3±11.4 TUNEL+ 
cells/mm2 liver section; C57BL/6: 3.9±6.2 TUNEL+ cells/mm2 liver section; P=0.0005) but rarely in tg1222 
and virtually absent in C57BL/6 mouse livers from the age of 6 months on (Fig. 17B and 19A, data not 
shown for tg1222 mice). 
Hepatitis persisted in both transgenic lines for ≥18 months. Phenotypes were much milder in tg1222 mice, 
implying that the LT expression level determined the severity of inflammation and liver injury. Therefore, 
tg1223 mice were selected for additional experiments and further key results were obtained from this mouse 
line. 
Nine month-old tg1223 and C57BL/6 livers were compared by DNA microarray and real-time PCR 
analysis. This revealed elevated mRNA expression of genes involved in embryogenesis (e.g. Dmrta1), liver 
inflammation (e.g. Pbfe1), carcinogenesis (e.g. Phlda3, Thrsp; (Kawase et al., 2009)), glucose homeostasis 
and insulin sensitivity (e.g. Fgf21), while mRNAs responsible for cell cycle control (Gadd45g) and protease 
inhibition (SerpinA9) were consistently downregulated (Fig. 19; data not shown). In contrast, genes found 
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to be strongly up- or downregulated at 3 months (Fig.15A) returned to normal levels in 9 month-old tg1223 
livers, except Lt and  mRNA, which remained at high levels. I found a significant upregulation of genes 
involved in cell division, liver inflammation, lipid metabolism, wound healing and tumorigenesis in 9 
month-old compared to 3 month-old tg1223 livers (P<0.001). Genes involved in growth arrest and 
apoptosis were significantly downregulated (P<0.001) (Figs. 19 and 20; data not shown). 
 
 
 
 
Figure 17: Chronic liver injury and HCC development in tg1223 mice. (A) Significant 
elevation of transaminases (ALT, AST) in sera of tg1223 mice from 19 weeks of age. Standard deviation (+/- SD) is 
indicated by error bars. (B) Increased hepatocyte cell death in tg1223 livers documented by H&E staining and 
TUNEL/DAPI assay. H&E: Hematoxylin & eosin: Black arrowheads indicate apoptotic hepatocytes. TUNEL: Green 
TUNEL+ hepatocyte nuclei indicate apoptosis (white arrowheads; scale bars: 50m). 
Results 
70 
A
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: HCC development in tg1223 mice. (A) Macroscopy of C57BL/6 (left panel) and tg1223 livers at the age 
of 12 (middle panel) and 18 months (right panel). White arrows indicate tumor nodules. White arrowhead indicates a 
liver lobe completely affected by HCC. Scale bar size is indicated. (B) Histological analysis of livers derived from 
C57BL/6 and tg1223 mice. Dashed line depicts the HCC border. Collagen IV staining highlights the broadening of the 
liver cell cords and loss of collagen IV networks indicative of HCC in tg1223 mice (scale bar: 200m). High numbers 
of Ki67+ proliferating hepatocytes (arrowheads) are onlyfound in tg1223 HCC (rightcolumn; scale bar: 100m). 
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Figure 19: Hepatocyte apoptosis and analysis of mRNA expression in 9 month-old tg1223 compared to age-
matched C57BL/6 livers. (A) Apoptotic hepatocytes were frequently observed in chronically inflamed tg1223 livers. 
Paraffin-sections of C57BL/6 and tg1223 livers were stained with H&E. Arrowheads indicate apoptotic hepatocytes 
with eosinophilic cytoplasms and shrunken nuclei surrounded by inflammatory cells in tg1223 but not in C57BL/6 
livers at the age of 9 months. Right panel: insert with higher magnification. (scale bars: 100m). (B, C) Based on a 
non-supervised DNA-microarray analysis, the expression of candidate genes was assessed by real-time PCR. 
Differences are reported as fold change. Standard deviation (+/- SD) is indicated by error bars. (B) At 9 months of age, 
strong upregulation of various genes involved in inflammatory processes and carcinogenesis (e.g. Spl1, Dmrta1, 
Results 
72 
Phlda3), cell adhesion and metastasis (e.g. P-Selectin), fibrogenesis (e.g. Fgf21), or carcinogenesis (Nrtk2, Tmem45b) 
were detected. (C) Genes responsible for cell cycle control (e.g. Gadd45g) were significantly downregulated in tg1223 
livers compared to C57BL/6 livers at the same age.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Analysis of mRNA expression in 9 month-old tg1223 compared to age-matched C57BL/6 livers. (A) 
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DNA-microarray analysis of C57BL/6 and tg1223 livers at 3 and 9 months of age. Indicated are the 100 highest up- 
and downregulated genes in 9 month-old tg1223 livers, when compared to 9 and 3 month-old C57BL/6 as well as 3 
month-old tg1223 livers. Columns indicate individual mice; rows represent particular genes. Data are presented in a 
log2 scale (blue: upregulated; red: downregulated). 
 
1.6.7 HCC development in tg1223 mice 
At 12 months of age, about 20% (6/34) of tg1223 mice developed macroscopically visible nodules that 
classified histologically as HCC, including broadening of liver cell cords, loss of collagen IV networks and 
increased proliferative activity. In contrast, age-matched C57BL/6 livers lacked HCC (0/20; P=0.05) (Figs. 
18A, B and Table 6 and 7). Tumor frequency increased with age reaching ~35% (18/51) by 18 months, 
whereas C57BL/6 mice did not develop HCC (0/35; P<0.0001) (Figs 19 - 21 and Table 6 and 7). 
 
Table 6: Chronic hepatitis and HCC incidence in tg1223 mice, tg1223 mice intercrossed with various knockout 
mice. (A) Chronic hepatitis and HCC incidence in 12 month-old tg1223 and C57BL/6 mice. (B) Chronic hepatitis and 
HCC incidence in 18 month-old tg1223 and intercrossed tg1223 mice. Statistical evaluation: *, **, *** indicate the 
degree of statistical significance: * = p<0.05; ** = p<0.001; *** = p<0.0001. 
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Table 7: (A) Tg1223 and (B) tg1223/tnfr1-/- mouse identification number (mouse ID), mouse age and sex, numbers of 
HCC/entire liver and HCC characteristics (size, cytological features) are described. I have divided the cytological 
variants found in HCC based on the diameter of hepatocytes and the mitosis frequency detected. Small cell: 
hepatocytes with a diameter < 18 m. Medium cell: hepatocytes with a diameter from 18 to < 21 m. Large cell: 
hepatocytes with a diameter > 21 m. Clear cell: Broad transparent cytoplasmic rim with strong increase of cytoplasm 
to nuclear ratio. All liver tumors were well differentiated HCC. 
 
(A)  
Mouse 
ID 
Age 
(months) 
Number of 
tumors 
Largest 
tumor (mm) 
Cytological 
variants 
Sex 
(F/M) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
12 
12 
12 
12 
12 
12 
18 
18 
18 
18 
18 
18 
18 
18 
18 
18 
18 
18 
18 
18 
18 
18 
18 
18 
4 
2 
3 
2 
1 
2 
7 
10 
2 
1 
3 
1 
8 
4 
4 
5 
10 
2 
7 
7 
3 
5 
2 
2 
2 
5 
4 
12 
4 
8 
9 
11 
25 
4 
12 
16 
5 
22 
18 
9 
4 
17 
10 
15 
5 
7 
6 
3 
Medium cell 
Medium cell 
Medium cell 
Large cell 
Medium cell 
Large cell 
Medium cell 
Clear cell 
Medium cell 
Medium cell 
Medium cell 
Large cell 
Clear cell 
Medium cell 
Small cell 
Medium cell 
Clear cell 
Large cell 
Medium cell 
Clear cell 
Small cell 
Medium cell 
Clear cell 
Medium cell 
F 
M 
F 
M 
F 
M 
M 
M 
M 
F 
F 
F 
F 
M 
M 
M 
F 
F 
M 
M 
M 
M 
F 
F 
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Mouse 
ID 
Age 
(months) 
Number of 
tumors 
Largest 
tumor (mm) 
Tumor 
histology 
Sex 
(F/M) 
19 
20 
21 
22 
18 
18 
18 
18 
4 
4 
1 
5 
18 
17 
12 
23 
Medium cell 
Medium cell 
Clear cell 
Medium cell 
M 
F 
F 
F 
Results 
76 
Figure 21: Macroscopic and histological analysis of HCC in 12 or 18 month-old tg1223 livers. (A) Macroscopic 
analysis of tg1223 HCC from 12 month-old mice. White arrows indicate HCC nodules. (inserts with higher 
magnification). Size of scale bars is indicated. (B) Consecutive sections of a tg1223 HCC revealed broadening of liver 
cell cords, loss of collagen IV networks (H&E; Collagen IV; arrow), and increased proliferative activity of 
hepatocytes. Ki67 cells are indicated by short arrows (scale bar: 100m). (C) Consecutive sections of a tg1223 HCC at 
the age of 18 months. The HCC compresses the adjacent hepatic parenchyma (scale bar: 5mm or 500m, 
respectively). Broadening of liver cell cords and loss of collagen IV networks was detected (H&E; Collagen IV). (D) 
Higher magnification of H&E stained liver sections from 18 month-old tg1223 mice reveals cellular changes (arrows) 
including apoptosis (left panel) or frequently observed atypical mitoses (middle and right panel) in tg1223 
hepatocytes. (E) Immunohistochemical analysis for A6+ cells (presumably oval cells) in or around HCC. 
Approximately 45% of tg1223 HCC were composed of A6+ cells, which were either focally or diffusely distributed. 
Other tg1223 HCC lacked A6+ cells within the tumor (very right panel) but were surrounded by these cells at the 
border zone of the tumor (second right panel). Tumor border is marked by dashed line (scale bar: 200m; insert: 
higher magnification). Tumors varied in size (1-25mm), histology and affected both genders with similar frequencies 
(males:females = 13:11; P=0 .3)(Fig. 18; Table 7). 
 
1.6.8 Chromosomal aberrations and local spread of HCC in tg1223 mice 
I further investigated micro-dissected tg1223 HCC (n=9) and age-matched C57BL/6 livers (n=5) for 
chromosomal aberrations. Array comparative genomic hybridization analysis (aCGH) revealed 
chromosomal aberrations in all tg1223 HCC (Fig. 22A and B; data not shown). 
Amplifications and deletions of chromosomal regions ranged from ≤ 1 mega-base (MB) to 160 MB and 
were detected in most autosomes of all analyzed tg1223 HCC. Of note, the pattern of chromosomal 
aberrations varied in HCC from different individual tg1223 mice (P=0.34). For control, aCGH analysis of 
independent C57BL/6 liver DNA samples did not reveal significant chromosomal aberrations (data not 
shown). 
I did not detect lung metastases but often saw multifocal intrahepatic disease in 18 month-old tg1223 mice. 
I therefore investigated whether multifocal tg1223 HCC represented intrahepatic spread of clonal tumors. 
Independent HCC (n=6) from different lobes of the same tg1223 liver were micro-dissected and 
subsequently analyzed by aCGH (Fig. 22B). All HCC taken from the same liver displayed significantly 
overlapping chromosomal aberrations throughout the entire genome (P<0.05), suggesting a clonal 
relationship of a tumor that has locally spread within the liver (Fig. 22B; data not shown). 
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Figure 22: aCGH analysis of tg1223 HCC. The q-arm of each chromosome is shown and chromosome numbers are 
indicated. Black ellipses on the top of each q-arm represent the centromere. Dark horizontal bars within the 
symbolised chromosomes represent G bands. Chromosomal deletions are indicated in blue, amplifications in red (see 
methods for details). (A) HCC of individual tg1223 mice were hybridized against liver tissue of age matched C57BL/6 
mice and analyzed by aCGH analysis. Columns next to each chromosome represent individual HCC (1; 2; 3) with 
numerous chromosomal aberrations on the q-arm of various autosomes. No common pattern of chromosomal 
aberrations could be detected. (B) aCGH analysis of six representative HCC (1, 2, 3, 4, 5 and 6) taken from different 
lobes of the same tg1223 liver. 
 
1.6.9 Expression of tumor markers GP73, GS and AFP in tg1223 HCC 
I then evaluated expression of human liver tumor markers golgi protein 73 (GP73), glutamine synthetase 
(GS) and -fetoprotein (AFP) in tg1223 livers (Bachert et al., 2007; Marrero and Lok, 2004; Marrero et al., 
2005; Sakamoto, 2009). GP73, GS and AFP protein expression was elevated in most tg1223 HCC as 
detected by immunohistochemistry and immunoblot analysis compared to C57BL/6 livers or unaffected 
liver regions adjacent to HCC (Fig. 23A-C; data not shown). 
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1.6.10 Mechanisms driving LT-induced chronic hepatitis and liver cancer 
To identify other receptors and molecular mediators potentially involved in LT-induced chronic hepatitis 
and HCC development, I intercrossed tg1223 with Tnfr1-/-, Tnfr2-/- or Ikkhep mice. The requirement of 
lymphocytes in chronic hepatitis and HCC formation was investigated by intercrossing with Rag1-/- mice, 
which lack mature lymphocytes. 
The absence of IKK, TNFR1 or lymphocytes per se did not appear to influence transgenic LT and LT 
mRNA expression (Figs. 15A and 23D; data not shown). Initially, at three months of age, tg1223/Ikkhep, 
tg1223/Tnfr1-/-, tg1223/Tnfr2-/- and tg1223/Rag1-/- mice lacked histological evidence of hepatitis similar to 
tg1223 mice (data not shown). The aberrant hepatic gene expression pattern described for 3 month-old 
tg1223 mice developed only partially in tg1223/Ikkhep and tg1223/Rag1-/- mice, whereas tg1223/Tnfr1-/- 
livers displayed an expression profile rather similar to that of tg1223 mice (Figs. 21 and 23D). 
At 9 months of age tg1223/Rag1-/- (n=26) and tg1223/IKKhep (n=18) livers lacked hepatitis, hepatocyte or 
oval-cell proliferation (Fig. 24), whereas tg1223/Tnfr1-/- (n=8) or tg1223/Tnfr2-/- (n=8) livers were 
indistinguishable from those of tg1223 mice (Figs. 21, 24A and B). At this age inflammatory foci were 
detectable in tg1223 and tg1223/IKKFF livers. In contrast, no inflammation could be observed in livers of 
C57BL/6, IKKhep and tg1223/IKKhep mice. Further investigation of liver paraffin sections of 9 month-
old tg1223/Tnfr1-/-  and tg1223/Tnfr2-/- mice showed severe inflammation within the liver while age-
matched Tnfr1-/- and Tnfr2-/- mice lacked signs of chronic hepatitis (Figs. 25 and 26). 
At the age of 18 months, tg1223/Rag1-/- (n=26) and tg1223/IKKhep (n=25) mice were devoid of hepatitis 
and HCC (P<0.0001) (Fig. 24C; Table 6) suggesting that both lymphocytes and hepatocyte-specific IKKβ 
expression are required for LT-induced chronic hepatitis and HCC development. Notably, tg1223/tnfr1-/- 
mice displayed HCC (4/12) with an incidence similar to tg1223 mice (Figs. 24C; Table 6 and 7) indicating 
that TNFR1 signaling is not essential for LT-induced HCC formation in tg1223 mice. 
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Figure 23: Expression of tumor markers in tg1223 HCC and mechanistic characterization of liver 
carcinogenesis in tg1223 mice. (A) Immunoblot analysis of C57BL/6 and tg1223 HCC homogenates for GP73. 
Strong to moderate signal intensities were detected in all tg1223 HCC, but not in C57BL/6 livers. (B) Immunoblot 
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analysis of C57BL/6 and tg1223 HCC homogenates for AFP. -Actin served as a loading control (kDa: kilo Dalton). 
(C) Immunohistochemistry for GP73 and GS in a representative tg1223 HCC and age-matched C57BL/6 control (scale 
bar: 100tm). (D) mRNA expression of candidate genes in livers of 3 month-old tg1223/Ikkhep, tg1223/Rag1-/- and 
tg1223/ TNFR1-/- mice. Data are presented in a log2 scale (blue: upregulated; red: downregulated). Rows indicate 
individual mice; columns represent particular genes. Each data point reflects the median expression of a particular 
gene resulting from 3-4 technical replicates, normalized to the mean expression value of the respective gene in 
C57BL/6 livers.  
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Figure 24: Expression of tumor markers in tg1223 HCC and mechanistic characterization of liver 
carcinogenesis in tg1223 mice. (A) Histological analysis of tg1223/Ikkhep, tg1223/Rag1-/-, tg1223/TNFR1-/-, and 
tg1223/TNFR2-/- livers at 9 months of age. H&E, B220 for B-cells, CD3 for T-cells (scale bar: 500m). (B) 
Immunohistochemical analysis of A6+ cells (oval cells) in livers of tg1223/Ikkhep, tg1223/Rag1-/-, tg1223/Tnfr1-/-, 
and tg1223/Tnfr2-/- mice at 9 months of age (scale bar: 500m). (C) Immunohistochemical analysis of tg1223/Ikkhep, 
tg1223/Rag1-/-, and tg1223/Tnfr1-/- livers (18 months of age). Dashed line depicts the HCC border (upper row; scale 
bar: 200m). Collagen IV staining highlights the broadening of liver cell cords and loss of collagen IV networks in 
tg1223/Tnfr1-/- HCC. Ki67+-proliferating hepatocytes are indicated by arrowheads (lower row; scale bar: 50m). 
 
 
 
Figure 25: mRNA expression analysis of 9 month-old tg1223, tg1223/IKKhep and tg1223/Rag1-/- compared to 
age-matched C57BL/6 livers. Based on a non-supervised DNA-microarray analysis expression of candidate genes 
was assessed by real-time PCR. Differences are reported as fold change. Backcrossing of tg1223 mice to IKKhep or 
to Rag1-/- mice resulted in a significant downregulation of some genes that were highly upregulated in 9 month-old 
tg1223 livers (Dmrta1, Phlda3, Pbef1, Fgf21; P=0.05). Standard deviation (+/- SD) is indicated by error bars. 
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Figure 26: Histological analysis of 9 month-old tg1223, tg1223/IKKhep and   tg1223/Rag1-/- compared to age-
matched C57BL/6 livers. (A) Hepatocyte-specific deletion of IKKhep prevents LT-induced inflammation in 
livers of tg1223 mice, whereas depletion of TNFR1 or TNFR2 does not affect chronic hepatitis development in tg1223 
mice. Histological and immunohistological analysis of liver paraffin sections from 9 month-old C57BL/6, tg1223, 
A 
B 
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IKKhep, tg1223/IKKFF, and Tg1223 /IKKhep mice. Sections were stained with H&E and antibodies detecting B- 
(B220), T- (CD3), and proliferating cells (Ki67). This revealed inflammatory foci in tg1223 and tg1223/IKKFF livers. 
In contrast, no inflammation was observed in livers of C57BL/6, IKKhep and tg1223/IKKhep mice (scale bar:200 
m). (B) Immunohistological analysis of liver paraffin sections of 9 month-old tg1223/Tnfr1-/-  and tg1223/Tnfr2-/- 
mice. Consecutive liver sections were stained with H&E and with antibodies detecting T- (CD3), and B-cells (B220). 
Age-matched Tnfr1-/- and Tnfr2-/- mice lacked signs of chronic hepatitis. Arrows denote foci of lymphocytic 
inflammation (scale bar: 200m). 
 
 
1.6.11 Hepatocytes are the major responsive liver cells to agonistic LTR antibody treatment 
To investigate whether hepatocytes represent the major LT-responsive liver cells and to investigate LTR 
signaling in Tnfr1-/- and Ikkhep livers, TNF (positive control), agonistic LTR antibody (3C8) and 
appropriate negative controls (PBS; rat IgG) were administered intravenously (i.v.) to C57BL/6 and various 
knock-out mice (Figs. 27-30; Table 7). Administration of 3C8 induced nuclear p65 translocation primarily 
in hepatocytes and some NPC of C57BL/6 livers (Fig. 27A), as well as transcriptional changes and 
upregulation of selected chemokines reminiscent of those observed in 3 month-old tg1223 livers (Fig. 27A). 
Similar results were obtained after 3C8 treatment of Tnfr1-/- mice, in contrast to IKKβhep livers which were 
devoid of nuclear p65 translocation in hepatocytes and NPC (Fig. 27A). 
As expected, TNF but not PBS treatment induced nuclear p65 translocation in hepatocytes and NPC of 
C57BL/6 mice. Moreover, transcription of selected NF-ĸB target genes was elevated in these mice similar 
to livers from 3 month-old tg1223 mice. Livers of TNFα treated Ikkhep mice did not exhibit nuclear p65 
translocation in hepatocytes but did in NPC. However, this sufficed to upregulate selected NF-ĸB target 
genes. Livers of TNF treated ltR-/- mice were indistinguishable from TNFα treated C57BL/6 livers.  
Furthermore, upregulation of selected NF-ĸB target genes could not be detected. For control, LtR-/- mice 
were treated with 3C8, lacking nuclear p65 translocation in hepatocytes or NPC as well as upregulation of 
selected NF-ĸB target genes. 
To examine whether lack of functional IKK on hepatocytes and NPC would suppress LTR induced 
upregulation of selected NF-ĸB responsive genes, I investigated livers of mice expressing a non-
phosphorylatable IkkAA/AA knock-in allele (IkkAA/AA; (Cao et al., 2001). Upon 3C8 treatment IkkAA/AA mice 
upregulated selected NF-ĸB responsive genes (Fig. 29). The degree of mRNA upregulation in liver was 
similar to 3C8-treated C57BL/6 mice. In contrast, control treated (rat IgG) IkkAA/AA mice lacked 
upregulation of selected NF-ĸB responsive genes. This suggests that 3C8-mediated hepatic LTR signaling 
is mainly integrated by hepatocytes involving canonical NF-ĸB pathway. 
Moreover increased levels of chemokines were detectable in sera and liver homogenates of C57BL/6 mice 
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after 3C8 but not after rat IgG treatment (Figure 30): 
 
 
 
Figure 27: Effects of acute 3C8 treatment in mice. Immunohistochemical analysis of nuclear p65 translocation and 
real-time PCR for mRNA expression of selected NF-ĸB target genes in livers of C57BL/6 and various knock-out mice 
treated with 3C8. Data are presented on a log 2 scale (blue: upregulated; red: downregulated). Rows indicate 
individual mice; columns represent particular genes. Each data point reflects the median expression value of a 
particular gene resulting from 3-4 technical replicates, normalized to the mean expression value of the respective gene 
in C57BL/6 livers. (scale bar: 50tm). Expression data are depicted according to treatment group: rat IgG (control) or 
3C8 (LTI 3R agonist). Statistical significance was evaluated by t-test: * = p≤0.05; ** = p<0.001; *** = p<0.0001. 
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Figure 28: Macroscopy and histology of 18 month-old tg1223/Tnfr1-/- HCC, as well as molecular and histological 
characterization of hepatic signaling induced by acute TNFα treatment. (A) Macroscopic analysis of 
tg1223/Tnfr1-/- HCC (white arrows indicate liver tumors; insert, higher magnification). (B) Consecutive paraffin 
sections of a tg1223/Tnfr1-/- HCC compressing the adjacent hepatic parenchyma. Dashed lines indicate the border zone 
of the HCC. Arrow highlights the tumor nodule. Collagen IV stain reveals abnormally broad liver cell plates (scale 
bar: 250m). (C) Immunohistochemical analysis of nuclear p65 translocation and real-time PCR for mRNA 
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expression of selected NF-ĸB target genes. Data are presented on a log2 scale (blue: upregulated; red: downregulated). 
Rows indicate individual mice; columns represent particular genes. Each data point reflects the median expression 
value of a particular gene resulting from 3-4 technical replicates 45 min after treatment. Data points were normalized 
to the mean expression value of the respective gene in C57BL/6 livers. Statistical significance was evaluated by t-test: 
* = p≤0.05; ** = p<0.001; *** = p<0.0001.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: Molecular and histological characterization of hepatic signaling induced by acute TNFα treatment. 
A 
B 
C 
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(A) Immunohistochemical analysis of nuclear p65 translocation and (A, B) real-time PCR for mRNA expression of 
selected NF-ĸB target genes. Data are presented on a log2 scale (blue: upregulated; red: downregulated). Rows 
indicate individual mice; columns represent particular genes. Each data point reflects the median expression value of a 
particular gene resulting from 3-4 technical replicates 45 min after treatment. Data points were normalized to the mean 
expression value of the respective gene in C57BL/6 livers. Statistical significance was evaluated by t-test: * = p≤0.05; 
** = p<0.001; *** = p<0.0001. (A) Acute i.v. administration of TNFα in Tnfr2-/- livers caused nuclear p65 
translocation in hepatocytes and NPC, as well as elevated expression of selected NF-ĸB target genes (e.g. Ch25h, 
Egr2, Cxcl1, Ccl2, Cxcl10) (scale bar: 50m). In contrast, acute i.v. administration of TNFα in Tnfr1/2-/- mice failed to 
induce nuclear p65 translocation in hepatocytes and NPC, as well as upregulation of selected NF-ĸB target genes 
(scale bar: 50m). The described changes upon TNFα treatment were mainly TNFR1-mediated. Tnfr1-/- or Tnfr1/2-/- 
livers lacked nuclear p65 translocation in hepatocytes or NPC, as well as upregulation of all selected NF-ĸB target 
genes except Ccl2. (B) Selected NF-ĸB target genes were also investigated in livers of IkkAA/AA (right panel) and 
C57BL/6 (left panel) mice either treated with 3C8 or rat IgG. (C) Quantification of p65+- hepatocytes and NPC after 
TNF treatment in C57BL/6, Tnfr1-/-, Tnfr2-/-, Tnfr1/2-/- and IkkΔhep livers. Percentages of nuclear p65+ hepatocytes or 
NPC/ mm2 liver section are indicated. Acute i.v. administration of TNF into Tnfr1-/-, Tnfr1/2-/- and IkkΔhep livers 
failed to induce nuclear p65 translocation in hepatocytes, whereas TNFα injection into C57BL/6 or Tnfr2-/- mice 
caused hepatic nuclear p65 translocation. The same results were found for NPC; apart from pronounced nuclear p65 
translocation detected in TNF-treated IkkΔhep livers. Standard deviation (+/- SD) is indicated by error bars. Nuclear 
p65 (RelA) translocation in hepatocytes and non-parenchymal cells (NPC: e.g. Kupffer cells, lymphocytes), alterations 
in the hepatic transcriptome and protein expression of selected chemokines were examined. 
 
 
 
 
 
 
 
 
 
 
Table 7: Hepatocytes are the major LT responsive liver cell type. Nuclear p65 translocation was analyzed in 
hepatocytes and NPC and mRNA expression of selected NF-ĸB target genes was quantified in C57BL/6 or knockout 
livers. (-) indicates that the number of cells with nuclear p65 translocation does not exceed the one of the background 
controls. (+) indicates that nuclear p65 translocation does exceed the background controls. (%) indicates the 
percentage of a particular cell type displaying nuclear p65 translocation. 
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Acute PBS or TNF administration 
Mouse genotype Nuclear p65 
translocation in 
hepatocytes 
Nuclear p65 
translocation in 
NPC 
Upregulation of 
NF-B target 
genes 
 
Treatment 
C57BL/6 
- 
+ (95±3%) 
- 
+ (73±6%) 
- 
+ 
PBS 
 
TNF 
tnfr1-/- 
- 
- 
- 
- 
- 
     -  (*) 
PBS 
 
TNF 
Ikkhep 
- 
- 
- 
+ (62±7%) 
- 
+ 
PBS 
 
TNF 
ltr-/- 
- 
+ 
- 
+ 
- 
+ 
PBS 
 
TNF 
 (*) CCL2 was upregulated in all TNF treated tnfr1-/- mice investigated. This upregulation was however 
abolished in tnfr1/2-/- mice.  
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Acute rat IgG or 3C8 administration 
Mouse genotype Nuclear p65 
translocation in 
hepatocytes 
Nuclear p65 
translocation in 
NPC 
Upregulation of 
NF-B target 
genes 
 
Treatment 
C57BL/6 
- 
+ (90±3%) 
- 
+ (35±10%) 
- 
+ 
Rat IgG 
 
3C8 
tnfr1-/- 
- 
+ (86±3%) 
- 
+ (38±9%) 
- 
+ 
Rat IgG 
 
3C8 
Ikkhep 
- 
- 
- 
- 
- 
- 
Rat IgG 
 
3C8 
ltr-/- 
- 
- 
- 
- 
- 
- 
Rat IgG 
 
3C8 
 
1.6.12 Inhibition of LTR signaling reduces chronic hepatitis and carcinogenesis 
I further investigated the involvement of LTR signaling in the transition of chronic hepatitis to HCC by 
long-term LTR-Ig administration in tg1223 mice. Nine month-old tg1223 mice with chronic hepatitis 
(n=31) or age-matched C57BL/6 mice (n=23) were treated with LTR-Ig for 2 months, remained untreated 
for another 4 weeks and were then sacrificed. LTR-Ig treatment significantly reduced chronic hepatitis 
incidence in tg1223 mice compared to untreated tg1223 mice (tg1223 mice LTR-Ig treated: 4/31; tg1223 
mice untreated: 34/34; P<0.0001). Furthermore, LTR-Ig treatment suppressed chronic hepatitis-driven 
HCC formation (tg1223 mice LTR-Ig treated: 0/31; tg1223 mice untreated: 6/34; P<0.05) (Table 8; Figs. 
31 and 32). LTR-Ig treatment did not lead to overt histopathological alterations in C57BL/6 livers nor did 
I detect overt changes in lymphocyte (B-, T-cells) or macrophage populations within spleens of LTR-Ig 
treated compared to untreated C57BL/6 or tg1223 mice (data not shown). Efficiency of LTR-Ig treatment 
was ascertained by the loss of LTR-dependent follicular dendritic cells (FDCs) within C57BL/6 and 
tg1223 spleens (Fig. 33). 
Results 
90 
 
Figure 30: Increase of chemokines in sera and liver homogenates of C57BL/6 mice after 3C8 treatment. ELISA 
and multiplex-bead assay analysis of sera and liver tissue. I.v. injection of 3C8 into C57BL/6 mice led to a rapid 
upregulation of (A) CXCL10, (B) CXCL1 and (C) CCL2 in contrast to rat IgG. Hepatic upregulation of CXCL10 and 
CXCL1 occurred earlier and was stronger in C57BL/6 liver homogenates than in sera. Lines depict the average result 
(+/- SD) from three individual mice analyzed (symbols).  
 
Table 8: Chronic hepatitis and HCC incidence in tg1223 mice and LTR-Ig treated tg1223 mice. (A) Reduced 
chronic hepatitis and HCC incidence in 12 month-old tg1223 mice treated with LTR-Ig. Statistical evaluation: *, **, 
*** indicate the degree of statistical significance: * = p<0.05; ** = p<0.001; *** = p<0.0001. 
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Figure 31: Effects of long-term LTR-Ig treatment in tg1223 mice. Histological analysis (H&E) of livers from 
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untreated (left column) and LTR-Ig treated (right column) C57BL/6 or tg1223 mice (12 months ofage). 
Representative sections show no hepatitis or HCC in untreated or LTR-Ig-treated C57BL/6 livers (upper row). 
Untreated tg1223 livers display hepatitis in 34/34 (middle panel, left column) and HCC in 6/34 cases (lower panel, left 
column). LTR-Ig treatment reduces the incidence of hepatitis (middle and lower panel, right column) and prevents 
HCC formation in LTR-Ig treated tg1223 mice. Arrowheads indicate inflammatory foci. Tumor border is indicted by 
a dashed line (scale bar: 200 m). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32: Immunohistological analysis of livers derived from LTR-Ig-treated mice. Liver sections were stained 
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with antibodies detecting T- (CD3), and B-cells (B220), macrophages and Kupffer cells (F4/80) as well as A6+ oval 
cells. LTR-Ig treatment reduced the incidence of chronic hepatitis significantly (tg1223 untreated: 34/34 mice; 
tg1223 LTR-Ig treated: 4/31). In the case of persistent inflammation in livers of LTR-Ig-treated mice I found B- 
(B220), T-cell (CD3) infiltrates, macrophages and Kupffer cells (F4/80), as well as oval cell proliferation 
(representative case with hepatitis in left panel, without any significant inflammation in right panel) (scale bar: 50m). 
 
 
 
Figure 33: Loss of LTR-dependent follicular dendritic cells (FDCs) within tg1223 and C57BL/6 mice upon 
LTR-Ig treatment. Immunohistologcial analysis for the presence of FDC networks in spleens of LTR-Ig-treated 
C57BL/6 or tg1223 mice. MFGE8 (FDC-M1) staining reveals a complete dedifferentiation of FDC networks in LTR-
Ig-treated C57BL/6 or tg1223 spleens. Arrowheads indicate FDC networks in spleens of untreated mice (scale bar: 
200m).  
 
These results can be summarized in a murine (Fig. 34) and a human model (Fig. 35) without claiming that 
these models already completely explain all facettes of carcinogenesis in the liver. 
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Figure 34: A model of chronic inflammation-induced hepatocarcinogenesis in tg1223 mice. Scheme of chronic 
inflammation-induced liver carcinogenesis in tg1223 mice: Transgenic hepatocytes (brown) express LT,  and 
induce chemokine production (e.g. CCL2, CCL7, CXCL1, CXCL10) in the presence of IKK and intrahepatic 
lymphocytes. Chemoattraction and activation of myeloid cells and lymphocytes expressing particular chemokine 
receptors (e.g. CXCR3, CXCR2, CCR2, CCR1) cause hepatitis: CXCL10 attracts CXCR3+ T- and NK-cells, CXCL1 
CXCR2+ T-, B-cells and neutrophils, CCL2 CCR2+ macrophages and CCL7+ attracts CCR1+ monocytes. Activated, 
infiltrating immune cells secrete cytotoxic cytokines (e.g. IL6; IL1, TNF, IFN, LT that cause tissue destruction, 
hepatocyte proliferation, cell death and tissue remodeling. In such an environment, hepatocytes are susceptible to 
chromosomal aberrations leading to HCC. Tissue destruction and remodeling supports the infiltration of activated 
inflammatory cells (e.g. myeloid cells) leading to a feed-forward loop towards chronic aggressive hepatitis. Asterisks 
indicate that genetic depletion ofthose components (IKK; T- and B-cells) blocks chronic hepatitis development and 
HCC. Blocking LTR signaling with LTR-Ig in 9 month-old tg1223 mice reduces chronic hepatitis incidence and 
prevents HCC. +: indicates the fortification of a described process. ┤: indicates the suppression of a described process. 
The transcription factor RelA is schematically depicted as a green circle, inducing transcription of NF-ĸB target genes 
(e.g. chemokines) (arrow). B, T: B- and T-cells. Mø: macrophages. N: neutrophils. NK: NK-cells. 
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Figure 35: Model describing chronic inflammation-induced liver carcinogenesis in humans. Hepatocytes are 
schematically shown in brown. Various factors can lead to hepatocyte cell stress: These include toxins (aflatoxin-b), 
chronic alcohol uptake, drug abuse, and most frequently viral infections (e.g. HBV or HCV). These stress conditions 
induce cell death and may lead to transcription of chemokines (e.g. CXCL10 leading to the attraction of neutrophils 
and macrophages (pink circles and white ellipses) as well as lymphocytes (red circle). Infiltrating lymphocytes 
attracted by chemokines or viral particles presented on MHC molecules, might become activated and upregulate 
cytokines (e.g. TNFα, IL6, IFN, LT) and may induce LTR signaling on hepatocytes. In the case of HBV- or HCV-
infection, LT is also upregulated on hepatocytes further promoting hepatocyte-specific chemokine expression (e.g. 
CXCL10 targeting CXCR3+ T- and NK-cells) and attraction of inflammatory cells. Chronic hepatitis leads to the 
sustained expression of cytotoxic cytokines in liver, inducing cell death and compensatory proliferation of 
hepatocytes. This drives secretion of chemokines and cytokines by hepatocytes and activated Kupffer cells, promoting 
a positive feed-forward-loop. Ultimately, local ongoing tissue remodeling and hepatocyte proliferation stochastically 
induces chromosomal aberrations in hepatocytes leading to a clonal progression towards HCC. Alternatively, chronic 
hepatitis can persist without resulting in HCC formation. Thus, these results imply that long-term suppression of LTR 
reduces chronic hepatitis incidence and can prevent the transition from chronic hepatitis to HCC in tg1223 mice.  
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1.7 DISCUSSION  
This study uncovered drastic and robust mRNA upregulation of LTR, LT and LT in HBVor HCV-
induced hepatitis and HCC. LT and LIGHT transcripts were mainly expressed by CD3+ T- and CD20+ B-
cells; a significant proportion of LT and LT expression was also attributable to hepatocytes. Notably, 
upregulation of LTR, LT and LT transcripts was also detected in non-virus related HCC, which could 
stem from activated, tumor infiltrating lymphocytes and/or from neoplastic hepatocytes that have 
upregulated LT, possibly in response to IL6. It was demonstrated that HCC derived cell lines express IL6 
(Baffet et al., 1991) and that LT levels are increased in response to IL6 in the latter (Subrata et al., 2005). 
Infection with HCVcc induced transcription of LT, LT, LTR, LIGHT and various chemokines in Huh-
7.5 cells recapitulating in part HCV-driven LT and chemokine expression of HCV-infected livers in vivo. 
LT signaling induces both, the canonical and the non-canonical NF-ĸB signaling pathways, whose role in 
controlling liver cancer formation remains controversial (Vainer et al., 2008). In a mouse model with acute 
DEN exposure, depletion of functional NF-ĸB signaling (IKKhep mice) increased hepatocyte cell death, 
enhanced Kupffer-cell activation and elevated HCC incidence (Maeda et al., 2005). In contrast, NF-ĸB 
signaling promotes HCC development in mdr2-/- mice (Pikarsky et al., 2004) and hepatocyte-specific 
depletion of IKK prevents HCC formation in tg1223 mice.  
How can this contradictory role of IKK signaling in HCC formation be reconciled? On the one hand IKK 
signaling might be required for hepatocytes to appropriately respond to and survive carcinogenic stimuli 
and acute liver injury (e.g. DEN exposure). On the other hand, IKKβ signaling might enable chemokine 
expression by hepatocytes leading to hepatitis and HCC. Consistent with this hypothesis, tg1223/Rag1-/- 
mice were devoid of chronic hepatitis, hepatocyte or oval-cell proliferation and failed to develop HCC. 
Why could immune cells contribute to liver tumorigenesis? One explanation might be that 
CD4+ or CD8+ T-cells expressing inflammatory cytokines (e.g. IL1β, TNFα, IFN) as well as 
cytolytic proteins (e.g. Granzyme B) contribute to hepatocyte cell death, tissue remodeling and 
transformation, finally leading to HCC (Budhu and Wang, 2006; Nakamoto et al., 1998). Intrahepatic 
lymphocytes may also influence the production of inflammatory mediators, as 3 month-old tg1223/Rag1-/- 
livers displayed markedly reduced cytokine and chemokine levels. I propose that rather than directly acting 
as a cell-autonomous oncogene on hepatocytes or A6+ oval cells, hepatic LT expression induces local 
upregulation of chemokines (e.g. Ccl2; Cxcl10, Cxcl1, Ccl7) by hepatocytes. This leads to the attraction of 
circulating inflammatory cells and a hyperproliferative, hepatotoxic environment stochastically leading to 
HCC formation (Figs. 34 and 35). It is worth mentioning that some chemokines found in this study (e.g. 
CXCL10) have been reported to be mainly expressed by human hepatocytes in chronic hepatitis C 
(Zeremski et al., 2007). 
Ablation of TNFR1 signaling did not prevent chronic hepatitis and HCC formation in tg1223 mice although 
anti-TNFα antibody treatment prevents HCC development in mdr2-/- mice (Pikarsky et al., 2004). I 
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investigated the mode of LT signaling in Tnfr1-/- livers upon 3C8 treatment. This induced analogous hepatic 
changes seen in tg1223 mice at 3 months of age. Similar to my results with tg1223/Tnfr1-/- mice, this 
suggests that heterotrimeric LT causes p65 translocation in hepatocytes and induces a TNFR1-independent 
signaling cascade via LTR, presumably contributing to chronic hepatitis and HCC. Most probably, HCC 
formation in mdr2-/- mice depends on pathways involving TNFR1 distinct from the LTR-dependent 
pathways described in my thesis. 
I sought to indentify the major LT responsive liver cell-type by using IKKhep mice. I.v. administration of 
TNF into IKKhep mice did not cause p65 translocation in hepatocytes but upregulated NF-ĸB target 
genes, presumably through TNFα-activated NPC. In contrast, 3C8 treatment in IKKhep mice neither 
induced nuclear p65 translocation in hepatocytes or NPC nor upregulation of selected NF-ĸB target genes. 
Therefore, hepatocytes but not NPC are likely to be the major liver cells integrating LT signaling. This 
explains why tg1223/IKKhep mice lack hepatitis and HCC although LTand  were constitutively 
expressed by transgenic hepatocytes. 
Upon 3C8 treatment, IKKAA/AA livers upregulated selected NF-ĸB target genes similar to C57BL/6 mice 
(Fig. 29). Therefore, the absence of IKK in both, hepatocytes and NPC, still allows NF-ĸB target gene 
expression upon 3C8 treatment, suggesting the involvement of the classical NF-ĸB pathway in LTR-
induced hepatic signaling. 
LTR signaling was reported to induce oval-cell proliferation (Akhurst et al., 2005), which is thought to 
contribute to the development of liver tumors (Lee et al., 2006). I observed proliferation of A6+ oval cells in 
chronically inflamed tg1223 livers at the age of 9 months and found A6+ cells within and at the border of 
tg1223 HCC. Whether those A6+ cells represent transformed oval cells contributing to liver carcinogenesis 
or whether A6 is upregulated on aberrant hepatocytes within HCC remains elusive.  
Lack of lymphocytes or chronic hepatitis prevented oval-cell proliferation, although LT,  transgene 
expression was unaltered. Therefore, it is conceivable that activated, infiltrating lymphocytes or Kupffer 
cells may contribute to oval cell proliferation by providing further LT or other cytokines in tg1223 livers. 
Based on the presented data, a sequence of events leading to chronic hepatitis and HCC in tg1223 mice can 
be proposed (Figs. 34 and 35). 
What are the possible clinical implications of my findings? Pharmacological inhibition of LTR signaling 
reduces virus-, bacteria- and concavalin A-induced liver injury (An et al., 2006; Anand et al., 2006; 
Puglielli et al., 1999), while triggering LTR signaling on hepatocytes appears beneficial during liver 
regeneration (Tumanov et al., 2008). Side-effects of pharmacologically inhibiting LTR signaling include 
alterations in the microarchitecture of white pulp follicles and disappearance of FDCs in non-human 
primates (Gommerman et al., 2002). Despite the loss of FDCs and a reduced capacity to trap immune 
complexes the primary antibody response to keyhole limpet hemocyanin was not significantly altered 
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(Gommerman et al., 2002). In tg1223 mice, inhibition of LTR signaling at the stage of chronic hepatitis 
partially reverted inflammation and prevented HCC formation, suggesting that LTR-Ig treatment might be 
beneficial in liver pathologies with sustained LTR, LT and LT expression. siRNA knock- down of 
various components of the LTR signaling pathway (e.g. LT; Rel A) interferes with HCV replication in 
vitro  (Ng et al., 2007). Therefore, inhibition of LTR signaling might also impede the efficiency of HCV 
replication.  
Through this study I can report that LTR and its ligands are drastically upregulated in chronic hepatitis B, 
C and in HCC. Immunohistochemistry and mRNA expression analysis revealed that LTs are expressed on 
both, lymphocytes and hepatocytes. Consistent with this result, challenge with infectious, cell culture 
derived HCV caused upregulation of LT, LT, LIGHT, LTR and various chemokines by a human 
hepatocyte cell-line in vitro. 
Sustained hepatic LT-expression caused chronic hepatitis and HCC formation in transgenic mice. 
Hepatitis and HCC development were prevented by the ablation of lymphocytes or hepatocyte-specific 
removal of IKK, yet HCC induction was TNFR1-independent. In vivo LTR stimulation with an agonistic 
LTR antibody identified hepatocytes as the major LT responsive liver cells and pharmacological in 
hibition of LTR signaling in LT-transgenic mice with hepatitis reduced liver inflammation and 
prevented HCC. These results demonstrate that sustained hepatic LT signaling is critically involved in 
hepatitis and HCC development.  
The presented results show that LT signaling is critically involved in hepatitis and subsequent HCC 
development and imply that blocking LTR signaling might become a beneficial therapeuticapproach in the 
context of HBV- or HCV-induced chronic hepatitis and other liver diseases displaying sustained hepatic 
LTR signaling. 
Additional tables with results that are not presented in this thesis and which are described as “data not 
shown” are found online under (Haybaeck et al., 2009) because these data sets are very large. 
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Summary: Prion transmission via the aerial route  
Transmissible spongiform encephalopathies (TSEs) are fatal neurodegenerative diseases of humans and 
animals. The cellular prion protein (PrPC) is absolutely required for disease development. In the central 
nervous system (CNS), prion infections cause spongiform vacuolation, neuronal loss and astrogliosis finally 
leading to the death of the infected individuals. In addition, the accumulation of misfolded, aggregated PrP 
(PrPSc) can be detected. The underlying infectious agent, the prion, was shown to accumulate not only in the 
CNS but also in secondary lymphoid organs of affected hosts. Only hosts with an intact immune system can 
be infected by a variety of extracerebral routes, including parenteral injection, transdermal administration 
after skin scarification, and oral administration. Up to date prions were not largely considered to be 
transmissible by aerial routes. Here I have investigated the transmissibility potential of prions administered 
by (1) aerosols in collaboration with Prof. Lothar Stitz’s laboratory and (2) intranasally (i.n.) together with 
Dr. Claire Bridel. Various transgenic mouse models expressing the cellular prion protein (PrPC) in specific 
compartments or cells (e.g. exclusively in the CNS) were investigated to identify the cellular and molecular 
mechanisms of prion infection via the (1) aerosolic and (2) intranasal route. Results of this study identify 
(1) inhaled prion aerosols and (2) prions administered i.n. as a startlingly efficacious pathway of prion 
transmission. Remarkably, in both paradigms prion transmission also occurred in the absence of B- and T-
cells pointing towards a direct transmission route after exposure to prion aerosols or upon i.n. inoculation. 
The brains of all diseased or subclinical mice contained PrPSc. These results identify (1) inhalation and (2) 
contact mediated absorption as a surprisingly efficacious route of prion transmission, and call for 
appropriate revisions of the current prion-related biosafety guidelines as these data may have important 
clinical implications. 
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Zusammenfassung: Prionen-Übertragung über die Luftwege  
Übertragbare spongiforme Encephalopathien (TSEs) sind tödliche neurodegenerative Krankheiten von 
Mensch und Tier. Das zelluläre Prion-Protein (PrPC) ist für die Krankheitsentwicklung absolut erforderlich. 
Im Zentralnervensystem (ZNS), verursachen Infektionen durch Prionen eine spongiforme Vakuolisierung, 
einen neuronalen Zellverlust und eine Astrogliose, was mit dem Tod der infizierten Individuen endet. 
Außerdem kann, angehäuftes, falsch gefaltetes PrP (PrPSc) detektiert werden. Es konnte gezeigt werden, 
dass das zu Grunde liegende, ansteckende Agens, das Prion, nicht nur im ZNS, sondern auch in sekundär 
lymphatischen Organen von betroffenen Wirten akkumuliert. Nur Wirtsorganismen mit einem intakten 
Immunsystem können über eine Vielzahl von extrazerebralen Wegen, einschließlich der parenteralen 
Injektion, transdermal nach Hautabschürfung, und nach oraler Aufnahme angesteckt werden. Bisher wurden 
Prionen generell nicht als über die Luftwege übertragbar angesehen. Hier haben ich gemeinsam mit meinen 
Kooperationspartnern aus dem Labor von Prof. Lothar Stitz das Übertragbarkeitspotenzial von Prionen über 
(1) Aerosole und gemeinsam mit Frau Dr. Claire Bridel nach (2) intranasaler Inokulation untersucht. 
Verschiedene transgene Maus-Modelle, die das zelluläre Prion-Protein (PrPC) an spezifischen 
Lokalisationen oder in speziellen Zellen (z.B. exklusiv im ZNS) exprimieren, wurden untersucht, um die 
zellulären und molekularen Mechanismen der Prionen-Übertragung durch (1) Aerosole und über den (2) 
intranasalen Weg herauszufinden. Die Ergebnisse dieser Studie identifizieren, dass Prionen in Form von (1) 
eingeatmeten Aerosolen und nach (2) intranasaler Applikation, erschreckend wirksam übertragbar sind. 
Bemerkenswerterweise konnten in beiden Experimenten Prionen auch in der Abwesenheit von B- und T-
Zellen übertragen werden, was auf einen direkten Übertragungsweg nach Aerosolexposition oder nach 
intranasaler Inokulation von Prionen hindeutet. Die Gehirne aller erkrankten oder subklinischen Mäuse 
enthielten PrPSc. Diese Ergebnisse identifizieren das (1) Einatmen bzw. die (2) Kontakt-vermittelte 
Aufnahme von Prionen als einen überraschend wirksamen Weg der Prionen-Übertragung, und verlangen 
somit nach einer entsprechenden Revision der derzeit gültigen Prionen-bezogenen Biosicherheits-
Richtlinien, da diese Daten von grosser klinischer Bedeutung sein könnten.  
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Selected Definitions  
Amyloid: Fibrillary, mostly -sheet-rich protein deposits. Amyloid is usually identified by apple-green 
birefringence when stained with congo red and analyzed under polarized light. PrP in amyloid form is found 
in some but not all forms of prion diseases in humans and animals. 
 
Incubation time: Period of time between exposure to the infectious agent and the manifestation of clinical 
signs (in animals) or symptoms (in humans). 
 
Prion: The term “prion” stands for protein-containing infectious agent causing TSEs, with unconventional 
biochemical properties, like resistance to agents known to inactivate nucleic acids, like proteinase K. 
 
‘Protein-only’ hypothesis: This hypothesis, stated by Stanley Prusiner in 1982 suggests that prions harbour 
a protein, which is basically a glycoprotein, as the exclusive pathogenic component and not any nucleic 
acid. The essential genetic evidence indicates that the protein is an abnormally folded form of PrP, perhaps 
identical with PrPSc. However, the association with other non-informational molecules, such as lipids, 
glycans or nucleic acids, is not excluded. 
 
PrPC: The physiologically occurring form of PrP, or prion protein (‘C’ refers to ‘cellular’) which can be 
glycosylated on one or both of two asparagine residues with a variety of glycans. Its presence in a given cell 
type is necessary, but not sufficient, for replication of the prion. 
 
PrPSc: An ‘abnormally folded’ form of the mature Prnp gene product that is almost invariably detectable in 
TSE-infected cells and tissues (‘Sc’ refers to ‘scrapie’, a prion disease occurring in sheep and mice). It is 
defined as being partly resistant to digestion by proteinase K under standardized conditions and is 
considered to be the major component of the transmissible agent. 
  
PRNP: The gene encoding the human prion protein. 
 
Prnp: The gene encoding PrP in animals. 
 
Prion strains: Types of prions differing either in the clinical course of the respective disease, their 
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neuropathlogical presentation, their transmissibility and the physicochemical properties of the PrP isoforms 
that they are associated with. 
 
Proteinase-K (PK): Proteinase-K is a proteolytic enzyme obtained from the fungus Tritirachium album, 
which is grown on keratins. Under specific, controlled digestion conditions it degrades PrPC and removes 
approximately 90-100 amino acids from the N-terminus of PrPSc. A large protease resistant C-terminal 
fragment remains. PK digestion is generally used to differentiate PrPC from its pathological misfolded 
isoform PrPSc. 
 
Peripheral prion inoculation: This defines any administration route of prion agents other than into the 
CNS, including intraperitoneal (i.p.), intravenous (i.v.), intranasal (i.n.), aerosolic, transdermal and oral (po) 
administration. 
 
TSE: Transmissible spongiform encephalopathies are fatal neurodegenerative diseases caused by prions. 
Not only the CNS but also extraneural tissues can contain prion infectivity. 
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2. INTRODUCTION: Prion transmission via the aerial route  
2.1 Prion diseases/Transmissible spongiform encephalopathies (TSEs) 
2.1.1 Prions affecting humans and animals 
Transmissible spongiform encephalopathies (TSEs), known as prion disorders, are fatal neurodegenerative 
diseases that affect humans and a wide variety of animals. Prion diseases are a major challenge to 
biomedical research. To date, no therapy other than palliation is available. TSEs in humans include 
diseases, such as Creutzfeldt-Jakob disease (CJD), fatal familial insomnia (FFI), Gerstmann-Sträussler-
Scheinker syndrome (GSS) and Kuru (Chesebro, 2003). In mammals, bovine spongiform encepaholopathy 
(BSE) is found in cattle, scrapie in sheep and goats, and chronic wasting disease (CWD) in elk and deer 
(Sigurdson and Miller, 2003). There are as well transmissible spongiform encephalopathies in cats and 
minks (Sigurdson and Miller, 2003). 
The neuropathological alterations within the central nervous system (CNS) include spongiform vacuolation, 
drastic neuronal cell loss and astrogliosis (Aguzzi et al., 2007). The main hallmark of prion diseases is the 
accumulation of the misfolded form of the host-encoded celluar prion protein PrPC, designated as PrPSc. 
“Sc” stands for scrapie, as an example of prion diseases in animals. The PrpSc deposits are detectable in the 
brain of affected individuals. An additional important of this disease entity is the extended incubation time 
between exposure to the infectious agent and manifestation of clinical symptoms. This time in humans can 
last from months to decades even (Collinge et al., 2006). Despite the fact that prion diseases show certain 
morphologic and pathophysiologic similarities to other progressive encephalopathies, such as Alzheimer‘s 
and Parkinson‘s disease (Aguzzi and Haass, 2003), TSEs are unique inthat they are transmitted through 
prion-contaminated material. This essential detail was identified more than half a century ago in the case of 
scrapie (Cuille and Chelle, 1939) and other TSEs. 
 
2.1.2 Prnp, the gene encoding the cellular prion protein (PrPC) 
The gene encoding the cellular isoform of the prion protein is located on chromosome 20 in humans and on 
chromosome 2 in mice (Basler et al., 1986).  
The Prnp genes of mice, sheep and cattle contain three exons, while those of humans and hamsters span 
over two exons (Lee et al., 1998). Prnp mRNA is constitutively expressed in a wide range of tissues in the 
adult organisms of the various species. In the CNS for example, high PrPC levels can be found in synaptic 
membranes of neurons, and in astrocytes. Apart from the CNS, Prnp is ubiquitously expressed (Doi et al., 
1988). Interestingly, this also includes lymphocytes (Cashman et al., 1990) and stromal cells of lymphoid 
and non-lymphoid organs (Aguzzi and Polymenidou, 2004; Heikenwalder et al., 2008). During 
embryogenesis Prnp mRNA is found in the central and the peripheral nervous system and in specific non-
neuronal populations (Miele et al., 2003). The mature form of murine PrPC consists of 210 amino acids. 
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Posttranslational modifications include glycosylation at two sites (aa 181 and 197) and plasma-membrane 
attachment via a glycosyl-phosphatidyl-inositol (GPI)-anchor (Riek et al., 1996; Stahl et al., 1987). Like 
other GPI-anchored proteins, it is enriched in detergent-resistant membranes (Naslavsky et al., 1997; Vey et 
al., 1996). The structure of mature PrPC from mice, humans, Syrian hamsters and cattle has some common 
features: a long, flexible amino-terminal tail (aa residues 23-128), three -helices, and two anti-parallel -
sheets that flank the first -helix (Riek et al., 1997). The second -sheet and the third -helix are connected 
by a large loop. The carboxyl terminus of PrPC is stabilized by a disulfide bond that links helices two and 
three (Riek et al., 1996). Despite the fact that the N-terminal portion of the molecule is probably structurally 
less defined, it contains two conserved regions. One region consists of a segment of five repeats of an 
octameric amino-acid sequence (octarepeat region: OR). This region has been reported to be involved in 
copper binding (Brown et al., 1997). The other region (central domain CD), downstream relative to the first 
region, contains a very hydrophilic, positively charged amino acid cluster (CC formerly known as stop 
transfer effector domain STE) followed by a highly hydrophobic and conserved profile, which was 
originally termed transmembrane region 1 (hydrophobic core HC, Fig. 1). It still remains unclear whether 
this domain indeed functions as a transmembrane region under physiological conditions. 
 
 
Figure 1. Structural features of the cellular prion protein. (A) Scheme of the primary structure of the prion protein 
and its posttranslational modifications. A secretory signal peptide resides at the extreme N-terminus. The numbers 
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describe the position of the respective amino acids. CC, charged cluster; HC, hydrophobic core; S-S, single disulfide 
bridge; MA, membrane anchor region; GPI, Glycosyl-phosphatidyl-inositol anchor: OR, octarepeat region; PK, 
proteinase K. The approximate cutting site of PK within PrPSc is indicated by the arrow. (B) Tertiary structure of the 
cellular prion protein inserted into a lipid bilayer, as deduced from NMR spectroscopy; modified from (Heikenwalder 
et al., 2007). 
 
2.1.3 The physiological role of PrPC 
The Prnp gene was identified in 1986 (Basler et al., 1986) and Prnp-/- mice were first generated in 1992. 
PrPC is a highly conserved protein in mammals. Up to date, clear knowledge about the physiological 
function of PrPC is still lacking. Various functions have been attributed to PrPC, including signal 
transduction (Mouillet-Richard et al., 2000), copper binding (Brown et al., 1997), synaptic transmission 
(Herms et al., 1999), induction of apoptosis (Paitel et al., 2003) and anti-apoptotic effects (Bounhar et al., 
2001; Kuwahara et al., 1999) regulation of circadian rhythm (Tobler et al., 1997; Tobler et al., 1996) and 
others (Aguzzi and Polymenidou, 2004; Bounhar et al., 2001; Brown et al., 1997; Chiarini et al., 2002; 
Hutter et al., 2003; Kuwahara et al., 1999; Paitel et al., 2003; Zanata et al., 2002). PrPC is also believed to be 
critical for axonal and dendritic outgrowth and synapse formation as well as their maintenance (Santuccione 
et al., 2005). The retrograde transport of PrPC from the endoplasmic reticulum to the cytoplasm as a key 
neurotoxic mechanism has been extensively discussed (Kunz et al., 1999; Ma et al., 2002). It is also thought 
that PrPC might act as a receptor for bacterial species like Brucella (Watarai et al., 2003). PrPC seems to 
display similarities to membrane-anchored signal peptidases (Watarai et al., 2003). Paralogues are present 
in turtles (Simonic et al., 2000), amphibians (Strumbo et al., 2001) and fish (Rivera-Milla et al., 2003). 
Furthermore, Prnp null alleles have not been observed in any mammalian species (Mead et al., 2003b). The 
expression pattern of Prnp (Miele et al., 2003) in skeletal muscle, kidney, heart, secondary lymphoid organs 
and the CNS, highlights a conserved and widely distributed function of the protein (Bendheim et al., 1992; 
Ford et al., 2002a; Ford et al., 2002b), but Prnp-/- mice display a normal life expectancy (Büeler et al., 1992; 
Manson et al., 1994). 
PrP has been reported to be expressed on long-term, re-populating hematopoietic stem cells being important 
for their self-renewal (Zhang et al., 2006) and the protein promotes neural precursor proliferation during 
developmental and adult mammalian neurogenesis (Steele et al., 2006). Surprisingly, postnatal depletion of 
PrPC in neurons does not result in neurodegeneration (Mallucci et al., 2002). Neuronal cell death was shown 
in the hippocampus and cerebellum following intracranial application of crosslinking anti-PrP-antibodies 
(Solforosi et al., 2004). Transgenic expression of PrP variants carrying amino-proximal interstitial deletions 
causes ataxia, progressive cerebellar granule cell degeneration in Prnp-/- mice (Baumann et al., 2007; 
Radovanovic et al., 2005; Shmerling et al., 1998). Most phenotypic changes reported in Prnp-/- mice have 
been moderate. Possible PrP-interaction partners are currently investigated, besides the anti-apoptotic 
protein Bcl-2 (Kurschner et al., 1995), the laminin receptor precursor (Rieger et al., 1997) and N-CAM 
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(Schmitt-Ulms et al., 2001). The conversion of PrPC to PrPSc results in neurodegeneration (Aguzzi et al., 
2007). The only definite phenotype of Prnp-/- mice is their resistance to prion inoculation (Büeler et al., 
1993). 
 
2.1.4 The “Protein only hypothesis” 
Transmission studies of TSEs showed not only the transmissibility of scrapie, Kuru and CJD to genetically 
appropriate recipients, they also revealed the existence of different prion strains. As indicated by incubation 
time, transmission of prions from one species to another is mostly less efficient than among individuals of 
the same species. This species barrier can, at least in some cases, be overcome, by introducing the Prnp 
gene of a donor into a recipient. Further transmission into individuals of the recipient species usually results 
in shortening of the incubation time. Therefore, prions can obviously adapt to different hosts (Perrier et al., 
2002; Prusiner et al., 1990). Purification of the infectious agent from the brain of scrapie-infected rodents 
was undertaken by using an animal bioassay to track infectivity (Prusiner et al., 1984). This resulted in the 
isolation of highly infectious particles that contained a single type of protein molecule, named PrPSc. 
Careful characterization of the infectious particles resulted in the finding of  exclusive biochemical 
properties like resistance to high temperatures, to formaldehyde treatment or to UV irradiation and, 
important from a diagnostic point of view, partially to proteinase K digestion (Griffith, 1967; Lehmann and 
Harris, 1996; Pattison, 1965; Prusiner, 1982). In contrast, PrPC is a cell surface protein that is sensitive to 
proteases. PrP is encoded by an endogenous gene. It exists in two isoforms (Basler et al., 1986). In TSE 
infected cells, PrPSc is partly protease resistant and extremely stable (Lehmann and Harris, 1996; Nunziante 
et al., 2003). Due to its biochemical properties and the fact that it is the main component of purified 
infectious material (Aguzzi et al., 2007), this protein was itself proposed to be the infectious agent causing 
TSEs. The important observation that PrPC and PrPSc are of the same amino-acid sequence, but differ 
significantly in their conformations, and the fact that the infectious agent lacks nucleic acids (DNA and 
RNA ≥ 50-60 nucleotides) (Riesner et al., 1993), resulted in the designation prion (for proteinaceous 
infectious particle) and a new hypothesis, the “protein only” hypothesis (Prusiner, 1982), which basically 
states that the causative agent is exclusively composed of a single kind of protein. Prion diseases are 
hypothesized to result from a conformational conversion of PrPC into PrPSc. In contrast to PrPC, PrPSc is 
enriched in -sheet content and it is characterized by its poor solubility in non-denaturing detergents and its 
propensity for aggregation, and partial resistance to proteinase K (PK) digestion (McKinley et al., 1983). 
Digestion of PrPSc with PK (under certain conditions) results in an N-terminally truncated fragment. The 
causative agent of prion disorders is thereby clearly distinguishable from other pathogens such as bacteria 
or viruses (Prusiner, 1982). However, PrPSc is a surrogate marker for prion infectivity, which cannot be 
fully equated with prion infectivity (Aguzzi and Polymenidou, 2004). The process of conversion from PrPC 
to PrPSc is believed to be induced by a physical interaction between host-encoded PrPC as a substrate and 
exogenous PrPSc as a template, which results in the PrPSc conformation being imposed on PrPC. It is well 
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established that PrPSc contains signicantly more -sheet than PrPC (Pan et al., 1993). For PrPC, a three helix-
structure has been determined by nuclear magnetic resonance (Donne et al., 1997; Riek et al., 1996; Riek et 
al., 1998) but it has not yet been possible to obtain a complete structure of PrPSc. Two models proposing a 
molecular mechanism of the conversion of PrPC into PrPSc are discussed: the template assistance or 
“refolding” model, and the nucleation-polymerization or “seeding” model (Cohen et al., 1994; Gajdusek, 
1988; Jarrett and Lansbury, 1993) (Fig. 2). 
 
1) The refolding model suggests that the conformational change is kinetically controlled and that a high 
activation energy barrier prevents spontaneous conversion at detectable rates. The interaction with 
exogenously introduced PrPSc leads to an induced conformational change of PrPC, resulting in the formation 
of PrPSc. This high energy barrier can be overcome by the catalytic action of PrPSc. It is believed that the 
process of unfolding and refolding is executed in conjunction with so far not determined enzymes and/or 
chaperones (Prusiner, 1991). This results in an exponential conversion cascade. In inherited prion disease, a 
rare pathogenic mutation is thought to favor spontaneous conversion of PrPC into PrPSc, without the 
requirement of an exogenous infectious agent. This is the cause why inherited prion diseases can 
spontaneously arise, albeit late in life. Sporadic CJD may be due to an extremely rare event (occurring in 
about one in a million individuals per year) leading to a spontaneous conversion of PrPC to PrPSc (Goldfarb 
et al., 1992). 
 
2) The seeding model hypothesizes that the conformational change is in a thermodynamically controlled 
equilibrium strongly favoring PrPC over PrPSc. PrPSc is only stabilized when it adds onto a crystal-like seed 
or aggregate of PrPSc. Seed formation most probably is a rare event. However, once a seed is formed, 
monomers are quickly added (Jarrett and Lansbury, 1993). The rate limiting step in this model is the 
formation of the seed. To explain exponential conversion rates, aggregates must be continuously 
fragmented, producing an increasing number of seeds and thereby new surfaces for accretion (Aguzzi and 
Sigurdson, 2004). 
 
A Refolding model 
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B Seeding model 
 
Figure 2. Models for the conformational conversion of PrPC to PrPSc. (A) The refolding or template-directed 
assistance model and (B) the seeding or nucleation polymerization model; adapted from (Aguzzi and Sigurdson, 
2004). 
 
One of the most compelling lines of evidence supporting the protein only hypothesis derives from studies 
of PrP transgenic and knockout mice. In a particularly important experiment, it was demonstrated that 
Prnp-/- mice are resistant to prion infection (Büeler et al., 1993). This demonstrates conclusively that 
endogenous PrPC substrate is essential for propagation of prion infectivity and disease development. It was 
also shown that the introduction of a hamster PrP transgene can abolish the species barrier that normally 
prevents infection of mice with hamster prions. Although a high degree of identity between the sequence of 
the incoming PrPSc and the resident PrPC is often observed (Priola and Chesebro, 1995; Prusiner et al., 
1990), it is not always essential for efficient prion replication. Even a single amino acid change in the PrPC 
that is expressed by a susceptible host might confer protection against susceptibility to prion disease 
(Manson et al., 1999; Perrier et al., 2002). The data propose that prion propagation involves a species-
specific physical interaction between exogenous PrPSc and host encoded PrPC. Furthermore, grafting 
experiments revealed that the presence of PrPC is required for neuronal damage in infected individuals 
(Brandner et al., 1996). 
One, if not the final proof of the “protein only hypothesis” would be the reproducibility of the conversion 
process from non-infectious PrPC to infectious material in a cell free environment. This strategy is based on 
the in vitro induction of full-length or truncated recombinant PrP protein misfolding, as well as on synthetic 
fragments of the polypeptide (Soto and Castilla, 2004). While various synthetic polypeptides were 
demonstrated to harbour PrPSc-like properties (for example formation of aggregates and enriched -sheet 
structures) (Bocharova et al., 2005; Jackson et al., 1999; Zhang H, 1995), none of the constructs tested have 
been able to induce TSE like diseases in wild-type animals. Biochemical studies of cell-free conversion of 
PrP have shown that partially purified hamster PrPC is not converted when mixed with purified PrPSc; on the 
other hand, conversion is restored when cell lysate is added to the sample (Deleault et al., 2005; Saborio et 
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al., 1999). 
PrPSc can be generated in vitro by a method named PMCA (for protein misfolding cyclic amplification), 
which was shown to generate infectivity in wild-type Syrian hamsters (Castilla et al., 2005). However, this 
experiment still could not completely rule out the involvement of other components in the infectious units 
since PrPSc was formed in brain homogenates. Whereas the prion hypothesis is very likely to be true, other 
mechanisms have also been proposed, suggesting viruses, virinos and other infectious agents containing 
small RNAs as the infectious agents (Chesebro, 1998; Manuelidis et al., 1995). The putative participation of 
nucleic acids as part of the infectious particle still remains a matter of debate. Retroviral RNA for example 
has been shown to co-sediment with PrPSc (Akowitz et al., 1994; Murdoch et al., 1990) and short RNA 
fragments are released after nuclease digestion from purified infectious fractions (Akowitz et al., 1990) and 
several reports have demonstrated that PrPSc can interact with RNA with variable affinity (Weiss et al., 
1997). However, the specificity of these interactions still remains to be determined (Safar et al., 2005).  
Rarely, a particular protein in a yeast cell can flip into a different conformation, causing conversion of its 
counterparts to the same state and giving rise to functionally inactive aggregates. These changed 
conformations can be transmitted to daughter cells (Glover et al., 1997; King and Diaz-Avalos, 2004; 
Tanaka et al., 2004). Though yeast proteins, displaying the “prion phenomenon” are not homologous to 
vertebrate PrPC at the amino acid sequence level, they share basic biochemical features like the formation of 
amyloid fibers and a highly specific species barrier. Therefore, the prion hypothesis appears not to be 
restricted to rare neurodegenerative disorders in mammals. Prion transmission represents a fascinating 
biological phenomenon.  
 
2.1.5 Prion transmission routes 
Studies of natural and experimental prion diseases have revealed various possible transmission routes. Oral, 
corneal, intraperitoneal (i.p.), intravenous (i.v.), intramuscular (i.m.), transdermal and intracerebral (i.c.) 
prion inoculation result in prion disease, where the intracerebral route has been shown to be the most 
efficient way of experimental prion transmission (Aguzzi, 2004 5849; Heppner et al., 2001; Herzog et al., 
2004; Hill et al., 1997a; Maignien et al., 1999 681 9; Weissmann et al., 2002; Zhang et al., 2004). 
Horizontal transmission is believed to be critical for the natural spread of transmissible spongiform 
encephalopathies (TSEs) among animals (Biacabe et al., 2004 6832; Dickinson et al., 1974; Foster et al., 
2006a; Foster et al., 2006b; Miller and Williams, 2003), although the pathway followed by the infectious 
agents from infected to healthy hosts is only partially understood. Different biological materials (e.g. saliva, 
milk, urine, blood, placenta) were reported to harbour significant levels of prion infectivity (Mathiason et 
al., 2006; Seeger et al., 2005; Vascellari et al., 2007), which may be the source for transmission of prion 
infectivity (Brown and Gajdusek, 1991; Georgsson et al., 2006; Johnson et al., 2006; Seidel et al., 2007). 
Infectivity dispersion in the environment may lead to disease transmission by feeding or drinking (Hadlow 
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et al., 1982; Miller et al., 2004). Superficial wounds of the tongue of animals have been suggested as 
possible source of prions (Bartz et al., 2003 1 877). 
While the presence of PrPC in many tissues has been well established during the past (Brown et al., 1990; 
Brown, 1990; DeArmond et al., 1987; Fournier et al., 1998) it has been clarified that PrPSc is not necessarily 
confined to central nervous and lymphoid tissues, but can also deposit in muscle (Glatzel et al., 2003), in 
inflamed organs (Heikenwalder et al., 2008; Heikenwalder et al., 2005; Ligios et al., 2005) and in the 
olfactory epithelium of the nasal cavity, even in the olfactory epithelium of sCJD patients (Tabaton et al., 
2004; Zanusso et al., 2003 1821). So far, unidentified routes of infection, such as airborne transmission, 
may occur as some evidence has already been provided for the natural spread of TSEs (Corona et al., 2009; 
DeJoia et al., 2006; Diringer, 1995; Doty, 2008; Hamir et al., 2008; Kincaid and Bartz, 2007; Park et al., 
2002; Sbriccoli et al., 2009) (Fig.3). In areas with high environmental contamination, infectivity adsorbed 
onto small soil particles may come in contact with the olfactory neuroepithelium and other nerve endings in 
the nasal mucosa. It has been proposed that inhaled dust particles from feed contaminated with the bovine 
spongiform encephalopathy (BSE) agent could lead to infection through the olfactory pathway (Shaw, 
1995b). Significant PrPTSE deposition and vacuolisation in the olfactory tract was reported in one patient 
suffering from variant CJD (vCJD) and presenting with loss of smell and taste as initial clinical symptoms 
(Reuber et al., 2001), and in genetic CJD cases associated with a novel 144-base pair insertion of the prion 
protein gene (Kovacs et al., 2007). Other studies showed that in deer with chronic wasting disease (Spraker 
et al., 2002b) and in BSE-affected cows (Vidal et al., 2005) the olfactory system is a permissive site for 
PrPTSE accumulation. I.c. challenged animals displayed PrpSc in the olfactory bulb (OB), olfactory 
epithelium (OE), vomeronasal organ (VNO), and nasal-associated lymphoid tissue (NALT) of animals 
killed at the terminal disease stage, indicating that the infectious agent spreads from the CNS to the nasal 
mucosa (DeJoia et al., 2006). Investigating the HY-TME strain in hamsters, nasal administration was shown 
to be 10–100 times more efficient in transmitting prion disease than oral uptake (Kincaid and Bartz, 2007). 
In the same study, NALT was reported to be the earliest site of PrPTSE deposition, followed by the 
submandibular and cervical lymph nodes and, eventually, by mesenteric lymph nodes, Peyer’s patches, and 
spleen. Therefore a primary involvement of the lymphoreticular system (LRS) in the spread of prion 
infectivity after i.n. administration has been proposed. The absence of PrPTSE deposition in the OE 
throughout the experiment (Kincaid and Bartz, 2007) has been claimed to indicate that the olfactory nerves 
are not involved in the spread of prion infection. The authors interpreted the presence of PrPTSE deposition 
in the dorsal motor nucleus of the vagus nerve (DMVN) and solitary tract nucleus (STN) during the pre-
symptomatic stage of the infection as suggestive that the scrapie agent is taken up by extrinsic nerve fibres 
and terminals of the vagus nerve in the respiratory tract (Getchell and Getchell, 1992; Kulkarni et al., 1994) 
or in the gastrointestinal system, following partial leaking of the inoculum from the nasal cavity. Finally, 
the finding that immunostaining was confined to the trigeminal nuclei in some animals was thought to be 
indicative of an involvement of the trigeminal nerve as an additional way of entry to the brain after i.n. 
application (Fig. 3). 
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Horizontal prion transmission may play a critical role in the maintenance of prion infection, in particular of 
scrapie in sheep flocks or CWD in free ranging deer and elk (Mathiason et al., 2006). From a mechanistic 
point of view it is believed that after peripheral application the pathological prion protein replicates in the 
LRS before it starts to invade the CNS (Sbriccoli et al., 2009). It is thought that besides direct contact 
predominantly environmental contamination by infectious saliva (Mathiason et al., 2006; Shaw, 1995a) 
urine (Seeger et al., 2005), milk (Konold et al., 2008; Ligios et al., 2005), blood (Mathiason et al., 2006) or 
placental tissue can serve as a reservoir for prion infectivity (Salman, 2003). In hamsters neuroinvasion 
could be experimentally shown (Bartz et al., 2003). Experimental transmission of scrapie by nasal routes 
has been reported in 2 out of 3 genetically susceptible sheep (Hamir et al., 2008). The HY-TME agent did 
not enter the CNS via the olfactory nerves in hamsters. Instead, PrP(Sc) accumulated in elements of the 
cranial LRS prior to neuroinvasion (Kincaid and Bartz, 2007). In the nasal cavity, PrPSc accumulation was 
found in the olfactory and vomeronasal epithelium, where its location was consistent with a distribution in 
cell bodies and apical dendrites of the sensory neurons (DeJoia et al., 2006)These reports have inspired me 
to test the possibility of prion transmission by aerosols and i.n. application since no clear evidence and 
mechanistic explanation for the transmission of prions by aerosols has been reported yet (CDC/NIH Manual 
“Biosafety in Microbial and Biochemical Laboratories”, Section VII: Agents Summary Statements. Section 
VII-D: Prions. Office of Health and Safety (OHS)(1999).  
Based on immunohistochemical data it has been postulated that neuroinvasion of the 263K pathways 
(Sbriccoli et al., 2009). In the mentioned study analysis at different time points revealed deposition of the 
pathological prion protein in NALT in the absence of brain involvement from 80 days post infection. 
Therefore, also the olfactory system is thought to be a feasible route by which inhaled prion containing dust 
particles of BSE contaminated feedstuffs is conveyled to the infection (Sawcer et al., 1993; Siso et al., 
2006a; Siso et al., 2006b; Smith et al., 1995; Spraker et al., 2002a). Recently, Bessen et al. (Bessen et al., 
2009) claimed that neuroinvasion from the tongue and nasal cavity can be independent of LRS infection. 
Their experimental outcome partially depended on the strain of the prion agent and/or the host species. 
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Figure 3. Possible prion transmission pathways to the CNS upon airway challenge. Prion transmission to the CNS 
may occur directly through the nasal mucosa via olfactory nerves (direct pathway) involving uptake of prions by the 
olfactory nerve terminals. Alternatively, uptake may require a lymphoid replication phase (immune mediated 
pathway): e.g. in the BLNs, the NALT or the spleen before entering the CNS. 
 
2.2 Human prion diseases 
In humans, prion diseases can be subdivided into three groups: infectious, sporadic and familial cases. All 
of them can be transmitted to non-human primates by ingestion or inoculation of brain tissue (Johnson and 
Gibbs, 1998), thus exemplifying one of the major hallmarks of TSEs. Creutzfeldt-Jakob disease (CJD) is 
the most common human TSE. The sporadic form accounts for about 85% of cases, about 10-15% of cases 
are familial, 1% of cases are iatrogenic. Variant CJD (vCJD) is largely limited to the UK and, to a much 
minor extent, other countries including France, Italy and Canada (Andrews et al., 2003). 
 
2.2.1 Sporadic Creutzfeldt-Jakob-Disease (sCJD) 
Sporadic Creutzfeldt-Jakob disease (sCJD) is rare and occurs throughout the world without overall 
geographic or seasonal clustering (Ladogana et al., 2005). Countries with surveillance programmes usually 
report a low yearly incidence (Baumann et al., 2007; Brandel et al., 2000), although higher incidences have 
also been reported (Glatzel et al., 2002). The first cases of sCJD were described more than 80 years ago 
(Creutzfeldt, 1920; Jakob, 1921); however, the etiology of sCJD is still unclear. The disorder appears to 
affect both men and women equally. The average age of onset is 60 years and is rare in people under the 
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age of 40. In contrast to other neurodegenerative diseases like Alzheimer‘s and Parkinson‘s disease, the 
incidence of sCJD declines after the age of 70 (Collins et al., 2004). Approximately one third of patients 
suffer from general symptoms such as fatigue, sleep disturbances and diminished appetite. Another third 
shows behavioral or cognitive alterations. The final third of patients display focal neurological symptoms 
such as visual loss, cerebellar ataxia, aphasia or motor deficits (Johnson, 2005). The disease progresses 
rapidly with prominent cognitive decline and the development of myoclonus. The median survival time 
from the onset of disease is five months and 90% of the patients suffering from sCJD die within one year 
(Johnson and Gibbs, 1998). The pathological changes in CJD are limited to the CNS and include neuronal 
cell loss and vacuolation within cell bodies and dendrites that give a spongiform appearance to the cortex 
and deep nuclei. The misfolded prion protein (PrPSc) can be detected by immunohistochemical staining and 
by Western blot analysis. It was originally thought that disease-associated PrPSc in sCJD patients was 
restricted to the nervous system; however, recent data indicate that it can also be detected in extraneural 
organs (Glatzel et al., 2003). sCJD can also be transmitted among humans through medical procedures 
(Brown et al., 1998; Matthews and Will, 1981). It is widely believed that spontaneous misfolding of the 
endogenous prion protein (PrPc) into the pathogenic isoform, and/or somatic mutations in the gene encoding 
the prion protein might be the causal event in sCJD. However, if this were the case, one might expect a 
continuously increasing incidence with age, which is not supported by the observation that the age-specific 
onset curve of sCJD peaks in the 6th decade of life. 
 
2.2.2 Variant CJD (vCJD) 
Variant CJD (vCJD) was first reported in 1996 in theUK (Will et al., 1996). The sudden onset of this 
disease in the United Kingdom (UK) and the young age of the affected individuals suggested a possible link 
to the BSE epidemic in cattle in the UK (Will et al., 1996). Subsequent biochemical analysis, 
neuropathological examination, and transmission studies have supported the idea that the disease might be 
zoonotically linked to BSE (Bruce et al., 1997; Hill et al., 1997a). Prions from patients with vCJD share 
some characteristics with those from cattle infected with BSE, indicating that they have a common source 
(Hill et al., 1997a). Furthermore, vCJD can be distinguished from sCJD based on several charcteristics. For 
example, patients suffering from vCJD display a disease course and pathology distinctive from that of 
sCJD, with younger age of onset, prominent psychiatric and sensory symptoms, and a longer disease course 
(Spencer et al., 2002). Neuropathological analysis reveals widespread vacuolation with multiple PrPSc-
containing plaques. The vast majority of cases analyzed so far have been homozygous at codon 129 for 
methionine (Spencer et al., 2002). In contrast to sCJD in which PK-resistant PrPSc seems to be present in the 
skeletal muscles and spleens of some affected individuals (Glatzel et al., 2003), the variant form of CJD is 
characterized by high amounts of PrPSc in lymphoreticular tissues such as tonsils and spleen, and to a lesser 
degree, in lymph nodes (Hill et al., 1999); (Wadsworth, 2001). It is likely that sCJD spread might have 
occurred through consumption of BSE-contaminated meat products. Over the past several years, about 170 
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cases of a new variant of CJD in the UK have been reported (www.cjd.ed.ac.uk). Outside the UK, only very 
few cases have occurred (e.g. France, Italy and Canada). Since 2000 the numbers in the UK seem to have 
subsided (Andrews et al., 2003) (www.cjd.ed.ac.uk). As 15 years have passed since the peak of BSE 
incidence in the UK and corresponding peak has never been observed in the human population, it has been 
proposed that humans are either partially resistant to BSE-induced disease and/or that the dose of BSE 
infectivity to which the population has been exposed was quite low. However, there are still concerns that 
some individuals exposed to BSE might be asymptomatic carriers of the infection and that these individuals 
might pose a risk of further transmission to others (e.g. iatrogenically by surgical instruments or via blood 
transfusions) (Aguzzi and Glatzel, 2006; Brandel et al., 2000; Houston et al., 2000). 
 
2.2.3 Kuru 
Kuru was the first human spongiform encephalopathy to be experimentally transmitted to non-human 
primates(Gajdusek et al., 1966). This slowly progressing neurodegenerative disease was initially identified 
in the eastern highlands of Papua New Guinea in the mid 1950s (Gajdusek and Zigas, 1957; Poser, 2002). 
At the peak of the epidemic, an annual prevalence of up to 10% was observed in some Fore villages 
(Gajdusek and Zigas, 1957; Zigas and Gajdusek, 1957). Kuru in the Fore language means “to shiver” or “to 
tremble” which refers to the cerebellar ataxia that occurs in this disorder. Various data indicate that Kuru is 
transmitted via cannibalistic rituals as part of the mourning for deceased relatives (Gajdusek, 1977). Since 
cessation of cannibalism in the late 1950s, the prevalence of Kuru has steadily declined, but a few Kuru 
cases are still observed in the Fore Tribe, indicating that the incubation time of the infectious agent can be 
even higher than four decades (Mead et al., 2003a). Interestingly, the polymorphism at codon 129 of the 
Prnp gene is one important factor that appears to influence susceptibility to Kuru (Cervenakova et al., 1998; 
Lee et al., 2001). 
 
2.2.4 Genetically determined human prion diseases 
Familial TSEs are caused by mutations in the PRNP gene (Aguzzi and Weissmann, 1996). There are three 
main sub-types, which are classified according to the phenotype: familial CJD, Gerstmann-Sträussler-
Scheinker syndrome (GSS), and fatal familial insomnia (FFI). These diseases account for 10 - 20% of all 
TSE cases in humans and all of them are inherited in an autosomal dominant fashion (Harder et al., 1999). 
Over 50 different mutations in the human PRNP gene have been found in kindreds with familial CJD. 
However, only four point mutations, namely at codons 102, 178, 200 and 210, together with insertions of 
five or six octapeptide repeats, account for 95% of the familial cases (Capellari et al., 2005). Moreover, a 
polymorphism at codon 129 encodes either methionine or valine, which influences the susceptibility to or 
the phenotype of human prion diseases (Palmer et al., 1991). 
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2.2.4.1 Familial CJD 
Familial CJD usually has an earlier onset and a prolonged clinical course compared to sporadic CJD. 
Familial CJD is not associated with distinctive clinical features (Windl et al., 1999). Different PRNP 
mutations have been recorded in patients dying of CJD (Kaneko et al., 2000). In neuropathologically 
confirmed cases, various point mutations and octapeptide repeat insertions have been described (Goldfarb et 
al., 1991). In general, penetrance of PRNP mutations is high, but the existence of healthy octogenarian 
carriers of certain mutations indicates that there are additional disease modifiers. 
 
2.2.4.2 Gerstmann-Sträussler-Scheinker disease (GSS) 
P102L and G131V mutations are the most common of the PRNP mutations that have been described by 
Gerstmann-Sträussler-Scheinker (GSS). The typical clinical course of this disease is slow and progressive 
cerebellar ataxia beginning in the fifth or sixth decade paralleled by cognitive decline (Collinge et al., 
1989). Patients suffering from GSS share the distinctive and defining neuropathological feature of wide-
spread, multicentric amyloid plaques, which are immunoreactive for PrP (Hsiao et al., 1989; Hsiao et al., 
1991). 
 
2.2.4.3 Fatal familial insomnia (FFI) 
Fatal familial insomnia (FFI) is a genetic human prion disease caused by a mutation at codon 178 of PRNP. 
The mutation results in the substitution of an asparagine for an aspartic acid at this residue (D178N) 
(Medori et al., 1992; Tateishi et al., 1995). In this disease the normal sleep-wake cycle of patients is 
profoundly disturbed. Additionally, the disease is characterized by insomnia and sympathetic over-
reactivity (Medori et al., 1992). The pathologic characteristics of FFI segregate with the D178N mutation 
exclusively in combination with methionine homozygosity at codon 129. Onset of the disease is usually in 
the fifth decade of life, with a clinical course of 13-15 months (McLean et al., 1997; Medori et al., 1992; 
Zerr et al., 1998). 
 
2.2.4.4 Iatrogenic CJD 
Iatrogenic CJD (iCJD) is caused by exposure of individuals to prions during surgical procedures, such as 
transplantation of human dura mater or corneal grafts. Stereotactically implanted electroencephalography 
electrodes as well as treatment with pituitary growth hormone and gonadotropins from human cadavers 
have also been reported to cause this form of human prion disease (Brown P, 2000). Dura mater transplants 
and pituitary growth hormone administration account for most of these cases. However, prion ingection 
through contaminated hormones has efficiently been eliminated with the advent of recombinant human 
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pituitary hormones. 
 
2.3 Prion diseases in animals 
2.3.1 Natural and experimental scrapie in sheep 
Scrapie is a type of prion disease that affects sheep and goats. The disease is characterized by scraping of 
fleece, stumbling and behavioral changes of affected animals and has a progressive course, leading to death 
within 3-6 months (Cuille and Chelle, 1939). Examination of the CNS from affected animals shows TSE-
characteristic changes with neuronal loss, vacuolation and gliosis. Scrapie was the first TSE to be 
experimentally transmitted (Pattison and Millson, 1961). The precise route of transmission is unclear, but 
lambs exposed in the pasture display infectivity first in tonsils, retropharyngeal lymph nodes, and intestine 
(Hadlow et al., 1982). Although in animals there are no known genetic cases of prion diseases as there are 
in humans allelic variations in the sheep Prnp sequence do occur, and variation at several residues in the 
PrP amino acid sequence influences susceptibility to both natural and experimental scrapie infection 
(Goldmann et al., 1994). 
 
2.3.2 Bovine spongiform encephalopathy (BSE) 
In 1985, the first cases of bovine spongiform encephalopathy (BSE; commonly known as “mad cow 
disease”) were reported in the UK. In the following decade, a rampant epidemic throughout the country 
affected hundreds of thousands of cattle in the UK (Anderson et al., 1996). The export of cattle and 
contaminated feed led to the spread of the disease in Europe and to other countries around the world. Even 
now it is still unclear whether scrapie-infected sheep carcasses or a sporadic case of BSE in cows rendered 
into bone meal initiated the epidemic. In any case, as a consequence of feeding other animals with prion 
contamionated meat and bone meal, BSE was subsequently transmitted to exotic felines in zoos and 
domestic house cats, leading to feline spongiform encephalopathy (FSE) (Lasmezas et al., 1996). The peak 
of the BSE crisis in cattle occurred in the years 1992 in the UK and in 1995 in Switzerland. Since that time, 
the BSE incidence has declined due to regulations prohibiting the feeding of ruminant-contaminated meat 
and bone meal to other ruminants. 
 
2.3.3 Chronic wasting disease (CWD) 
Chronic wasting disease (CWD) was initially identified as a fatal wasting disease of captive mule deer in 
the late 1960s in Colorado and was classified as a TSE in the 1970s (Williams and Young, 1982). CWD has 
become a serious health problem in farms and wild deer and elk populations in North America and Canada 
with a current incidence of about 10% in certain wild deer populations in Colorado and Wyoming. Affected 
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animals become emaciated, experience behavioral changes, unsteadiness and massive salivation. Death 
occurs within weeks to months, and pathological examination of the brain show widespread spongiform 
changes in grey matter (Sigurdson and Miller, 2003). Furthermore, inoculation with brain tissue from a 
CWD-infected mule deer led to the development of a neurodegenerative disease in the host species 
confirming that CWD is transmissible (Marsh et al., 2005). Studies involving inoculation of CWD in mice 
have shown transmission in transgenic mice expressing cervid PrP, but not in wild-type mice or transgenic 
mice expressing human PrP (129MM), which is suggestive that a species barrier still prevents the spread of 
the infectious particles to humans (Browning et al., 2004). 
 
2.3.4 Transmissible mink encephalopathy (TME) 
Trasmissible mink encephalopathy (TME) has culminated as confined outbreaks in various mink ranches 
mainly in the US and it is assumed that the disease is acquired by feeding animals tissue from scrapie-
infected sheep (Hartsough and Burger, 1965). There is some evidence that it might have originally 
developed from a cattle TSE disease (Marsh et al., 1991). However, TME, but not BSE, has been readily 
transmitted to hamsters (Kimberlin and Marsh, 1975). Therefore, agents causing TME and BSE are 
currently believed to be distinct. 
 
2.4 Peripheral prion pathogenesis and neuroinvasion 
2.4.1 Prions and the role of the immune system 
Following peripheral exposure, many of the acquired TSE agents accumulate and replicate in lymphoid 
tissues and the lymphoreticular system including the spleen, lymph nodes, Peyers‘s patches (PPs) and 
tonsils (Beekes and McBride, 2000; Hill et al., 1997b; Hilton et al., 1998; Mabbott and MacPherson, 2006; 
Mould et al., 1970; Sigurdson et al., 1999; Wadsworth, 2001). TSE agents often persist within the lymphoid 
tissues for the duration of the infection, but the magnitude and duration of lymphoid tissue involvement can 
vary considerably depending on the particular TSE agent (Foster et al., 2001). In experimental inoculations 
in cattle, accumulation of the BSE agent in lymphoid tissues is restricted to the terminal ileum (Terry et al., 
2003) and PrPSc is only detected in the spleens of a proportion of sporadic CJD (sCJD) cases at the clinical 
stage of disease (Glatzel et al., 2003). Furthermore, the route of administration influences the tissue 
distribution of extraneuronal PrPSc accumulation. For example after oral inoculation, the scrapie agent 
accumulates in the gut-associated lymphoid tissues (GALT), such as the Peyer‘s patches and mesenteric 
lymph nodes before neuroinvasion (Andreoletti et al., 2000; Beekes and McBride, 2000; Kimberlin and 
Walker, 1989; Mabbott et al., 2003; Prinz et al., 2003b). In mice, the spatio-temporal prion distribution 
patterns depend on the type and dose of the prion strain, the application route and the genetic background of 
the host. 
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2.4.1.1 Prion and secondary lymphoid tissue 
The main function of secondary lymphoid tissues is to provide an optimal microenvironment in which 
antigen-presenting cells and rare antigen-specific T- and B-lymphocytes can interact to survey all entering 
or circulating antigens and to initiate an efficient immune response. Secondary lymphoid organs are located 
at sites where foreign antigens and pathogenic microbes enter the body, either by penetrating the skin, by 
crossing the mucosal barrier or by entering the blood circulation (e.g. during blood transfusion; Fig. 4). The 
major secondary lymphoid organs are the spleen, lymph nodes and Peyer‘s patches. Additionally there are 
secondary lymphoid tissues associated with the surfaces of the gastrointestinal and respiratory tracts. These 
organs comprise nasopharyngeal-associated lymphoid tissue (NALT) (Fukuyama et al., 2002), 
cryptopatches (Saito et al., 1998) and isolated lymphoid follicles (Hamada et al., 2002). Although quite 
different in appearance, the lymph nodes, spleen, and mucosa-associated lymphoid tissues (MALT) share 
the same basic architecture. They are all highly structured, composed of a stromal matrix providing the 
optimal environment for B- and T-lymphocytes, antigen presenting cells (APCs) and other accessory cells. 
The spleen is grossly divided into two compartments. The red pulp is the site of red blood cell disposal 
interspersed with lymphoid white pulp. The lymphocytes surround the arterioles entering the organ, forming 
areas of the white pulp, the inner region of which is divided into a periarteriolar lymphoid sheath (PALS), 
containing mainly T-lymphocytes and a rim of B-lymphocytes. The marginal zone is the zone of 
lymphocyte entry into the spleen from the blood and contains a layer of reticular cells, macrophages and 
resident B-lymphocytes that surrounds the PALS and the follicular areas. Primary B-cell follicles are 
located in the periphery of the PALS. In addition to naive and re-circulating B-lymphocytes, B-cell follicles 
contain follicular dendritic cells (FDCs), which function as efficient antigen capturing cells. Some of the B-
cell follicles include germinal centres, which are then denoted as secondary follicles. There, B-lymphocytes 
proliferate after encountering their specific antigen and cooperating with T-lymphocytes. The importance of 
secondary lymphoid tissue for the neuroinvasion of prions was corroborated by findings that showed the 
stromal compartment to be the site of replication of the scrapie agent (Clarke and Kimberlin, 1984), and that 
the cells involved in scrapie replication were not mitotically active (Fraser and Dickinson, 1978). 
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Figure 4. Human tissues involved in propagation and transport of prions. After oral uptake and peripheral replication 
in the LRS (spleen, appendix, tonsils or other lymphoid tissues), prions are transported to the CNS primarily by 
peripheral nerves; from (Aguzzi and Heikenwalder, 2006).  
 
2.4.2 Prion propagation from the periphery to the CNS 
Neuroinvasion, the transfer of prion infectivity from the sites of prion propagation in the periphery of the 
body, like spleen or lymph nodes, to the CNS, is crucially dependent on PrP expression in radio-resistant 
cells (Blättler et al., 1997; Kaeser et al., 2001). Innervation of secondary lymphoid organs is a rate-limiting 
step in prion neuroinvasion (Glatzel et al., 2001). The distance between FDCs and splenic nerve endings has 
been shown to have an impact on the speed of neuroinvasion (Prinz et al., 2003a). This was shown 
experimentally by manipulating the position of FDCs via ablation of the CXCR5 chemokine receptor 
(Forster et al., 1996). After initial infection and peripheral prion replication, prions migrate from the 
peripheral nerves of the host to the CNS, setting the stage for the onset of fatal, progressive 
neurodegeneration. 
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2. Results  
2.5 Experiments to elucidate mechanisms of prion transmission via aerial routes 
2.5.1 Aerosol inhalation in WT, PrP transgenic and knockout animals  
In a first set of experiments together with my collaborators from Tübingen and under Professor Dr. Lothar 
Stitz’s guidance, aerosols were tested as potential prion vectors. All aerosol-related experiments were 
performed by Professor Lothar Stitz’s group. Mice were exposed to prion aerosols that were produced from 
RML-infected brain homogenates using a nebulizer device. Thereby, particle sizes capable of reaching 
upper and lower airways (100% particles below 10 µm with 60% of the particles below 2.5 µm and 52% 
below 1.2 µm) were generated. Depending on the duration of exposition to aerosols made from a 20% 
RML6 mouse brain homogenate (1 minute, 5 minutes, 10 minutes), Tga20 mice (overexpressing PrPC) as 
well as CD1 and C57BL/6 control mice developed scrapie (Fig. 5 and 6 A-C). Moreover, all Tga20 mice 
that had been exposed to prion aerosols generated from a 2.5%, a 5%, a 10% or a 20% brain homogenate 
resulted in terminal scrapie. C57BL/6 mice that had been exposed to aerosols of 20% brain homogenates for 
10 min also developed scrapie. Western blot and histoblot analysis revealed the presence of PrPSc in brains 
of all clinically affected animals (Fig. 6; data not shown). Although the incubation time was prolonged and 
transmission was slightly less efficient in CD1 compared to Tga20 mice, variation of disease onset among 
individual CD1 mice was considerably low. 
In addition, at day 360 post-exposure, PrPSc was detected in the brains of Tga20 mice which had been 
exposed to aerosolic 0.1% RML infected brain homogenate for 5 minutes (Fig. 6C). However, at that time 
point mice did not show any clinical signs of prion disease, suggesting preclinical or subclinical disease.                     
From these experiments I conclude that aerosols are efficacious prion vectors.  
 
2.5.2 Prion infection of pulmonary tissue 
In a next set of experiments, the amout of prion infectivity reaching the lungs after aerosolic infection was 
investigated. Lungs of Tga20 mice that were exposed to RML prion-contaminated aerosols contained PK-
resistant material when isolated and analyzed immediately after exposure. PrPSc levels were detected by 
sodium phosphotungstic-enhanced Western blot analysis (Fischer et al., 1996; Tabaton et al., 2004) (Fig. 6).  
Moreover, these results were confirmed using the Misfolded Protein Assay (MPA) (Fig. 6J; courtesy of Rita 
Moos). To investigate whether the prion infectivity load reaching the pulmonary system would suffice to 
induce scrapie in mice, two additional experiments were performed. Identical lung homogenates were 
inoculated i.c. into Tga20 indicator mice. These animals developed scrapie 80±3 dpi, corresponding to a 
prion titre of approximately 5-6 log LD50/mg of lung tissue, and the brains of these mice contained 
detectable levels of PrPSc (Figs. 6E and F).  
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Figure 5: Efficient prion transmission via the aerosol route. (A) Tga20 and (B) CD1 mice were exposed for 1, 5 or 
10 minutes to aerosols generated from a 20% RML6 mouse brain homogenate. These experiments were repeated two 
times. (C) Tga20 mice were also exposed to aerosols generated from a 2.5%, 5%, 10% or 20% RML6 mouse brain 
homogenate for 10 min. (D) C57BL/6 mice were exposed for 10 minutes to aerosols generated from a 20% RML6 
mouse brain homogenate. Kaplan-Meier curves describe the percentage of survival after particular time points post 
prion aerosol treatment (y-axis represents percentage of living mice; x-axis demonstrates survival time in days). 
Different colors and symbols describe the various experimental groups.  
 
Second, lung homogenates (10%) of aerosol-exposed, terminally sick Tga20 mice were inoculated i.c. into 
Tga20 indicator mice. This finally resulted in terminal scrapie and the death of the exposed animals. The 
animals were sacrificed with terminal scrapie after 71 days (n=9; lung homogenates used as inoculum after 
an exposure to prion aerosols for 10 minutes) or 78 days (n=9; lung homogenates used as inoculum after an 
aerosol exposition for 1 minute). Again, PrPSc could be detected in the brains of the affected animals by 
Western blot analysis (Fig. 6 D; data not shown). These experiments were performed in Tübingen. 
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Figure 6: PrPSc deposition in brains of mice infected with prion aerosol and PrPSc in brains of Tga20 mice 
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inoculated i.c. with aerosol exposed lung homogenates. 
Brain homogenates (10%;w/v) from (A) Tga20 or from (B) CD1 mice which had been exposed to prion aerosols. (C) 
Brain homogenates (10% w/v) from Tga20 mice exposed to prion aerosols from 20% brain homogenate for 10 minutes 
or 0.1% homogenate for 5 minutes. (D) Lung homogenates (10% w/v) from terminally sick Tga20 mice which had 
been exposed to RML aerosols for 1 or 10 minutes. Homogenates were prepared as a pool from 5 mice and were used 
for i.c. inoculation into Tga20 mice. (E) Tga20 mice that had been exposed to aerosol were sacrificed immediately 
after the end of aerosol inoculation. Lanes 1-3 represent a pool of lung homogenates (10% w/v) from 5 mice each. (F) 
Brain homogenates (10% w/v) from Tga20 mice inoculated i.c. with lung homogenate from mice which had been 
exposed to aerosol and were sacrificed immediately after the end of aerosol inoculation. Lanes 1-3 represent individual 
mice. (G and H) Western blot analysis of brains from Tga20 mice inoculated with phosphotungstic acid-precipitated 
brain homogenate directly intratracheally by means of tracheal tubes. Brains were collected from diseased mice at 
terminal stage. Different days post inoculations are indicated. (I) Histoblot analysis of brains from mice exposed to 
prion aerosols. As positive and negative controls for histoblot analysis served the spleen of a Prp-/- mouse showing no 
signal (negative control; outer left panel) and the spleen of a wild type (C57BL/6) mouse (positive control; second 
panel from left) with positive signal in the white pulp follicles. Brains of mice challenged with a 10% (third panel from 
left) or 20% (right panel) showing deposits of PrPSc in cortex and mesencephalon. (J) Analysis of lung tissues from 
terminally scrapie sick mice by the “misfolded protein assay” (MPA) reveals positive signals as indicators of PrpSc 
deposition in all nine cases investigated (blue). Dilution curve is shown in the left (red) part of the graph. The lung of a 
PrP0/0 and a lung of a clearly infected, terminally sick mouse were used as controls. Y-axis: RLU: Relative (Chemi) 
Luminescence Units, X-axis: mouse number; two blue columns represent two different dilutions: full represents a 1:10 
dilution and the hatched one a 1:40 dilution of a 10% lung homogenate. Data for uninfected lung and brain controls are 
not shown here, but did not display a positive signal. 
 
2.5.3 Where do prions go after inhalation? 
To trace the path of prions after inhalation, mice were exposed to aerosols composed of RML6 mouse brain 
homogenate (20%) mixed with an equal volume of Coomassie blue (resulting in a 10% inoculum). The 
paranasal sinuses, the ethmoid bone and the upper part of the trachea were clearly stained. Additionally, in 
the stomach and in the upper part of the small intestine Coomassie blue could be found, whereas no staining 
was macroscopically detectable in the lungs. This suggests that only a minimal part of the infectious 
particles reaches the lungs after aerosolic infection. However, these results also indicate that even this small 
amount of infectivity is high enough to ultimately cause prion disease (data not shown).  
 
2.5.4 Intratracheal prion inoculation as an efficient infection route  
To obtain further evidence that prions can be transmitted aerially, mice were inoculated i.t. by means of 
small tracheal tubes. These experiments were also performed in Tübingen. Tga20 mice (n=2) exposed to 20 
µl of phosphotungstic acid-precipitated brain homogenate (20% w/v) developed disease at 118 and 131 dpi, 
respectively, whereas mice (n=4) receiving 10 µl of precipitated material were sacrificed with clinical signs 
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of scrapie between days 147 and 169 after inoculation (days 147, 150, 169, 169) (Fig. 6 G-H). Again, all 
i.t.-inoculated mice contained PrPSc (Fig. 6H) in the brain. 
 
2.5.5 Intranasal prion inocualion is also extremely efficient in transmitting prion infectivity 
In order to study the aerial transmission pathway, different mouse lines (age matched, 6-8 week-old mice) 
were inoculated with prions [RML 6.0, low dose, high dose and healthy brain homogenate (HBH) 
inoculum] by direct application of inocula on the nasal mucosa (Figs. 7-9). It should be mentioned that mice 
breathe exclusively through their noses, strengthening the relevance of the performed experiments. Mice 
were sacrificed at various time points up to the terminal stage of the disease, and various organs were 
subsequently examined. This provided a dynamic overview of the progression of PrPSc from the respiratory 
entry portal to the CNS. The following organs were analyzed by histoblot analysis, Western blot analysis, 
histology and immunohistochemistry: nasal mucosa, lung tissue, bronchial lymph nodes (BLNs), spleen, 
brain hemispere, olfactory bulb, cerebellum and spinal cord. 
 
Figure 7: Efficient prion transmission via the intranasal route. Survival curves of (A) 129Sv/C57BL/6, (B) 
C57BL/6 that were i.n. inoculated with RML6 0.1%. Western blots of (C) C57BL/6 mice that were i.n. inoculated with 
RML6 0.1%. Survival curves of (D) Prp-/- and (E) Tga20 mice that were i.n. inoculated with RML6 0.1%. Western 
blots of (F) Tga20 mice that were intranasally inoculated with RML6 0.1%. Survival curves of (G) C57BL/6 mice i.n. 
challenged with HBH. Various mice were analyzed by Western blots for the presence of PrPSc. Brain homogenates 
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were analyzed with (+) and without (-) previous proteinase K (PK) treatment as indicated. Homogenate derived from a 
terminally scrapie-sick mouse served as positive control (sick), and healthy C57BL/6 mouse tissue as negative control 
(healthy), respectively. Molecular weights are indicated on the left side of the blots. All terminally sick mice showed 
considerable amounts of PrPSc in the brain. 
 
Figure 8: Efficient prion transmission via the intranasal route. Survival curves of (A) Rag1-/- mice i.n. inoculated 
with RML6 0.1% or (B) with HBH. (C) Rag1-/- mice i.c. inoculated with RML6 0.1% are shown. Kaplan-Meier curves 
describe the percentage of survival after particular time points post i.n. prion inoculation (y-axis represents percentage 
of living animals; x-axis demonstrates survival time in days). (upper right panel) Respective Western blots of Rag1-/- 
mice with C57BL/6 controls are shown. Survival curves of (D) CRag2-/- mice i.n. inoculated with RML6 0.1% or (E) 
with HBH. (second row, right panel) Respective Western blots of CRag2-/- mice with C57BL/6 controls are shown. 
Survival curves of (F) Balb/c mice i.n. inoculated with RML6 0.1% or (G) with HBH. (third row, right panel) 
Respective Western blots are shown. Survival curves of (H) C57BL/6 mice treated with LTR-Fc or (I) with mu-IgG. 
(lower right panel) Respective Western blots are shown. Various mice were analyzed by Western blots for the 
presence of PrPSc. Brain homogenates were analyzed with (+) and without (-) previous proteinase K (PK) treatment as 
indicated. Homogenate derived from a terminally scrapie-sick mouse served as positive control (sick), and healthy 
C57BL/6 mouse tissue as negative control (healthy), respectively. Molecular weights are indicated on the left side of 
the blots.  
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Figure 9: Efficient prion transmission via the intranasal route. (A) C1qa-/- mice i.n. inoculated with RML6 0.1% 
and (B) CXCR5-/- mice i.n. inoculated with RML6 0.1% are shown. Respective Western blots of (upper row, left 
panel) C1qa-/- mice i.n. inoculated with RML6 0.1% and (upper row, right panel) CXCR5-/- mice i.n. inoculated with 
RML6 0.1% are shown. Survival curves of (C) CCR7-/- mice i.n. inoculated with RML6 0.1% and (D) CD21-/- mice 
i.n. inoculated with RML6 0.1% are shown. Respective Western blots of (second row, left panel) CD21-/- mice i.n. 
inoculated with RML6 0.1% and (second row, right panel) CCR7-/- mice i.n. inoculated with RML6 0.1% are shown. 
Survival curves of (E) LTR-/- mice i.n. inoculated with RML6 0.1% and (F) TNFR1-/-mice i.n. inoculated with RML6 
0.1% are shown. Respective Western blots of (third row, left panel) LTR-/- mice i.n. inoculated with RML6 0.1% 
and (third row, right panel) TNFR1-/- mice i.n. inoculated with RML6 0.1% are shown. Survival curves of (G) LT-/- 
mice i.n. inoculated with RML6 0.1% and (H) NSE-PrP mice i.n. inoculated with RML6 0.1% are shown. Respective 
Western blots of (lower row, left panel) LT-/- mice i.n. inoculated with RML6 0.1% and (lower row, right panel) 
NSE-PrP mice i.n. inoculated with RML6 0.1% are shown. 
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2.5.5.1 Various mouse strains intranasally infected with prions succumb to scrapie  
In order to elucidate the impact of specific cellular comparments, I analyzed as experimental cohorts a 
“molecular group” with PrP -/- (n=11), Tga20 (n=10) and NSE-PrP mice (neuron specific PrPC expression) 
(n=6), a “deficiency group” with Rag1-/- (n=9), CRag2-/- (n=20), LT-/- (n=6), LTR-/- (n=6), TNFR1-/- 
(n=3), CD40L-/- (n=4), C1qa-/- (n=4), CD21-/- mice (n=10), a “chemokine group” with CCR7-/- (n=2), 
CXCR5-/- mice (n=5), respective controls, and an “induced mouse model group” with C57BL/6 mice treated 
with LTR-Fc (n=8) or murine IgG (n=9) as control. C57BL/6 (n=20) and C57BL/6129Sv (n=5) mice 
served as internal positive controls. Tga20 mice overexpressing PrPC underlined the role of PrPC in prion 
pathogenesis with a shortened incubation time. As negative controls, Prp-/- (n=11) mice were used. The 
results from these experiments are summarized below.  
 
2.5.5.2 Intranasal prion propagation depends on the PrPC expression levels 
Tga20 (PrPC overexpressing) and 129SvC57BL/6 mice succumbed to scrapie after i.n. prion inoculation 
with an attack rate of 100% (survival time Tga20 mice: 160 dpi, stdev +/- 28 days). Tga20 mice, displaying 
a reduced incubation time in comparison to C57BL/6 mice (survival time C57BL/6 mice: 259 dpi, stdev +/- 
64 days) (Fig. 7) and 129SvC57BL/6 mice (survival time 129SvC57BL/6 mice: 220 dpi, stdev +/- 21 days) 
(Fig. 7), showed a minimally shortened incubation period when compared to control mice after i.n. 
inoculation or compared to i.c. inoculation (Fig. 7; data not shown). NSE-PrP mice (survival time NSE-PrP 
mice: 291 dpi, stdev +/- 86 days) displayed longer survival times (Fig. 9) compared to control animals, 
whereas Prp-/- mice, lacking PrPC, remained resistant to prions (Fig. 7D). These findings are consistent with 
the current understanding of prion pathogenesis. NSE-PrP mice are characterized by an almost exclusive 
expression of PrPC in neurons within the CNS and display a higher expression level of PrP protein in the 
CNS when compared to C57BL/6 mice. All i.n. challenged NSE-PrP mice also developed scrapie, although 
the incubation times were significantly prolonged.  
 
2.5.5.3 Relevance of the complement system for prion pathogenesis after intranasal challenge  
The complement system is an important part of immune defense mechanisms and has also been shown to be 
involved in peripheral prion infection of lymphoid organs.  The complement C1qa is known to be involved 
in the binding of PrPSc to follicular dendritic cells (FDCs), and accordingly, C1qa-/- mice are resistant to 
prion infection upon low-dose peripheral inoculation. CD21-/- mice (complement receptor 2-deficient which 
also lack the C3d/C4b-opsonized antigen receptor), on the other hand, display a normal lymphoid 
microarchitecture while showing a reduction in germinal centre (GC) size. The incubation time in these 
mice is greatly increased upon peripheral prion inoculation via the i.p. route. To determine whether 
complements were involved in prion infection via the intranasal route, C1qa-/- and CD21-/- were inoculated 
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i.n. C1qa-/- mice (n=6), as well as CD21-/- (n=10) mice succumbed to scrapie with an attack rate of 100% 
after i.n. inoculation (survival time in C1qa-/- mice: 288 dpi, stdev +/- 26 days; survival time in CD21-/- 
mice: 235 dpi, stdev +/- 24 days) (Fig. 9). These results indicate that these complement components are not 
essential for prion propagation following i.n. application. Additionally, I also i.n. inoculated CD40L-/- mice 
with prions. As these mice cannot switch the isotype, they cannot respond with antigen-specific antibodies 
following prion infection. They also lack GC B-cells; however, small FDCM1+ networks are still present. 
No effect on incubation time upon i.c. prion inoculation and a reduced incubation time following i.p. prion 
inoculation were previously described in CD40L-/- mice. In my experiments, all i.n. challenged CD40L-/- 
mice succumbed to terminal scrapie (survival time CD40L-/- mice: 107 dpi, stdev +/- 12 days) (data not 
shown). 
 
2.5.5.4 CCR7 or CXCR5 deficiency does not protect against intranasally administered prions  
CCR7-/- mice show an impaired migration of dendritic cells (DCs) from the periphery, which are exposed to 
antigens in secondary lymphoid organs. FDCs in CXCR5-/- mice are in closer proximity to nerve terminals 
compared to WT mice. This leads to a reduced incubation time upon peripheral prion inoculation. In 
contrast, upon i.n. prion inoculation both mouse strains reacted with a prolonged incubation time (survival 
time CCR7-/- mice: 273 dpi, stdev +/- 21 days; survival time CXCR5-/- mice: 280 dpi, stdev +/- 119 days) 
(Fig. 9). 
 
2.5.5.5 Induced mouse models  
Treatment of C57BL/6 mice with LTR-Fc blocks LTβR signaling and leads to dedifferention of FDCs and 
ablated GCs. To determine whether inhibition of LTβR signaling would affect the rate of i.n. prion 
infection, I once again treated C57BL/6 mice with 100g LTR-Fc/mouse prior and post prion challenge (-
7 days, 0 days, +7 days). These mice were then tested for their capability of prion infection upon i.n. 
administration and remarkably, again 100% of the i.n. challenged mice died because of scrapie (survival 
time C57BL/6 mice treated with LTR-Fc: 476 dpi, stdev +/- 200 days) (Fig. 8H). C57BL/6 mice treated 
with muIgG (survival time C57BL/6 mice treated with muIgG: 246 dpi, stdev +/- 29 days) served as control 
group (Fig. 8I). 
 
2.5.5.6 Mechanisms of neuroinvasion and the role of the immune system 
Next, I sought to determine how prions enter the CNS following i.n. application. Is a functional immune 
system required for neuroinvasion upon i.n. infection with prions? To address this question, I inoculated 
either Rag1-/- mice (n=9), which lack mature B- and T-cells and CRag2-/- mice (n=20), which lack mature 
B-, T- and NK-cells either i.n. or (as a control) i.c.. In addition, both mouse strains were also i.n. inoculated 
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with HBH to exclude the possibility that the inoculation strategy itself impacts the life expectancy of treated 
mice. None of the mice inoculated with HBH displayed a shortened life span, and none developed clinical 
signs resembling scrapie. As expected i.c. prion infection very efficiently led to terminal scrapie after 
approximately 150 days (survival time Rag1-/- mice: 131 dpi, stdev +/- 8 days) in Rag1-/- (Fig. 8). As Rag1-/- 
mice were generated on a C57BL/6 background and CRag2-/- mice on a BalbC background these mouse 
strains were also i.n. challenged with RML prions (Fig. 8). As additional controls, Rag1-/- and CRag2-/- 
mice were i.p. inoculated; however in this case the dosage used for the i.n. prion challenge did not suffice to 
induce scrapie in mice (data not shown). Remarkably, 100% of the i.n. inoculated Rag1-/- or CRag2-/- mice 
i.n. exposed to prions succumbed to scrapie (survival time Rag1-/- mice: 203 dpi, stdev +/- 6 days; survival 
time CRag2-/- mice: 235 dpi, stdev +/- 29 days; survival time BalbC mice: 209 dpi, stdev +/- 48 days) (Fig. 
8), providing evidence for an LRS-independent mechanism of prion neuroinvasion upon i.n. prion 
administration. PK-resistant material was present in different regions of the CNS (OB, frontal lobe, 
temporal and parietal lobe, midbrain, cerebellum, s.c.), but was not detectable in spleens, BLNs, lungs and 
tracheae of scrapie sick Rag 1-/- mice. The onset of scrapie in the absence of a functional immune system 
favors a direct peripheral transmission route without the involvement of the LRS.  
 
2.5.5.7 TNF superfamily members (TNFR1 and Lymphotoxin) and i.n. applicated prions 
Additionally, I also challenged LT-/-, LTR-/- and TNFR1-/- mice i.n. with RML prions. Both, LT-/- and 
LTR-/- mice lack Peyer`s patches and lymph nodes as well as an intact NALT. Furthermore, these mice 
display chronic inflammation of the lungs. Consistent with a role for lymphotoxin signaling in peripheral 
prion infection, these mice are not capable of efficiently replicating prions upon peripheral administration. 
On the other hand, TNFR1-/- mice lack Peyer`s patches, show an aberrant splenic microarchitecture, an 
abnormal NALT, but have intact lymph nodes where prion replication can occur. However, the prion 
replication efficacy in spleen was reduced or absent. These mice die due to scrapie after a prolonged 
incubation time when peripherally challenged with prions. Interestingly, when i.n. infected, most of these 
mice efficiently succumbed to scrapie (survival time LT-/- mice: 250 dpi, stdev +/- 20 days; survival time 
LTR-/- mice: 251 dpi, stdev +/- 52 days; survival time TNFR1-/- mice: 213 dpi, stdev +/- 1 days) (Fig. 9). At 
terminal disease stages, mice were sacrificed and organs were isolated for further examination and scrapie 
confirmation. 
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Figure 10: Histological, immunohistochemical and immunoblot confirmation of prion disease. (A) Histological 
and immunohistochemical characterization of scrapie affected C57BL/6 mouse brains. Representative olfactory bulbs 
(HE and Neurofilament stains) are shown. (B) Histological and immunohistochemical characterization of scrapie 
affected C57BL/6 mouse brains. Representative olfactory bulbs display spongiosis, astrogliosis, microglial activation 
and PrpSc deposits (HE, GFAP, Iba-1 and SAF-84 staining). (C) Histoblot analysis of prion infected mouse brains. 
Upper panel: shows healthy brain of a Prp-/- mouse as negative control, other panels demonstrate PrpSc deposits in 
C57BL/6 mice. Arrow bars indicated the sizes of the respective figures. 
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Figure 11: Efficacy of prion transmission through aerosols in immunocompromised and newborn mice. Various 
mouse strains (A-D) were exposed to aerosolized RML infected brain homogenates (JH-/-, CRag2-/-, 129Sv/C57BL/6 
treated with LTR-Fc or with mu-IgG, LT-/-, LT-/-, LTR-/-, TNFR1-/-, C3-/-C4-/-).(E) Newborn C57BL/6 mice were 
exposed for 10 minutes to aerosols generated from a 20% RML6 mouse brain homogenate. Kaplan-Meier curves 
describe the percentage of survival after particular time points post prion aerosol treatment. Exposure to aerosols 
generated from healthy mouse brain homogenates did not have any effect (data not shown). 
 
 
2.5.6 Experiments with newborn mice argue against an ocular infection  
Another possible mechanism of prion transmission via aerosols may be through the ocular route, namely via 
cornea and/or retina (Safar et al., 1998; Wadsworth, 2001). In order to verify or exclude this possibility, 
newborn, under one day old, Tga 20 (n=3) and CD1 (n=3) mice with eyelids still closed were exposed to 
prion aerosols. These experiments were performed in Tübingen by Lothar Stitz and his co-workers. All 
these mice developed scrapie and PrPSc was detectable in their brains when sacrificed at terminal disease 
stages after an incubation time between 157 (Tga20) and 211 (CD1) days (Fig. 11E; data not shown).  
These experiments prove that (1) mice have not contracted scrapie via the ocular route, and (2) a 
functionally active immune system is not essential for aerosolic prion transmission. However, as mice were 
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exposed to aerosols under saturating conditions in an inhalation chamber, I cannot exclude the possibility 
that they may have contracted infection via their airways or might have ingested a portion of condensed 
inoculum, analogously to oral transmission. Nevertheless, in similar experimental setups (e.g. using RML 
or Me7 prion strains), oral inoculation with prions is much less efficient than aerosol exposure, and it leads 
to much longer incubation times (Russelakis-Carneiro et al., 1999; Scott et al., 1993) arguing against this 
possibility. 
 
2.5.7 Evaluation of transmission efficacy and exclusion of side-pathways  
The results obtained after aerosol exposition of newborn mice lacking a functional immune system, 
including gut associated lymphoid tissue (GALT) functions, support the idea of an LRS-independent prion 
transmission route. In addition, untreated littermates or other sentinels which were reared or housed 
together with aerosol-treated mice immediately following exposure to aerosols neither showed signs of 
scrapie nor the presence of PrPSc in brains, even after 482 dpi. This indicates that prion transmission was the 
consequence of direct exposure to the particular aerosols rather than the result of transmission by other 
routes like ingestion of PrPSc from fur by grooming. 
 
2.5.8 Aerosolic infection occurs independently of a functionally intact immune system  
The next question that arose was how important the LRS is for prion infection upon aerosolic challenge in 
adult immunocompromised mice. Therefore, several immune deficient mouse strains were exposed to 
aerosolized prion infected brain homogenates. These included JH-/- mice (n=6) lacking B- and T-cells, 
CRag2-/- mice (n=11) lacking mature B-, T- and NK-cells, LT-/- (n=4), LT-/- (n=10), LTR-/- (n=6), 
TNFR1-/- mice (n=6), CD40L-/- mice (n=6) and C3-/-C4-/- (n=3) mice. In addition, C57BL/6 mice treated with 
LTR-Fc displayed a dedifferentiation of mature FDCs paralleled by ablation of GCs. To achieve an 
immunocompromised state control mice were i.p. treated with 100g LTR-Fc/mouse prior and post-prion 
challenge (-7 days, 0 days, +7 days). Upon application of reduced dosages of prions (RML 5), peripheral 
prion replication is known to be either decreased or abolished. C57BL/6 mice that had been treated with 
LTR-Fc (n=3) or murine IgG (n=3) as a control were also exposed to RML prions. Even NSE-PrP mice 
(n=4) were susceptible to prion aerosol exposure. Remarkably, all these mouse lines were susceptible to 
prions given as aerosols to the respective host (Fig. 11; data not shown). This indicates that aerosolic prion 
infection is an efficient prion transmission route that does not require a preserved immune status.  
 
Additionally, I tried to find differences in the distribution pattern of PrPSc by evaluating histoblots and 
Western blots in all mice challenged with prions via the aerial route. Some examples are shown in Fig. 12. 
No clear differences could be identified with respect to the genetic background.  
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Figure 12: Histoblot profiling of i.n. prion infected mice. (A-E) Histoblot analysis of spleens of LT-/-, LTR-/-, 
C1qa-/-, CCR7-/- mice. (F) Western blot analysis of spleens of CCR7-/- and Tga20 mice. Mice were investigated for the 
presence of PrPSc. Spleen homogenates were analyzed with (+) and without (-) previous proteinase K (PK) treatment 
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as indicated. Homogenate derived from a terminally scrapie-sick mouse served as positive control (pos. ctr.), and 
healthy C57BL/6 mouse tissue as negative control (neg. ctr.), respectively. Molecular weights are indicated on the left 
side of the blots. All terminally sick mice showed considerable amounts of PrPSc in the brain. (G, H) Histoblot analysis 
of spleens of NSE-PrP and LT-/- mice. Scale bars: sizes are indicated. 
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2.6 DISCUSSION  
The transmissibility of prion diseases was initially described for scrapie in goats as early as 1939 (Cuille 
and Chelle, 1939). Since then, numerous natural and experimental transmission routes have been reported. 
Whereas variant Creutzfeldt-Jakob Disease (vCJD) is transmitted via ingestion of contaminated food from 
BSE-infected cattle, possible transmission of CJD via blood has also been recently reported (Allain et al., 
2009; Choi et al., 2009; Head et al., 2009; Jones et al., 2009; Murray et al., 2009). In addition to well 
established peripheral routes (oral, i.p., i.c., ocular, intramuscular, transdermal), other experimental routes 
have revealed the possibility of transmission of prion disease after intraveneous injection and even after 
exposure of the tongue to PrPSc (Mulcahy et al., 2004). The aerial transmission route is common for various 
microbes; however, to my knowledge this has never been investigated for prion aerosols, and incompletely 
for i.n. applicated prions (Bessen et al., 2009; Corona et al., 2009; DeJoia et al., 2006; Diringer, 1995; Doty, 
2008; Hamir et al., 2008; Kincaid and Bartz, 2007; Park et al., 2002; Sbriccoli et al., 2009). Therefore, in 
collaboration with Prof. Stitz’s laboratory, I sought to experimentally evaluate whether prion disease could 
be transmitted by (1) aerosols and upon (2) contact-mediated i.n. challenge. 
For the experimental aerosol infection paradigm, the particle size generated by the nebulizer device ensured 
that the entire respiratory tract was flooded by the aerosol and that the aerosolized brain homogenate 
containing the pathological form of the prion protein was able to reach the inner surface of the lung. There 
prions may colonize airway-associated lymphoid tissues and, thereafter, gain access to the CNS. This 
prediction was proven correct by the experiments where the pulmonary deposition of PrPSc-containing 
inoculum was investigated.  
 
2.6.1 Dissecting prion neuroinvasion after nasal prion administration  
I sought to determine whether the reported lack of involvement of the olfactory nerves is a general 
phenomenon or a strain-dependent feature, as well as to determine the pathways and timelines for 
dissemination of the infectious agent into the brain upon exposure to prion aerosols or i.n. administration of 
prions. The experiments clearly demonstrate that transmission of aerosolized, scrapie terminal brain 
homogenates very efficiently leads to terminal scrapie. In this study, PrPC expression levels and the site of 
PrPC expression (NSE-PrP mice for example) were shown to determine the length of the incubation time 
upon (1) aerosolic infection and (2) contact-mediated i.n. inoculation. 
 
2.6.2 Prion neuroinvasion after i.n. application in immunocompromised mice 
Following peripheral exposure, many of the acquired TSE agents accumulate and replicate in lymphoid 
tissues and the LRS, including the spleen, lymph nodes, Peyers‘s patches (PPs) and tonsils (Beekes and 
McBride, 2000; Hill et al., 1997b; Hilton et al., 1998; Mabbott and MacPherson, 2006; Mould et al., 1970; 
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Sigurdson et al., 1999; Wadsworth, 2001) After peripheral replication in the LRS, prions are transported to 
the CNS primarily via peripheral nerves (Aguzzi and Heikenwalder, 2006). It has been shown that 
innervation of secondary lymphoid organs is a rate-limiting step in prion neuroinvasion (Glatzel et al., 
2001). The distance between FDCs and splenic nerve endings has been reported to have an impact on the 
speed of neuroinvasion (Prinz et al., 2003a).  
Remarkably, in these experiments prion transmission occurred in the absence of B-, T- and NK-cells as 
evidenced by i.n. prion infection of Rag1-/- or CRag2-/- mice, indicating a direct transmission route after 
aerosolic and i.n. prion inoculation. Rather than depending on the LRS, I propose an alternative pathway of 
direct, contact-mediated prion neuroinvasion which occurs via the dendrites of olfactory neurons extending 
to the surface of the olfactory epithelium. This is supported by the finding that immunodeficient mice such 
as newborns, Rag1-/- or CRag2-/- mice are equally susceptible to aerosolic and i.n. prion infection as control 
mice.  
Various explanations could underlie these findings: the data either stand in contrast to Sbriccoli`s work 
(Sbriccoli et al., 2009), or alternatively, the mechanism may also depend on the particular prion strain 
investigated. However, the data presented here are consistent with recent work by Bessen et al (Bessen et 
al., 2009) who could show that prion neuroinvasion from the tongue and nasal cavity can occur in the 
absence of LRS infection. These reported findings partially depended on the strain of the prion agent and/or 
the host species. This group explained the paucity of PrpSc deposits in the oral and nasal mucosa from LRS 
replication-deficient hosts following neuroinvasion by an infection of nerve fibres. These authors 
hypothesized that the amount of infectivity lies below the detection limit of PrpSc. Alternatively, they 
suggest prion transport along cranial nerves without replication (Bessen et al., 2009). Consistent with these 
data, here I show that horizontal prion transmission can be achieved through airborne infection. I have 
investigated the transmissibility potential of prions administered by aerosols or i.n.. As prion aerosols may 
be generated by prion-infected individuals, either of human or of animal origin, prion-contaminated 
aerosols are highly relevant for horizontal prion transmission. Interestingly, prion transmission occurred in 
the absence of B-, T- and NK-cells, suggesting a direct transmission route upon i.n. prion inoculation.  
Various transgenic mouse models (e.g. NSE-PrP; Tga20) expressing the cellular prion protein (PrPC) in 
specific tissues or cells of the brain or the periphery (e.g. exclusively in the CNS) were investigated to 
identify the cellular and molecular mechanism(s) of prion invasion via the i.n. route.  
In contrast to data provided by others (Bessen et al., 2009), in my hands, LT-/- mice are also infectable with 
the RML prion agent via the i.n. route. These contradictory results are most probably due to the detection 
limits of minute amounts of prions. In summary, these results identify aerosols as a highly efficacious mode 
of prion transmission. In an experimental model of mouse scrapie, I found in collaboration with Prof. Stitz’s 
laboratory that (1) prion aerosols can efficiently transmit the disease in various mouse lines, which depends 
on the PrPC expression level. In addition, different strains of knock-out and immunodeficient mice were 
tested for the efficiency of prion transmissibility. These data were reproducible upon (2) i.n. challenge of 
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mice.  
I was also able, despite the limitations of prion diagnostics in mice, to elucidate the cellular and molecular 
mechanism driving (1) aerosolic and (2) i.n. prion transmission and the subsequent infection of the CNS by 
prions. A scheme describes the possible ways of the infectious particles after prion infection via the aerial 
route (Figure 3). Prion transmission to the CNS may occur directly through the nasal mucosa via olfactory 
nerves (direct pathway) involving uptake of prions by the olfactory nerve terminals. Alternatively, uptake 
mmight require a lymphoid replication phase (immune mediated pathway): e.g. in the BLNs, the NALT or 
the spleen before entering the CNS. 
This novel pathway of prion transmission is not only conceptually relevant for the field of prion research, 
but also highlights a thus far unappreciated risk factor for laboratory personnel and personnel of the meat 
processing industry. In the light of these findings, it may be appropriate to revise our current prion-related 
biosafety guidelines and public health standards. 
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Abbreviations: 
AA       amino acid 
1AT       1-antitrypsin deficiency 
ALD       alcoholic liver disease 
ALT       alanine aminotransferase 
ASH       alcoholic steatohepatitis 
AST       aspartate aminotransferase 
BLC       B lymphocyte chemoattractant 
BM       bone marrow 
bp       base pair 
CASH       chemotherapy associated steatohepatitis 
CCC       Cholangiocellular carcinoma 
CD       cluster of differentiation 
cDNA       complementary DNA 
CH       cholestasis 
CJD       Creutzfeldt-Jakob-disease 
CNS       central nervous system 
cT       threshold cycle 
Ctrl       control 
CWD       chronic wasting disease 
DC       dendritic cell 
DNA       Deoxyribonucleic acid 
dNTP       Deoxynucleotide 
dpi       days post infection 
DTT       Dithiothreitol 
ECL       enhanced chemiluminescence 
EDTA       Ethylendiamintetraacetic acid 
ELC       EBl-1 ligand chemokine 
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ELISA       Enzyme-linked immunosorbent assay 
FDC       follicular dendritic cell 
FFI       fatal familial insomnia 
FITC       fluorescein isothiocyanate 
FLF       focal liver fibrosis 
FNH       focal nodular hyperplasia 
GALT       gut associated lymphoid tissue 
GAPDH     glyceralaldehyde 3-phospate deghydogenase 
GC       germinal centre 
GFAP       glial acidic fibrilarry protein 
GPI       glycosyl-phosphatidyl-inositol 
GSS            Gerstmann-Sträussler-Scheinker disease 
H&E       hematoxylin and eosin (also HE) 
HBV       hepatitis B virus 
HCC       hepatocellular carcrinoma 
HCV       hepatitis C virus 
HE/SID      hemochromatosis/siderosis 
Hep       hepatocytes 
HEV       hepatitis E virus 
HVEM       Herpes virus entry mediator 
IFN       Interferon gamma 
IgG       Immunoglobulin G 
IKK       IkB kinase complex 
IL       Interleukin 
i.n.        intranasal  
I.p.        intraperitoneal 
IKB       Inhibitor of KB 
kD       Kilo dalton 
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LD       lethal dose 
LIGHT       Homologous to lymphotoxins, exhibits inducible expression, and competes with HSV    
                   glycoprotein D for HVEM, a receptor expressed by T lymphocytes 
LN       Lymph node 
LOH       Loss of heterozygosity 
LPS       Lipopolysaccharide 
LTα       Lymphotoxin  
LT       Lymphotoxin  
LT       Lymphotoxin 
LT-R       Lymphotoxin receptor 
M       Molar 
MALT       Mucosa associated lymphoid tissue 
MHC       Major histocom patibility com plex 
MMP       Matrix metalloproteinase 
mRNA       messenger RNA 
muIgG       murine IgG 
NALT       nasopharyngeal-associated lymphoid tissue 
NASH       non alcoholic steatohepatitis 
NEMO       NF-ĸB essential modifier 
NF-ĸB       Nuclear factor of KB 
NIK       Nuclear factor of KB inducing kinase 
NLS       Nuclear localization signal 
NOD       Non obese diabetes 
NSAID       Non steroidal anti-inflammatory drug 
NVH       non-virus induced HCC 
OLD       other liver diseases  
ORF       Open Reading Frame 
PAGE       Polyacrylamid gel electrophoresis 
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PBC       primary biliary cirrhosis/ autoimmune cholangitis 
PBS       Phosphate-buffered saline 
PCR       Polymerase chain reaction 
PE       Phycoerythrin 
PNA       Peanut agglutinin 
PP       Peyers Patch 
PTA       Sodium phosphotungstic acid 
RML       Rocky mountain laboratory (prion strain) 
RNA       Ribonucleic acid 
ROS       Reactive oxygen species 
RT       Room temperature 
RT-PCR     Reverse transcription PCR 
SAF       Spongiosis associated fibrils 
SDS       Sodium dodecyl sulfate 
TCR       T cell receptor 
Tg       Transgenic 
TLO       Tertiary lymphoid organ 
TNF       Tumor necrosis factor 
TNFR       TNF receptor 
U       unit 
VCAM-1    Vascular cell adhesion molecule 1 
WD       Wilson`s disease 
WHO       world health organization 
WT       wild-type 
w/v       weight/volume 
-/- or 0/0       knockout 
 -                 negative for 
+                 positive for 
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4 Material and Methods 
4.1 Human liver tissue 
Human liver biopsies were obtained from the University Hospital Zurich, Switzerland, the University 
Hospital Freiburg, the University Hospital Heidelberg, Germany, the University of Graz, Austria and 
the University Hospital Grenoble, France. All samples were registered in the respective biobanks and 
were kept anonymous. The research project was authorized by the ethical committees of the 
“Gesundheitsdirektion Kanton Zürich” (Ref. Nr. StV 26-2005) Switzerland, Freiburg 
(Forschungsvorhaben Nr. 299/2001) and Heidelberg (Prof. Bannasch), Germany, “Ethikkomission der 
medizinischen Universität Graz“ (Ref. Nr. Version 1.0 24/11/2008; Prof. Zatloukal) University of 
Graz, Austria, and by the ethical committee of the University Hospital Grenoble (Ref. Nr. 03/APTF/1, 
promoter APTFC, Prof. V Leroy). The study protocol was in accordance with the ethical guidelines of 
the Helsinki declaration and was approved by the review board of the University Hospital Grenoble. 
Patients were enrolled after giving their written informed consent. HBV- or HCV infected patients 
suffering from chronic hepatitis were not treated with ribavirin or other immunomodulatory drugs at 
the time point of needle biopsy. 
 
4.2 Mice  
Animals were devoid of any bacterial, viral, and parasitic pathogens listed in the Federation of 
European Laboratory Animal ScienceAssociations recommendations and were maintained under 
specific pathogen-free (spf) conditions. Housing and experimental protocols were in accordance with 
the Swiss Animal Protection Law and mice were held according to the regulations of the Veterinary 
office of the Canton Zurich. AlbLT transgenic mice were generated as published (Heikenwalder et 
al., 2005). Tnfr1-/-, Tnfr2-/-, Rag1-/-, Ltr-/-, IkkAA/AA and Ikkhep mice were published previously 
(Alimzhanov et al., 1997; Bluethmann et al., 1994; Browning et al., 1995; Cao et al., 2001; Futterer et 
al., 1998; Koni et al., 1997; Mackay et al., 1997; Maeda et al., 2005). Tg1223, Tnfr1-/-, Tnfr2-/-, Rag1-/- 
and Ikkhep mice were intercrossed to create Tg1223/Tnfr1-/-, Tg1223 /Tnfr2-/-, Tg1223/Rag1-/- and 
Tg1223/Ikkhep. 
 
4.3 Generation of bitransgenic mice overexpressing LT specifically on hepatocytes 
As previously published, bitransgenic mice expressing LT and LT in liver under the control of the 
albumin promoter were generated (Heikenwalder et al., 2005). pBluescript II KS was cut with KpnI, 
blunted, religated and linearized with BamHI and SahI. A BamHI-SahI restriction product (ca. 5.4 kb) 
of the PrP 5‘HG construct was inserted. The resulting construct was termed AKpnI pBluePrP 5‘HG. 
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The albumin promoter cassette (ca. 2.9 kb) was isolated by digesting pPrP 5‘HGAlbSalI with BamHI 
and NotI. Murine LT and LTcDNA open reading frames were amplified by PCR from plasmids 
donated by Prof. Sergei Nedospasov using primers incorporating 50bp and 15bp overhangs with 
homologous sequences to non-coding regions of Prnp (Raeber et al., 1999) as well as MfeI and KpnI 
restriction sites. LT primer fwd.: 5’-CGG GGT ACC AGT CCAATT TAG GAG AGC CAA GCA 
GAC TAT CAT CAT GAC ACT GCT CGG CCG TCT CC-3’. LT primer fwd.: 5’-CGG GGT ACC 
AGT CCA ATT TAG GAG AGC CAA GCA GAC TAT CAT CAT GGG GAC AGG GGA CTG 
CAG G-3’.LT primer rev.: 5’-CCACCTCAATTGAATCTACAGTGCAAAGGCTCC-3’. LT 
primer rev.: 5’-CCA CCT CAA TTG AAT TCA CCC CAC CAT CAC CGC-3’. PCR products (610 
bps for LTa and 921 bps for LT were subcloned into AKpnI pBluePrP5’HG vector. LT and LT 
ORFs plus flanking regions were sequenced. AKpnI pBluePrP 5‘HGLTFI1 or FI1 vectors were 
linearized with BamHI and NotI for the insertion of the promoter cassette. All enzymes were 
purchased from Roche and New England Biolabs. Fragments were isolated from 0.7% agarose gels 
(Qiagen, according to the manufacturer’s manual) and dissolved in microinjection buffer. Both 
constructs were linearized with SahI and NotI and co-injected (equimolar ratio) into male pronuclei of 
C57BL/6 oocytes. For identification of transgenic mice, the primers below were used: LTforward 
primer: (Prp 5‘): 5‘- CTG AGT ATA TTT CAG AAC TG- 3‘. Reverse primer: (LT rev): 5‘- CAG 
AGA AAA CCA CCT GGG AG- 3‘. For transgenic LTthe following primers were used: Primers for 
LT PCR: forward primer(Prp 5‘): 5‘- CTG AGT ATA TTT CAG AAC TG- 3‘. Reverse primer: 
(LT rev): 5‘- GAG TCT CTG AGA GGC TAG AG- 3‘. PCR conditions on a GeneAmp PCR System 
9700 (Applied Biosystems) were: 95°C 60 sec. denaturation; 55°C 50 sec. annealing; 72°C 50 sec. 
elongation; 35 cycles; 72°C 7 mins shoot out; 4°C forever cool down. RNA from wild-type and 
trangenic mice was isolated in Trizol (Invitrogen) and reverse transcribed using the Geneamp kit 
(Roche). C57BL/6-Tg(LT)1222 and C57BL/6-Tg(LT)1223 mouse lines contained one copy per 
haploid genome of both AlbLT and AlbLT transgenes, with expression restricted to liver and absent 
from spleen, thymus, mesenteric lymph nodes, pancreas, and kidney. C57BL/6-Tg(LT)1223 mice 
were identified as the highest expressors and were selected for further experiments.
 
4.3.1 Genomic Southern Blot 
For genomic Southern blot analysis mouse tail biopsies were received on dry ice and digested in a 
lysis buffer containing 100mM Tris-HCl pH 8.5, 5mM EDTA, 0.2% SDS, 20mM NaCl, and 100g 
Proteinase K/ml. 10 - 20g of purified genomic DNA (after Phenol: Chloroform: Isoamylalcohol 
precipitation) were digested over night and electrophoresed through 0,7% agarose (GIBCO BRL ultra 
Pure agarose; 15510-027) gels. Genomic digest and DNA separation was checked by ethidium 
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bromide staining, depurinated by treatment with 1M HCL for 15 mins and 0.4M NaOH for 30mins and 
transferred to HybondTMN+membranes (Amersham) by vacuum blotting at 50-55 mbar with a Vacu 
Gene Pump and a Gene XL blotting apparatus (Pharmacia, Biotec) and solutions were used according 
to the manufacturer’s manual (Pharmacia). After the agarose gel was examined for residual DNA, the 
blot was marked, washed for 5 mins in 2xSSC and prehybridized according to Church and Gilbert 
(1984). After hybridization (over night at 65°C) with a radioactively labeled probe, the blot was 
washed and membranes were subjected either to autoradiography using X-ray films (Kodak) or a 
PhosphorI mager (Molecular Dynamics). Exposed PhosphorImagers were analyzed with a scanner 
(Aida) and signals were quantified with the Aida 2.41. imaging anaylsis program. To label the probe, 
template DNA (50ng) was diluted in sterile water and random primer (random Nonamers or 
Hexamers) were added (Prime-IT® II; Random Primer labeling kit cat# 300385; Stratagene). After 
gentle mixing, incubation was performed on 95°C for 5 mins. Short centrifugation was followed by 3 
mins incubation on ice. This was followed by addition of 5x Primer-buffer (-dCTP), radioactive 
labeled a32P-dCTP (corresponding to the 25LICi/Amersham Biosciences) and Klenow 5U/l (Prime-
IT® II; Random Primer labeling kit cat# 300385). For purification of the probe a QIAquick PCR-
purification kit was used, according to the manufacturer’s manual (Quiagen). 10ml sonicated salmon 
sperm (stock 10g/ml; Stratagene) were added to the radioactive labeled, purified probe per ml 
hybridization solution (final conc.: 100g/ml). The mixture was incubated at 95°C for 5 mins, briefly 
spinned and chilled on ice for 3 mins before added to the pre-hybridized membrane (2hrs at 65°C). 
This experiment was performed by Nicolas Zeller and Mathias Heikenwälder. 
 
4.4 TNFα and 3C8 treatment  
Twelve to fourteen weeks old male mice (C57BL/6 and various knock-out mice) were i.v. injected 
with either PBS, murine recombinant TNFα (50g/kg bodyweight; R&D Systems) and agonistic 
LTR antibody (50g/mouse; clone 3C8; eBioscience) or rat IgG (50g/mouse; eBioscience) and 
sacrificed for analysis 45 min post injection. All substances were injected at a total volume of 100l 
dissolved in PBS. 
 
4.5 Isolation of intrahepatic murine lymphocytes (IHL) 
Mice were anesthetized and liver was perfused with PBS to remove circulating leukocytes. Liver 
tissue was minced and digested in medium containing collagenase (1mg/ml) and DNase (25g/ml) at 
37°C for 40 min. Cells were centrifuged at 300rpm for 3 min to sediment the majority of hepatocytes. 
Supernatant was removed and centrifuged again at 1200rpm for 10 min. Cell pellet was resuspended in 
the 40% fraction of a 40:80 Percoll gradient. Upon centrifugation at 2500rpm for 20 min, IHL were 
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collected at the interface. IHL were analyzed for surface marker expression by staining with anti-CD4, 
anti-CD8, anti-TCR-, anti-NK1.1 or anti-CD19 antibodies, and for cytokine production capacity by 
intracellular staining with anti-IFN and anti-IL17 antibodies (all from eBioscience) upon 
PMA/Ionomycin stimulation by using a two-laser FACScalibur (BD). Analysis was executed with 
CellQuest and FlowJo software. Cytokine production by IHL was determined by intracellular staining 
with anti-IFN and anti-IL17 antibodies (all from eBioscience) after 4 hrs stimulation with PMA and 
Ionomycin. 
 
4.6 Measurement of aminotransferases  
The analysis for AST and ALT was performed with mouse serum on a Roche Modular System (Roche 
Diagnostics) with a commercially available automated colorimetric system at the Institute of Clinical 
Chemistry at the University Hospital Zurich using a Hitachi P-Modul (Roche). 
 
4.7 RNA isolation from liver tissue  
Total RNA from human and mouse liver samples was isolated using RNeasy Mini kit (Qiagen) or 
RNA-NOW kit (Biogentex-Ozyme). The quantity and quality of the RNA was determined 
spectroscopically using a nanodrop (Thermo Scientific). For microarray analysis, RNA quality was 
tested using a bioanalyzer (Agilent). Purified RNA was reversely transcribed into cDNA using 
Quantitect Reverse Transcription Kit (Qiagen) according to the manufacturer’s protocol. 
 
4.8 Real-time RT-PCR 
For mRNA expression analysis real-time PCR was performed using Fast Start SYBR Green Master 
Rox (Roche) or specific TaqMan probes (Applied Biosystems, AB). Primers were custom made by 
Microsynth or purchased from AB or on a LightCycler® 480 Probes Master (Roche Diagnostics). 
Real-time PCR was performed on an ABI PRISM 7700 Sequence Detection System or on a 7900 HT 
Fast Real-Time PCR System (AB). Data were generated and analyzed using SDS 2.3 and RQ manager 
1.2 software.  
For human LT and LT Taqman Gene Expression assays from AB were purchased. Hu LT 
Hs00242739m1(FAM-labelled); probe sequence: 5’-GCC CAC CTC ATA GGC GCT CCG CTG A-
3’. Hu LT Hs00236874 m1(FAM labelled); probe sequence 5’-ACC TCA TTG GAG ACC CCA 
GCA AGC A-3’. TaqMan analysis for human 18s rRNA was performed with a TaqMan® ribosomal 
RNA control reagent (VICTM Probe; AB; Part. No.4308329). mRNA expression levels were 
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normalized to the housekeeping gene GAPDH (mouse) or 18S rRNA and HPRT (human). Further 
primers used are listed in the Supplemental material. Efficiency of DNase digest was controlled by 
PCR of DNase+RT- treated liver RNA samples.  
 
4.8.1  Preparation of mouse-tail lysates for PCR analysis 
For PCR screeing of mice, 5-10mm of the tail were cut and lysed in 100Ul lysis buffer containing 
50mM Tris-HCl (pH 9.0), 0.5% Nonidet P-40, 0.5% Tween-20 and 0.1mg/ml proteinsae K, at 55°C 
with agitation over night at 600rpm (Thermomixer 5436, Eppendorf). Following complete digestion, 
proteinase K was then inactivated by incubation at 95°C for 10 mins. After centrifugation (12000rpm/ 
15min/ RT) the lysates were immediately used for PCR or stored at -20°C. 
 
4.8.2 PCR specific for tg1222 and tg1223 mice  
For transgenic LTα the following primers were used: Forward primer: (Prp 5’): 5’-CTG AGT ATA 
TTT CAG AAC TG-3’. Reverse primer: (LTα rev): 5’-CAG AGA AAA CCA CCT GGG AG-3’. For 
transgenic LT the following primers were used: Forward primer (Prp 5’): 5’-CTG AGT ATA TTT 
CAG AAC TG-3’. Reverse primer: (LT rev): 5’- GAG TCT CTG AGA GGC TAG AG-3’. The 
following PCR conditions were established on a Gene Amp® PCR System 9700 PCR machine 
(Applied Biosystems): 95°C 60 sec denaturation; 55°C 50 sec annealing; 72°C 50 sec elongation; 35 
cycles. 
Gene fwd-sequence (5’-3’) rev-sequence (5’-3’)
ak006094 CGG TTT TAA TCT GAG TGC GCA ATG AAA GTT TCT TTT AG 
ak03 1632 CCT AAT TAG GTT CTA TAG TG GTT CTA AGA AAC ATC AAA TGC 
ak032385 GGA TCC AAC TCT AGT CCT TT GAT GTGATG GGT TCT AAT C 
ak080904 CTT GTC TTT ACT TAC GTC TC CCT TGG ACT AAA TCA GAA ACC 
ak084087 GGT GGT GGA AAT ACT ATC ATG GCC AAG AAG TAA CAT CTC 
arid5a TCC CGC AGC TTC CTG TAT C GAC CAG CCT CTC ATA GGT GC 
arrdc3 ATG GTG CTG GGA AAG GTA AAG CGC TAG AAT ACA CGG GGA CAT TA 
bc013561 CTG AGG TTT CTT GGT AAT GC CAC TTT CAA CAG CCA ATT TAA C 
Blc CCA TTT GGC ACG AGG ATT CAC ATG AGG CTC AGC ACA GCA AC 
btg2 ATG AGC CAC GGG AAG AGA AC GCC CTA CTG AAA ACC TTG AGT C 
ccl2 TTA AAA AAC CTG GAT CGG AAC CAA GCA TTA GCT TCA GAT TTA CGG GT 
ccl7 GCT GCT TTC AGC ATC CAA GTG CCA GGG ACA CCG ACT ACT G 
c-fos AGA CTT CTC ATC TTC AAG TT AAG ATG GCT GCA GCC AAG T 
ch25h TGC TAC AAC GGT TCG GAG C AGA AGC CCA CTG AAG TGA TGA T 
cxcl1 CTG GGA TTC ACC TCA AGA ACA TC CAG GGT CAA GGC AAG CCT C 
cxcl10 AAG TGC TGC CGT CAT TTT CT CCT ATG GCC CTC ATT CTC AC 
edg8 GCT TTG GTT TGC GCG TGA G GGC GTC CTA AGC AGT TCC AG 
egr1 AGG TTC CCA TGA TCC CTG ACT GGT ACG GTT CTC CAG ACC CTG 
egr2 CAG GAG TGA CGA AAG GAA GC GAA GAC TGG GCA GAT GGA GG 
Material and Methods 
147 
Elc GCC TCA GAT TAT CTG CCA T AGA CAC AGG GCT CCT TCT GGT 
e-selectin CTG CAG TTC TGA CGT GTG GT GAG CAA TGA GGA CGA TGT CA 
extl-1 TTC TGG CTG GCG TTG TCA G GGG TTC GTC TCA GAC TGG GA 
fgf21 CTG CTG GGG GTC TAC CAA G CTG CGC CTA CCA CTG TTC C 
gadd45g GGG AAA GCA CTG CAC GAA CT AGC ACG CAA AAG GTC ACA TTG 
Gapdh CCA CCC CAG CAA GGA GAC T GAA ATT GTG AGG GAG ATG CT 
gas1 CCA TCT GCG AAT CGG TCA AAG GCT CGT CGT CAT ATT CTT CGT C 
gpr109b CTG GAG GTT CGG AGG CAT C TCG CCA TTT TTG GTC ATC ATG T 
g0/g1switch TAG TGA AGC TAT ACG TTC TGG GC GTC TCA ACT AGG CCG AGC A 
hist1 h1c AAC CCC AGG CTA AGA AGG C TGG CTT TAC GGC TTT AGA CGC 
hist1h1d GTG GAG AAG ACA CCT GTG AAG CCT TGG CTG GAC TCT TTG CT 
icam1 TGC GTT TTG GAG CTA GCG GAC CA CGA GGA CCA TAC AGC ACG TGC CAG 
Ifny TCA AGT GGC ATA GAT GTG GAA GAA TGG CTC TGC AGG ATT TTC ATG 
igfbp1 ATG GGT GCT GCC TGC GGT GTG G GGT GAG GGC ATG CAG GGG ACG AG 
igf1 GGA CCG AGG GCT TTT ACT TCA A TCG ATA GGG ACG GGG ACT TCT G 
igf2 CCG GCT ACC ACA ATG TCC TGC TCT GCT CCC GCC TGA TGT AAC CTG TCT 
Inhbe AAA AGC CCA GCT CTG GCT AAT CTG GTT AGG TGC AGT CCC TC 
jun-b TCA CGA CGA CTC TTA CGC AG CCT TGA GAC CCC GAT AGG GA 
Lmln TGC TGA CGG GCA TTT ACG AAT TGT CGC ACA TTG TCT GCT AAG 
LTα TCC ACT CCC TCA GAA GCA CT AGA GAA GCC ATG TCG GAG AA 
Lt TAC ACC AGA TCC AGG GGT TC ACT CAT CCA AGC GCC TAT GA 
mkiaaa1 853 GTC TCG GGG CCA GGA GAA G GAG CTC CGG GCT GTG GAT G 
nm025719 ATG TCG CCT GTA TCC CGA TCT GTA GCG GTC GTT CTC CAG A 
nr1d1 TAC ATT GGC TCT AGT GGC TCC CAG TAG GTG ATG GTG GGA AGT A 
Pdxp ATG AGT CAC ATT CGG GAC CAT AGG GCA GGA AAT AAG GCC AC 
Periplakin CAA AGG CAA ATA CAG CCC AAC TTC CAC CTG GTC TGC ATT CTT 
p-selectin GAA AGG GCT GAT TGT GAC CCC AGT AGT TCC GCA CTG GGT ACA 
Rantes ATG CCG ATT TTC CCA GGA CC TTT GCC TAC CTC TCC CTA GAG CTG 
serpine-1 TTC AGC CCT TGC TTG CCT C ACA CTT TTA CTC CGA AGT CGG T 
Slc ATG ATG ACT CTG AGC CTC C GAG CCC TTT CCT TTC TTT CC 
socs3 TCC CCG ACT GGG TCT TGA C GCG GGC ACC TTT CTT ATC C 
TNFα CAT CTT CTC AAA ATT CGA GTG ACA A TGG GAG TAG ACA AGG TAC AAC CC 
TNFαip3 GAA CAG CGA TCA GGC CAG G GGA CAG TTG GGT GTC TCA CAT T 
Vcam TAC CAG CTC CCA AAA TCC TG CGG AAT CGT CCC TTT TTG TA 
Vmaf TTC GAC CTT CTC AAG TTC GAC G TCG AGA TGG GT TTC GGT TCA 
xm1 34539 CAC TGG TCA ACT GCT TTT C CTC TCT ACC TAT ACC CGA TG 
adcyap1r1 CTG CGT GCA GAA ATG CTA CTG AGC CGT AGA GTA ATG GTG GAT AG 
baz2a CAG AGG GTA TGT GTC TGT CTG A GAA CTC CAC GAT GGT CAA GCA 
dmrta1 CCC AAC TTT CGA GGT TTT CCA CCC AGA GAA TGG TGA TGA GTG TT 
Dntt CTG GCA TTC ATG CGA GCA TC GAA GGC CCG GCG ATC ATA G 
elovl6 GAA AAG CAG TTC AAC GAG AAC G AGA TGC CGA CCA CCA AAG ATA 
fbxl5 TTC AGC AGC GCA GTC AGA C CAG CAT CTC GGA GAG CTT ATT G 
fbxo21 CCT GTA CCT GGC GAT GTA CC AGC ACC TTC AAG ACA AGA CAG A 
hmgcll1 ATG GGG AAT CTA CCA TCT GCT AGG GAG TCC AGG TAA CTG AGA 
nrtk2 CTG GGG CTT ATG CCT GCT G AGG CTC AGT ACA CCA AAT CCT A 
olfr1 508 ACT GTG GTC CTG ATG AGA TTG A GGG GTA ACA GCA GTG AAA AAC AC 
pbef1 GCA GAA GCC GAG TTC AAC ATC TTT TCA CGG CAT TCA AAG TAG GA 
per3 AAC ACG AAG ACC GAA ACA GAA T CTC GGC TGG GAA ATA CTT TTT CA 
phlda3 CCG TGG AGT GCG TAG AGA G TCT GGA TGG CCT GTT GAT TCT 
prm1 CCG TCG CAG ACG AAG ATG TC CAC CTT ATG GTG TAT GAG CGG 
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serpina9 AAA CCC AGG TCA GAA TAT CCT CT GGA CGA GGT ACT CGA AGC C 
Slpi GGC CTT TTA CCT TTC ACG GTG TAC GGC ATT GTG GCT TCT CAA 
srgap3 TCC TGT GAA CAA CTG TCG TCT CAC GCC CAC AAT TCC CTC C 
st8sia3 AGT GTG CTA GGG CTG GTC AT TGG CGT ACT TGG GAG TGG T 
sulf1 TGT GTT CCA CCG TTC GGT C CAC ATC CTG GTC GTC AGT GAG 
Thrsp ATG CAA GTG CTA ACG AAA CGC CCT GCC ATT CCT CCC TTG G 
tmem45b ACC ACA AGG GCT TGA AGA ATA AC GGT GCA GGT GAG GTC CAT C 
tmem51 CAA AGC CAA CGG CTC ACA CTA GCT TAT CCG CAG GGC TGA AA 
tnnt2 CAG AGG AGG CCA ACG TAG AAG CTC CAT CGG GGA TCT TGG GT 
ucp2 ATG GTT GGT TTC AAG GCC ACA CGG TAT CCA GAG GGA AAG TGA T 
upp2 GGG AGC GTC CAG AGT ATG G CTG GTA GGT TGT GTG TTT TGG T 
wee1 GTC GCC CGT CAA ATC ACC TT GAG CCG GAA TCA ATA ACT CGC 
Ltr TCA AAG CCC AGC ACA ATG TC TTA TCG CAT AGA AAA CCA GAC TTG C 
tnfr1 GCA GTG TCT CAG TTG CAA GAC ATG TCG G CGT TGG AAC TGG TTC TCC TTA CAG CCA C 
 
4.8.3 Primer sequences used for real-time PCR analysis (murine) 
Gene fwd-sequence (5’-3’) rev-sequence (5’-3’)
ak006094 CGG TTT TAA TCT GAG TGC GCA ATG AAA GTT TCT TTT AG 
ak03 1632 CCT AAT TAG GTT CTA TAG TG GTT CTA AGA AAC ATC AAA TGC 
ak032385 GGA TCC AAC TCT AGT CCT TT GAT GTGATG GGT TCT AAT C 
ak080904 CTT GTC TTT ACT TAC GTC TC CCT TGG ACT AAA TCA GAA ACC 
ak084087 GGT GGT GGA AAT ACT ATC ATG GCC AAG AAG TAA CAT CTC 
arid5a TCC CGC AGC TTC CTG TAT C GAC CAG CCT CTC ATA GGT GC 
arrdc3 ATG GTG CTG GGA AAG GTA AAG CGC TAG AAT ACA CGG GGA CAT TA 
bc013561 CTG AGG TTT CTT GGT AAT GC CAC TTT CAA CAG CCA ATT TAA C 
Blc CCA TTT GGC ACG AGG ATT CAC ATG AGG CTC AGC ACA GCA AC 
btg2 ATG AGC CAC GGG AAG AGA AC GCC CTA CTG AAA ACC TTG AGT C 
ccl2 TTA AAA AAC CTG GAT CGG AAC CAA GCA TTA GCT TCA GAT TTA CGG GT 
ccl7 GCT GCT TTC AGC ATC CAA GTG CCA GGG ACA CCG ACT ACT G 
c-fos AGA CTT CTC ATC TTC AAG TT AAG ATG GCT GCA GCC AAG T 
ch25h TGC TAC AAC GGT TCG GAG C AGA AGC CCA CTG AAG TGA TGA T 
cxcl1 CTG GGA TTC ACC TCA AGA ACA TC CAG GGT CAA GGC AAG CCT C 
cxcl10 AAG TGC TGC CGT CAT TTT CT CCT ATG GCC CTC ATT CTC AC 
edg8 GCT TTG GTT TGC GCG TGA G GGC GTC CTA AGC AGT TCC AG 
egr1 AGG TTC CCA TGA TCC CTG ACT GGT ACG GTT CTC CAG ACC CTG 
egr2 CAG GAG TGA CGA AAG GAA GC GAA GAC TGG GCA GAT GGA GG 
Elc GCC TCA GAT TAT CTG CCA T AGA CAC AGG GCT CCT TCT GGT 
e-selectin CTG CAG TTC TGA CGT GTG GT GAG CAA TGA GGA CGA TGT CA 
extl-1 TTC TGG CTG GCG TTG TCA G GGG TTC GTC TCA GAC TGG GA 
fgf21 CTG CTG GGG GTC TAC CAA G CTG CGC CTA CCA CTG TTC C 
gadd45g GGG AAA GCA CTG CAC GAA CT AGC ACG CAA AAG GTC ACA TTG 
Gapdh CCA CCC CAG CAA GGA GAC T GAA ATT GTG AGG GAG ATG CT 
gas1 CCA TCT GCG AAT CGG TCA AAG GCT CGT CGT CAT ATT CTT CGT C 
gpr109b CTG GAG GTT CGG AGG CAT C TCG CCA TTT TTG GTC ATC ATG T 
g0/g1switch TAG TGA AGC TAT ACG TTC TGG GC GTC TCA ACT AGG CCG AGC A 
hist1 h1c AAC CCC AGG CTA AGA AGG C TGG CTT TAC GGC TTT AGA CGC 
hist1h1d GTG GAG AAG ACA CCT GTG AAG CCT TGG CTG GAC TCT TTG CT 
icam1 TGC GTT TTG GAG CTA GCG GAC CA CGA GGA CCA TAC AGC ACG TGC CAG 
Material and Methods 
149 
Ifny TCA AGT GGC ATA GAT GTG GAA GAA TGG CTC TGC AGG ATT TTC ATG 
igfbp1 ATG GGT GCT GCC TGC GGT GTG G GGT GAG GGC ATG CAG GGG ACG AG 
igf1 GGA CCG AGG GCT TTT ACT TCA A TCG ATA GGG ACG GGG ACT TCT G 
igf2 CCG GCT ACC ACA ATG TCC TGC TCT GCT CCC GCC TGA TGT AAC CTG TCT 
Inhbe AAA AGC CCA GCT CTG GCT AAT CTG GTT AGG TGC AGT CCC TC 
jun-b TCA CGA CGA CTC TTA CGC AG CCT TGA GAC CCC GAT AGG GA 
Lmln TGC TGA CGG GCA TTT ACG AAT TGT CGC ACA TTG TCT GCT AAG 
LTα TCC ACT CCC TCA GAA GCA CT AGA GAA GCC ATG TCG GAG AA 
Lt TAC ACC AGA TCC AGG GGT TC ACT CAT CCA AGC GCC TAT GA 
mkiaaa1 853 GTC TCG GGG CCA GGA GAA G GAG CTC CGG GCT GTG GAT G 
nm025719 ATG TCG CCT GTA TCC CGA TCT GTA GCG GTC GTT CTC CAG A 
nr1d1 TAC ATT GGC TCT AGT GGC TCC CAG TAG GTG ATG GTG GGA AGT A 
Pdxp ATG AGT CAC ATT CGG GAC CAT AGG GCA GGA AAT AAG GCC AC 
Periplakin CAA AGG CAA ATA CAG CCC AAC TTC CAC CTG GTC TGC ATT CTT 
p-selectin GAA AGG GCT GAT TGT GAC CCC AGT AGT TCC GCA CTG GGT ACA 
Rantes ATG CCG ATT TTC CCA GGA CC TTT GCC TAC CTC TCC CTA GAG CTG 
serpine-1 TTC AGC CCT TGC TTG CCT C ACA CTT TTA CTC CGA AGT CGG T 
Slc ATG ATG ACT CTG AGC CTC C GAG CCC TTT CCT TTC TTT CC 
socs3 TCC CCG ACT GGG TCT TGA C GCG GGC ACC TTT CTT ATC C 
TNFα CAT CTT CTC AAA ATT CGA GTG ACA A TGG GAG TAG ACA AGG TAC AAC CC 
TNFαip3 GAA CAG CGA TCA GGC CAG G GGA CAG TTG GGT GTC TCA CAT T 
Vcam TAC CAG CTC CCA AAA TCC TG CGG AAT CGT CCC TTT TTG TA 
Vmaf TTC GAC CTT CTC AAG TTC GAC G TCG AGA TGG GT TTC GGT TCA 
xm1 34539 CAC TGG TCA ACT GCT TTT C CTC TCT ACC TAT ACC CGA TG 
adcyap1r1 CTG CGT GCA GAA ATG CTA CTG AGC CGT AGA GTA ATG GTG GAT AG 
baz2a CAG AGG GTA TGT GTC TGT CTG A GAA CTC CAC GAT GGT CAA GCA 
dmrta1 CCC AAC TTT CGA GGT TTT CCA CCC AGA GAA TGG TGA TGA GTG TT 
Dntt CTG GCA TTC ATG CGA GCA TC GAA GGC CCG GCG ATC ATA G 
elovl6 GAA AAG CAG TTC AAC GAG AAC G AGA TGC CGA CCA CCA AAG ATA 
fbxl5 TTC AGC AGC GCA GTC AGA C CAG CAT CTC GGA GAG CTT ATT G 
fbxo21 CCT GTA CCT GGC GAT GTA CC AGC ACC TTC AAG ACA AGA CAG A 
hmgcll1 ATG GGG AAT CTA CCA TCT GCT AGG GAG TCC AGG TAA CTG AGA 
nrtk2 CTG GGG CTT ATG CCT GCT G AGG CTC AGT ACA CCA AAT CCT A 
olfr1 508 ACT GTG GTC CTG ATG AGA TTG A GGG GTA ACA GCA GTG AAA AAC AC 
pbef1 GCA GAA GCC GAG TTC AAC ATC TTT TCA CGG CAT TCA AAG TAG GA 
per3 AAC ACG AAG ACC GAA ACA GAA T CTC GGC TGG GAA ATA CTT TTT CA 
phlda3 CCG TGG AGT GCG TAG AGA G TCT GGA TGG CCT GTT GAT TCT 
prm1 CCG TCG CAG ACG AAG ATG TC CAC CTT ATG GTG TAT GAG CGG 
serpina9 AAA CCC AGG TCA GAA TAT CCT CT GGA CGA GGT ACT CGA AGC C 
Slpi GGC CTT TTA CCT TTC ACG GTG TAC GGC ATT GTG GCT TCT CAA 
srgap3 TCC TGT GAA CAA CTG TCG TCT CAC GCC CAC AAT TCC CTC C 
st8sia3 AGT GTG CTA GGG CTG GTC AT TGG CGT ACT TGG GAG TGG T 
sulf1 TGT GTT CCA CCG TTC GGT C CAC ATC CTG GTC GTC AGT GAG 
Thrsp ATG CAA GTG CTA ACG AAA CGC CCT GCC ATT CCT CCC TTG G 
tmem45b ACC ACA AGG GCT TGA AGA ATA AC GGT GCA GGT GAG GTC CAT C 
tmem51 CAA AGC CAA CGG CTC ACA CTA GCT TAT CCG CAG GGC TGA AA 
tnnt2 CAG AGG AGG CCA ACG TAG AAG CTC CAT CGG GGA TCT TGG GT 
ucp2 ATG GTT GGT TTC AAG GCC ACA CGG TAT CCA GAG GGA AAG TGA T 
upp2 GGG AGC GTC CAG AGT ATG G CTG GTA GGT TGT GTG TTT TGG T 
wee1 GTC GCC CGT CAA ATC ACC TT GAG CCG GAA TCA ATA ACT CGC 
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Ltr TCA AAG CCC AGC ACA ATG TC TTA TCG CAT AGA AAA CCA GAC TTG C 
tnfr1 GCA GTG TCT CAG TTG CAA GAC ATG TCG G CGT TGG AAC TGG TTC TCC TTA CAG CCA C 
 
4.8.4 Primer sequences used for real-time PCR analysis (human) 
Gene fwd-sequence (5’-3’) rev-sequence (5’-3’)
ltR GAG AAC CAA GGT CTG GTG GA GAG CAG AAA GAA GGC CAG TG 
Light CTG GCG TCT AGG AGA GAT GG CTG GGT TGA CCT CGT GAG AC 
cd45 CCA ATG CAA AAC TCA ACC CTA CTC CTC TCT CCT GGG ACA TCT 
cytokeratin18 CCC GCT ACG CCC TAC AGA GCG GGT GGT GGT CTT TTG 
CD3 GTG ACC TGG CTT TAT CTA CTG GA GGT ATC TTG AAG GGG CTC ACT 
CD20 AAC AAA ATC TCT ACT TTG ATG GCA AGG CCT ACT GCT GAG TT 
Hprt GAC CAG TCA ACA GGG GAC AT GTG TCA ATT ATA TCT TCC ACA ATC AAG 
ccl2 CAT TGT GGC CAA GGA GAT CTG CTT CGG AGT TTG GGT TTG CTT 
ccl3 CTC TGC ACC ATG GCT CTC TGC AAC TGT GGA ATC TGC CGG GAG GTG TAG 
ccl5 CCC CTC ACT ATC CTA CC TCA CGC CAT TCT CCT G
cxcl1 ATG GCC CGC GCT GCT CTC TCC GTT GGA TTT GTC ACT GTT CAG 
cxcl10 TAT TCC TGC AAG CCA ATT TTG TC TCT TGA TGG CCT TCG ATT CTG 
TNFα CTC TGG CCC AGG CAG TCA GA GGC GTT TGG GAA GGT TGG AT 
tnfr1 CTG CCT CAG CTG CTC CAA A CGG TCC ACT GTG CAA GAA GAG 
LTα CCA CCC TAC ACC TCC TCC TT AGT CTG GGC AGC TGA AGG T 
Lt GAG GAC TGG TAA CGG AGA CG GGG CTG AGA TCT GTT TCT GG 
 
4.9 Histology and immunohistochemistry 
Paraffin sections (2µm) and frozen sections (5 or 10µm) of livers were stained with 
haematoxylin/eosin or various primary and secondary antibodies. Paraformaldehyde (4%) fixed and 
paraffin embedded liver tissue was incubated in Ventana buffer and staining was performed on a 
NEXES immunohistochemistry robot (Ventana instruments, Switzerland) using an IVIEW DAB 
Detection Kit (Ventana). Antibodies against B220+ B-cells (Pharmingen; 1:400), F4/80 (Serotec, 1:50) 
for macrophages, CD4 (YTS 191; 1:200) and CD8 for T-cells (YTS 169; 1:50) and CD3 for T-cells 
(clone SP7, Neomarkers; 1:300) were kindly provided by R. Zinkernagel (Odermatt et al., 1991). Anti 
human and murine GP73 (both Santa Cruz Biotechnology, Inc.) were used as a tumor marker to 
characterize HCC. Anti murine Glutamine Synthetase (Abcam, Code ab 16802; 1:500) was also used 
as tumor marker. Liver micro-architecture was evaluated by Collagen IV (IVIEW DAB Kit; 1:50), 
oval cell proliferation by A6 staining (1:50), kindly provided by Dr. Valentina Factor; both on a 
Ventana stainer from Roche. Ki67 (NeoMarkers Code RM-9106-S; 1:200) stained proliferating 
hepatocytes and lymphocytes. Image acquisition was either performed on an Axiophot-microscope 
(Zeiss), or an Olympus SZX12, equipped with a JVC digital camera (KY-F70; 3CCD) or on an 
Olympus BX61TRF fluorescent microscope equipped with an F-View camera and analyzed with the 
Analysis software. 
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For prion related experiments the following techniques were used: Paraffin sections (2µm) and frozen 
sections (5 or 10µm) of spleen or brain were stained with hematoxylin/eosin. Antibodies FDC-M1 for 
mature FDCs (clone 4C11; 1:50; Becton Dickinson), FDC-M2265 (1:50; Immunokontakt212-M/C-
1FDCM2), B220/CD45R for B cells (RA3-6B2, Pharmingen 553084; 1:400 in PBS/0. 15% BSA), 
CD35 for CR1 (8C12, Pharmingen, San Diego, CA; 1.100), CD4 for T-helper cells (YTS 191; 1:200) 
and CD8 for cytotoxic T-cells (YTS 169; 1:50), both rat anti-mouse kindly provided by Dr. Rolf 
Zinkernagel, NLDC-145 for dendritic cells (BMA T-2013; 1:1 ’000), PNA for germinal centre B-cells 
(Vector L-1 070; 1:100), F4/80 (Serotec, 1:50) for macrophages, GFAP (1:300; DAKO, Carpinteris, 
CA) for astrocytes, and Ki-67 for proliferating cells (NeoMarkers, USA) were applied and visualized 
using standard methods. Iba-1 was used for highlighting activated microglial cells. 
For PrP staining, formalin-fixed brain, renal and pancreatic tissues were treated with concentrated 
formic acid for 60 min to inactivate prion infectivity. Postfixation in formalin was performed for ~8 
hrs and tissues were embedded in paraffin. After deparaffination, sections (1-2 tm) were incubated for 
6 min in 98% formic acid and washed in distilled water for 30 min. Sections were heated to 100°C in a 
steamer in citrate buffer (pH 6.0) for 3 min, and allowed to cool down to room temperature. Sections 
were incubated in Ventana buffer and stains were performed on a NEXEX immunohistochemistry 
robot (Ventana instruments, Switzerland) using an IVIEW DAB Detection Kit (Ventana). After 
incubation with protease 1 (Ventana) for 16 min, sections were incubated with anti-PrP SAF-84 (SPI 
bio, A03208, 1:200) for 32 min. Sections were counterstained with hematoxylin. GFAP 
immunohistochemistry for astrocytes (1:1,000 for 24 min; DAKO) and Iba1 (1:2500 for 32 min; Wako 
Chemicals) for microglia was similarly performed, but with antigen retrieval by heating to 
100 °C in EDTA buffer (pH 8.0). 
 
4.10 In situ hybridization  
In situ hybridization was performed as recently described in (Prinz et al., 2004). In brief, sense and 
antisense probes for mLT, mLT derived from a pGEM4 plasmid containing KpnI/ BamHI fragment 
of mLT (GenBank: Y00467, corresponding to exon 4 of mLT) or a pGEM plasmid containing 
Sau3AI fragment of mLT (GenBank: U06950, corresponding mainly to exon 3). Sense and antisense 
probes for mEGR1 were derived from a pBluescript plasmid containing BglII fragment of mEGR1 
cDNA (NM_007913). Sense and antisense probes for CCL2 were derived from a pGEM-1 plasmid 
containing mCCL2 cDNA (Rollins et al., 1988). Sense and antisense probes for mCXCL10 were 
derived from a pBluescript plasmid containing 1065bp ofthe mCXCL10 cDNA. Sense and antisense 
probes were Digoxygenin (DIG) labelled according to the manufacturer’s protocol with a DIG-
labeling kit (Roche). Efficiency of Dig-labeling was quantified on a dotplot on a positively charged 
nylon membrane (GE Healthcare, Germany). In situ hybridization was performed on freshly cut frozen 
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sections (10-20m, air-dried), post fixed in 4% PFA/PBS. Treatment with 0.1M HCl was performed 
for Egr1 and Ccl2 for 10 min. Tissues were then acetylated in 300ml of 0.1 M triethanolamine 
containing 750l acetic anhydride. Prehybridization was performed 3 hrs at RT (or at 60°C for 6hrs for 
Cxcl10) in 50% formamide, 5x SSC (5x), 5x Denhardt’s solution, 250g/ml E. coli t-RNA (Roche). 
Hybridization solutions consisted of prehybridization solution containing 50ng/50l DIGlabelled RNA 
sense or antisense probes. Probes were denatured at 85°C for 5 min and then placed on ice. 
Prehybridization solution was then replaced by hybridization-solution, covered with a cover slip, 
sealed in a box, heated to 85°C for 30 min. (Egr1, Ccl2) and then incubated over night at 58-60°C. 
Washing was performed in pre-warmed SSC of different concentrations (and subsequently in PBT for 
CXCL10). For CXCL10 an RNase treatment (5g/ml RNase in 2 x SSC) was performed between the 
washing steps. (Blocking was performed using blocking reagent in buffer 1 (100mM Tris-HCl pH 7.5; 
150mMNaCl). Slides were incubated with anti-DIG AP (1:2000, Roche) at RT for 2-3 hrs. After 
subsequent wash in buffer 1 for 20mins twice, detection was performed in buffer 3 (100mM Tris-HCl 
pH 9.5; 150mMNaCl; 50mM MgCl2) containing 1mM Levamisol; NBTand BCIP (Sigma, Germany). 
Reaction was stopped in 10mM Tris pH8.0 and 1mM EDTA. Slides were mounted in DAKO aqueous 
mounting medium and analyzed on an Axiophot-microscope (Zeiss), or an Olympus SZX12, equipped 
with a JVC digital camera (KY-F70; 3CCD). 
 
4.11 Multiplex-bead assay 
Cytokine protein levels from liver homogenates or sera were measured using a multiplexed particle-
based flow cytometric cytokine assay (Vignali, 2000). Bioplex mouse cytokine kits were purchased 
from BioRad (Ismaning, Germany). The procedures closely followed the manufacturer’s instructions. 
The analysis was conducted using a conventional flow cytometer (FC500 MPL, BeckmanCoulter, 
Nyon, Switzerland). The detection limits were as follows: CCL2 (12 pg/ml), CXCL1 (1 pg/ml), IL1 
(0.3 pg/ml), IL6 (0.3 pg/ml), IFN (2.8 pg/ml). The homogenization buffer was tested as a negative 
control. 
 
4.12 Analysis of different HCV genotypes 
Different HCV genotypes were analyzed as recently published (Neumann-Haefelin et al., 2006) 
 
4.13 ELISA 
CXCL10 protein levels from liver homogenates or sera were measured using a Quantikine-Elisa-Kit 
from R&D Systems (Oxon, UK). The procedures closely followed the manufacturer’s instructions. 
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The detection limit was 16 pg/ml. The homogenization buffer was tested as a negative control. 
 
4.14 Cytokine assay for TNF  
Livers were homogenized with a Dispomix (Medic tools) in 10 vol of Tris-HCl buffer (50mM, pH 7.4) 
with NaCl (0.6M), Triton X-100(0.2%)and bovine serum albumin (0.5%) containing freshly dissolved 
protease inhibitors: benzamidine (1 mM), phenylmethyl-sulfonylfluoride (0.1mM) and Complete Mini 
Tablets (protease inhibitor cocktail Tablets; Roche). The supernatants were aliquoted and frozen at -
80°C until the cytokine assays were performed. Profiling mouse kit for TNFα was purchased from 
R&D Systems (Wiesbaden-Nordenstadt, Germany). The procedures closely followed the 
manufacturer’s instructions. The analysis was conducted using a conventional flow cytometer (LSRII 
from Becton Dickinson). The detection limit for TNFα was 0.4 pg/ml. 
 
4.15 Gene expression microarray experiment and data analysis  
An Agilent one-colormicroarray-based gene expression analysis (Mouse DNA Microarray 4x 44K) 
was performed on 3 and 9 month-old tg1223 (n=4) and IKKβhep (n=4) livers in comparison to age 
matched C57BL/6 livers (n=3) according to the manufacturer’s protocol. For HCC arising in 12 or 18 
month-old tg1223 (n=3) or tg1223/tnfr1/(n=4) livertissue was compared to non-affected Tg1223  
(n=3), non-affected tg1223/tnfr1-/- (n=4) liver regions as well as age matched C57BL/6 livers. In 
addition to biological replicates technical replicates were investigated. 
Gene expression was quantified using Agilent Feature Extraction Software Version 9.5.3.1. 
Expression values were imported into GeneSpring 7.3 (Agilent Technologies, USA) and following 
Agilent’s recommendation, all values less than 5.0 were set to a value of 5.0. For each sample all 
values were normalized to the respective 50th percentile. In case of the characterization of the tg1223 
and IKKβhep liver samples at 3 and 9 months of age, hierarchical clustering and principal component 
analysis of the normalized values indicated a slight confounding effect based on different dates for the 
hybridization of the different samples. In order to compensate this effect, for each gene on each array, 
the expression values were normalized to the median of the values obtained from the C57BL/6 control 
samples on the respective day, giving rise to ratio values. Those genes were filtered out that did not 
have at least 75% present flags in at least one of the C57BL/6, tg1223 or IKKβhep conditions at 3 or 9 
months. Assuming normal distribution ofthe data, statistically significant, differentially expressed 
genes in tg1223 or IKKβhep livers were selected using a one-sample t-test that assessed whether the 
respective ratios did significantly differ from 1. The false discovery rate was controlled at a level of 
0.05 using the method of Benjamini and Hochberg (Benjamini, 1995 ). In the study of individual HCC 
samples, each value for each sample was normalized to the 50th percentile of all expression values of 
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the respective sample. For each pair of samples representing tumor-affected and unaffected region of 
the same liver, for each gene, the values were normalized to the values of the respective sample from 
the unaffected region. Individual fold changes of the strongest up- and downregulated genes of each 
HCC samples in comparison to the median values of the C57BL/6 samples were reported after filtering 
out genes that did not have a present flag. 
 
4.16 Gene Ontology microarray data analysis  
Lists of significantly differentially expressed genes were investigated in respect to enrichment of Gene 
Ontology categories using the Gene Ontology Browser as implemented in GeneSpring 7.3. A Fisher’s 
exact test was used to show whether more genes belonging to a Gene Ontology category are found in 
the list under investigation than in a randomized gene list of the same size. 
 
4.17 Array-based Comparative Genomic Hybridization (aCGH)  
Agilent oligonucleotide array based CGH for Genomic DNA analysis for FFPE samples (Mouse 
Genome CGH Microarray 4x44K) was performed on paraffin embedded liver tissues according to the 
protocol provided by Agilent Technologies. Chromosomal copy number aberration in HCC samples of 
tg1223 livers in relation to C57BL/6 samples was investigated using aCGH (Agilent DNA Analytics 
4.0 CGH Module User Guide). Log2-ratios of signal intensity values of C57BL/6 (Cy5) versus signal 
intensity values of HCC (Cy3) samples were computed with Agilent Feature Extraction software 
Version 9.5.3.1. Log2 ratios were imported into the DNA Analytics Software 4.0.76 (Agilent 
Technologies, USA). Saturated and non-uniform data points were filtered out. Values of probes that 
occurred several times within one chip were combined and averaged. The aCGH data were then 
normalized in a linear way using DNA Analytics centralization method. Aberrations were detected 
using the Aberration Detection Method Nr.1 (ADM-1) as implemented in the DNAAnalytics software 
(Agilent DNAAnalytics 4.0 CGH Module User Guide, Agilent Technologies, Inc. 2008) with standard 
settings. Those aberrations that were not covered by more than two probes were filtered out. Single 
log2 ratio intensities, moving average of these ratios and aberration detection results were graphically 
displayed in the genome browser of the DNA Analytics software. 
In addition, the aCGH data were analyzed using Partek® Genomics Suite software, version 6.4 
(Copyright © 2008, Partek Inc., St. Louis, USA). After importing the array data into Partek, together 
with Dr. Stefan Zoller from the Functional Genomics Centre Zürich I transformed it into adjusted copy 
number data as described in the manual. Amplifications and deletions were detected by applying the 
genomic segmentation workflow. The optimal segmentation and region report parameters were found 
by following an iterative procedure (Partek support, personal communication) and finally set as 
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follows: minimum number of genomic markers = 10, segmentation P-value = 0.001, signal to noise 
ratio = 0.2, expected range = 0.3, region p-value = 0.01. On the resulting segmentation data, together 
with Dr. Stefan Zoller, I applied the workflow to find regions in multiple samples, reporting all regions 
that were significant in at least two samples. The related cytobands are indicated for each chromosome 
as horizontal bars. Annotations for these regions are available under supplemental online material. The 
cytoband information was obtained from the UCSC genome bioinformatics database 
(http://genome.ucsc.edu).  
Statistical significance of amplification and deletion patterns in aCGH for monoclonal tumors was 
calculated by applying a permutation test. The samples were compared pair-wise as follows using an 
in-house written program. First, the sequence overlap (o) of amplifications/deletions was calculated for 
the two samples. Then, the amplifications/deletions of one sample were kept but randomly distributed 
on the other sample and the new overlap (ri) calculated. This step was repeated n = 1 x 107 times and r 
= sum (ri>o) computed. Finally, the p-value for the pair-wise comparison was estimated as p = r/n. 
 
4.17.1 Online data on DNA microarray analysis and aCGH analysis 
DNA microarray analysis and aCGH analysis 
1. Original DNA-microarray data of differentially regulated mRNAs of 3 month-old tg1223, 
tg1223/IKKhep and C57BL/6 livers (normalized version) - analyzed on an Agilent 
microarray platform. Individual samples analyzed are described in detail in the excel file. 
Accession numbers: 
These data were submitted to the Gene Expression Omnibus (GEO) database. 
“Gene expression microarray data can be retrieved from Arrayexpress database using the 
accession number E-MEXP-1998”. 
2. Original DNA-microarray data of differentially regulated mRNAs of 9 month-old tg1223, 
tg1223/IKKhep and C57BL/6 livers (normalized version) - analyzed on an Agilent 
microarray platform. Individual samples analyzed are described in detail in the excel file. 
Accession numbers: 
These data were submitted to the Gene Expression Omnibus (GEO) database. 
“Gene expression microarray data can be retrieved from Arrayexpress database using the 
accession number E-MEXP-1998”. 
3. Original DNA-microarray data of differentially regulated mRNAs of HCC in 18 month-old 
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tg1223, tg1223/tnfr1-/-, of unaffected regions of the identical livers and of age matched 
tg1223 and C57BL/6 livers (normalized version) - analyzed on an Agilent microarray 
platform. Individual samples analyzed are described in detail in the excel file. 
Accession numbers: 
These data were submitted to the Gene Expression Omnibus (GEO) database. 
“Gene expression microarray data can be retrieved from Arrayexpress database using the 
accession number E-MEXP-1998”. 
4. aCGH-data of various tg1223 HCC and C57BL/6 control liver tissues which demonstrate 
chromosomal aberrations in autosomes by the use of an Agilent aCGH platform. 
The q-arm of each autosome is shown. Log ratios of C57BL/6 versus tg1223 signal 
intensities or C57BL/6 versus C57BL/6 signal intensities are shown. Negative log ratios 
represent deletions, positive log ratios amplifications of the respective genetic loci. 
Log ratio of 0.5 corresponds to the background level ofindividual C57BL/6 liver DNA 
samples hybridized with other C57BL/6 liver DNA samples (n=5). Lines represent smoothed 
moving averages. Estimated copy number aberrations are indicated with colored surfaces. 
These data can be directly accessed without any password on: 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=zhwdtmksyosskhm&acc=GSE14467  
 
4.17.2 Statistical evaluation of aCGH results  
Statistical significance of amplification and deletion patterns in aCGH for monoclonal tumors was 
calculated by applying a permutation test. The samples were compared pair-wise using an in-house 
written program: First, the sequence overlap (o) of amplifications/deletions was calculated for the two 
samples. Then, the amplifications/deletions of one sample were kept but randomly distributed on the 
other sample and the new overlap (ri) calculated. This step was repeated n = 1 x 107 times and r = sum 
(ri > o) computed. Finally, the p-value for the pair-wise comparison was estimated as p = r/n. 
 
4.18.1 Western blot analysis 
10% liver homogenates were prepared in RIPA buffer (50mM Tris; 1% NP40; 0.25% Deoxycholic 
acid sodium salt; 150mM NaCl; 1mM EGTA) containing 1 mM Na3VO4 and a protease inhibitor 
cocktail (Complete Mini Tablets; Roche) and quantified with a BCA protein assay kit (Pierce) 
according to the manufacturer’s manual. 60g protein were denatured in Laemmli buffer containing 
5% b-mercaptoethanol and separated by gel electrophoresis on a 12% Bis-Tris gel (Invitrogen) with a 
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1 x NuPAGE MES-SDS running buffer (Invitrogen) and blotted by wet blotting onto a nitrocellulose 
membrane (Protran BA 85 pore size 0.45 mm; Whatman). After blotting the membrane was blocked in 
Roti-Block (Carl Roth) for 2 hrs at RT. Primary antibody GP73 (sc-48011; Santa Cruz; 1:500 dilution) 
was incubated at 4°C over night under shaking conditions. Incubation with the secondary antibody 
(HRP-donkey anti goat IgG H+L; 705.035-147 Lot72963; 1:15000; Jackson) was performed under 
shaking conditions for 1 hr. Primary antibody AFP (#2137; Cell Signaling; 1:20) was incubated at 4°C 
over night under shaking conditions. Detection was achieved with Supersignal West chemiluminescent 
Substrate (Pierce). For signal detection a VersaDoc, standard exposure 15-30 sec was used. To assure 
equal loading, the membranes were reprobed with anti-13-actin antibody (Sigma) and detected as 
described above. 
For prion experiments tissue homogenates were adjusted up to 50 g protein and not treated or treated 
with proteinase K (25-50g/ml, 30 min, 37oC after denaturation and adding of loading dye). Total 
protein (up to 50µg) was electrophoresed through 12% SDS-PAGE. Proteins were transferred to 
nitrocellulose (Schleicher-Schuell, Germany and Protran BA 85 pore size 0.45 mm; Whatman) by wet-
blotting. Membranes were blocked with TBS-T containing 5% Topblock (Juro, Switzerland; 
LuBioScience GmbH), incubated with monoclonal anti-mouse PrP antibody POM1/POM19 in 1% 
Topblock TBST. 
 
4.19 Liver-cell extraction and freezing  
For the isolation and analysis of liver cells I included six patients with histologically proven HCC 
infection who had undergone curative hepatectomy and proven persistent HCV infection in the 
University Hospital, Grenoble where the analysis was done by my collaborators. Exclusion criteria 
included co-infection with human immunodeficiency, hepatitis B or hepatitis delta virus, additional 
causes of liver disease, alcohol consumption higher than 30g/day, inflammatory syndrome, previous 
antiviral treatment and previous liver transplantation. Liver and tumor tissues derived from curative 
hepatectomy were washed twice in a complete medium, containing RPMI 1640 supplemented by 10% 
Fetal Calf Serum (Gibco), and continuous shaking for 2 min. Tissues were cut into pieces with in Petri 
dishes containing 10ml complete medium and 100μl DNase (3mg/ml) (Boehringer Mannheim). 10% 
collagenase D (10mg/ml) (Roche Diagnostic Germany) was added and incubated for 20 to 30 min at 
37°C. Cell suspensions were then filtered (100μm mesh) and 10% of fetal calf serum (FCS) was added 
in the final volume and then centrifuged at 15000 rpm twice to remove debris. The cells were then 
counted with a hemocytometer and stored in 10% DMSO in liquid nitrogen or on - 80°C. 
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4.20 Separation of CD45+ and CD45- cells by microbeads 
Frozen cell suspensions were thawn and viability was checked by Acridine/propidium iodide with the 
help of fluorescent microscope and the percentage of living cells was quantified. Leukocytes numbers 
were then counted with a hemocytometer. Cell sorting was performed as previously described (Vigan 
et al., 2003) with the following modifications: Cells were incubated with a biotinylated anti-human 
CD45 antibody (BD Pharmingen) (1 μl of anti CD45 for 1×106 of target cells) for 20 min on ice and in 
dark followed by a washing step with 10 volumes of PBS to remove unbound antibody. Then, the cells 
were incubated with streptavidine coupled microbeads (Invitrogen, Norway) in PBS with 0.1% BSA 
and 2mM EDTA, pH 7.4 for 30 min at 2-8°C with gentle tilting and rotation as manufacturer 
instructions (50 μl of microbeads for 2.5×106 target cells). Cells were then separated into two fractions 
with a magnetic column i.e. one with cells bound to microbeads (leukocytes) and the second fraction 
consisting of unbound cells (hepatocytes, tumor cells and others). After performing additional washing 
steps to remove trapped liver or tumor cells, cells were eluted from the column. Both cell fractions 
were then used for RNA extraction. 
 
4.21 Counting of proliferating hepatocytes  
The total number of Ki67+ hepatocytes was counted (number of Ki67+ hepatocytes/visual field of 2 
mm2). For each mouse/genotype (n=8) 10 visual fields were counted. Statistics was performed (tg1223 
versus C57BL/6 mice). 
 
4.22 Statistical evaluation  
Human specimens and various mouse groups were compared using a oneway ANOVA with post-hoc 
Bonferroni test and a Fisher’s exact test with Bonferroni correction and a chi-square test with exact P-
values to evaluate statistical significance. Analyses were evaluated by using the program SPSS 13.0 
(SPSS Inc., Chicago, IL). Student’s t-test was used to evaluate the statistical significance of hepatic 
cytokine and transaminase levels. 
 
4.23 Exposure to prions 
- Aerosols: Exposition of Tga20 mice to aerosols was performed in inhalation chambers with a 
Nebuliser device (Pari GmbH, Munich, Germany) run with a pressure of 1.5 bar generating 100% 
particles below 10 µm with 60% of the particles below 2.5 µm and 52% below 1.2 µm. Such particle 
sizes are considered to be able to reach upper and lower airways. Prion material used throughout this 
study was RML strain obtained from the brains of diseased CD1 mice in its 6th passage (RML6). Mice 
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were exposed to aerosolized prion infected brain homogenates for two, five or ten minutes.  
- Intracerebral prion inoculation of mice: Tga20 mice serving as indicator mice were inoculated i.c. 
with brain or lung tissue homogenate using 30 µl volumes.  
- Intranasal RML prion application in mice: Mice were anesthetized with Ketamine/Xylazin 
hydrochloride anaesthesia. 10 l of RML 6.0 (0.1%) were i.n. inoculated in each nostril and on the 
nasal epithelium by using a 10 l pipette. The mice were held horizontally during inoculation process 
and for 1 minute following the inoculation. The whole procedure was repeated after a break of 20 
minutes, reaching a final volume of 40 l of RML 6.0 (4 log LD50). 
Mice were monitored every day, and scrapie was diagnosed according to clinical criteria including 
ataxia, kyphosis, tail rigidity and hind leg paresis. Mice were sacrificed at the onset of terminal 
disease. All mice described were maintained under specific pathogen-free conditions. Breeding and 
experiments were performed in compliance with the guidelines of the Kanton of Zürich. 
 
4.24 Sodium phosphotungstic acid (PTA) precipitation 
10% homogenates of spleen, brain, pancreas and kidney were prepared in 0.32 M sucrose or PBS. 
Gross cellular debris was removed by centrifugation at 80 g for 1 min. 300l of PBS were added to 
200l of the resultant supernatant, and mixed 1:1 with 4% Sarkosyl in PBS. Samples were incubated 
for 15 min at 37°C under constant agitation. Benzonase and MgCl2 were added to a final concentration 
of 50 U/ml and 12.75 mM respectively, and incubated for 30 min at 37°C under continuous agitation. 
Pre-warmed PTA stock solution (pH 7.4) was added to a final concentration of 0.3% and the sample 
was incubated at 37°C for 30 min with constant agitation, followed by centrifugation at 37°C for 30 
min at maximum speed in an Eppendorf microcentrifuge. The pellet was resuspended in 30l 0.1% 
Sarkosyl in PBS and digested with 30Llg/ml proteinase K (PK) for 30 min at 37°C with agitation. The 
sample was heated at 95°C for 5 min in SDS-containing loading buffer before loading onto 12% or 
16% Novex SDS polyacrylamide gels (Invitrogen, USA) (experiments performed in Tübingen). 
 
4.25 Misfolded Protein Assay (MPA) 
The assay, which was performed on a 96-well plate is divided into two parts: the PSR1 Capture and an 
ELISA. For the PSR1 Capture the set up of each reaction was as following: 3L of PSR1 beads (buffer 
removed) and 100 L of 1 x TBSTT were spiked with brain homogenate, incubated at 37°C for 1hr 
with shaking at 750rpm, the beads were washed on the plate washer (ELX405 Biotek) 8 times with 
residual 50 L/well TBST. Then 75 L/well of denaturing buffer was added. This was incubated at RT 
for 10min with shaking at 750rpm. Subsequently 30 L/well of neutralizing buffer were added. An 
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additional incubation at RT for 5min with shaking at 750rpm followed. The beads were pulled down 
with a magnet. The ELISA was performed as follows: 150 L/well of the sample was transferred to an 
ELISA plate which was coated with POM19. An incubation step at 37°C for 1hr with shaking at 
300rpm followed. That was washed 6 times with wash buffer. POM2-AP conjugate had to be diluted 
to 0.01 g/mL in conjugate diluent. 150 L/well of diluted conjugate was added. Incubation at 37°C 
for 1hr without shaking followed. Washing 6 times with wash buffer was followed by preparation of 
enhanced substrate by adding 910 L of enhancer to 10mL of substrate (Lumiphos plus, Lumigen). 
150 L/well of enhanced substrate was added. Incubation at 37°C for 30min was followed by reading 
by luminometer (Luminoskan Ascent) at default PMT, filter scale=1.  
 
4.26 FACS analysis 
Secondary lymphoid tissues were harvested and cells and single cell suspensions were generated by 
gentle pushing the tissue through a cellstrainer (Becton Dickinson (BD), USA). Alternatively, 
peripheral blood from the tail vein was collected in pre-cooled FACS-buffer (960 l PBS, 20l FCS, 
20 l EDTA 0.5M, 1g NaN3). Next samples were spun down for 5min at 300g at 4°C and the 
supernatant was discarded. Cells in the pellet were resuspended in 100 l of FACS-buffer containing 
the conjugated antibodies with a concentration based on the manufacturer’s recommendations. 
Samples were gently vortexed and incubated for 20 min at 4°C in the dark. Afterwards samples were 
washed with FACS-buffer and spun down, supernatant was discarded. In case the primary antibodies 
were not directly conjugated with fluorochromes the staining step was repeated. Red blood cell lysis 
was performed with 1 ml of 1x lysis solution (BD). Samples were incubated for 3min at room 
temperature before the reaction was terminated by adding 3 ml of FACS-buffer. Again samples were 
spun down and resuspended accordingly to the cell density. FACS was performed at a two-laser 
FACScalibur (BD). The analysis was executed with cell-quest and flow-jo software. 
 
4.27 Histoblot analysis 
Histoblots were performed as described previously (Taraboulos et al., 1992). Frozen brains that were 
cut into 12-m-thick slices were mounted on nitrocellulose membranes. Total PrP, as well as PrPSc 
after digestion with 50 or 100 g/ml proteinase K for 4 hrs at 37°C, were detected with the anti‐prion 
POM1 antibody. (1:10000, NBT/BCIP, Roche Diagnostics).  
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